























Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 

















Novel in vitro models to investigate 
pharmacological targets in genital 
resistance vasculature
Jude S Morton




Neuroscience & Biomedical Systems 
Faculty o f Biomedical & Life Sciences 
University o f  Glasgow 
Glasgow, Scotland.
G12 8QQ
Copies of this thesis may be produced by photocopying
ProQuest N um ber: 10390990
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction  is d e p e n d e n t  u p on  the quality of the co p y  subm itted .
In the unlikely e v e n t  that the author did not send a c o m p le te  m anuscript 
and there are missing p a g e s ,  th ese  will be n o te d . Also, if m aterial had to be rem o v ed ,
a n o te  will in d ica te  the d e le tio n .
uest
ProQ uest 10390990
Published by ProQuest LLO (2017). C opyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected  a g a in st unauthorized  copying  under Title 17, United States C o d e
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 4 8 1 0 6 -  1346





Male and female sexual dysfunctions are prevalent, multifactorial disorders, which 
significantly impact on the quality of life of sufferers. The development of treatments for 
male sexual dysfunction has been based on an understanding of the function of the genital 
tissues. However, much of this knowledge has been gained using techniques to investigate 
responses of penile and vaginal tissue strips to exogenous agonists and antagonists. In the 
few studies that have considered the function of isolated male penile arteries it has been 
demonstrated that vascular responses may differ from those of penile tissues. A fuller 
understanding of the function of isolated penile arteries will provide a more sophisticated 
approach to novel pharmacological therapies for male sexual dysfunction.
In addition, very little research has been carried out into the physiology of female genital 
tissues and no studies have considered the function of isolated female genital arteries. 
Treatments for sexual dysfunction in the female sex have largely been based on successes 
in the male field with mixed results. A fuller understanding of the function of female 
vaginal arteries may provide a more coherent basis for the development of novel 
phannacological therapies for female sexual dysfunction.
The present study utilised the method of small vessel wire myography to perform a 
detailed pharmacological investigation into the vascular function of isolated genital arteries 
from male and female New Zealand White rabbits. The arteries chosen for study were the 
male dorsal and cavernous arteries and the female vaginal artery, divided into two 
preparations, upstream ‘extra-vaginal’ artery (EVA) and downstream ‘intra-vaginaT artery 
(IVA). Mechanisms of vasoconstriction and vasodilation were examined and related to 
current published knowledge.
Adrenoceptor-Mediated Responses
Male and female arteries were shown to be innervated by sympathetic adrenergic nerves 
using immunohistochemistry and/or EPS. During the investigation of adrenoceptor (AR)- 
mediated pathways, noradrenaline (NA)-induced vasoconstriction and active NA uptake 
mechanisms were demonstrated in both penile and vaginal arieries. AR-induced 
vasoconstriction was mediated by a combination of uia-ARs and a2-ARs, potentially the
Œ2A-AR subtype, in maie penile arteries. The U2-AR was shown to be of particular 
importance in the vasoconstriction of dorsal penile arteries; reflected by the potency order 
of AR agonists, UK 14,304 > Medetomidine > NA = phenylephrine (PE). A clear role for 
uia-ARs was demonstrated in the cavernous arteries, while U2-ARs could not be excluded.
In female vaginal arteries the presence of functional ai-ARs was confirmed. However, U2- 
ARs were shown to make little or no contribution to AR-mediated responses in isolated 
vaginal arteries. The lack of a2-AR-mediated responses highlights a clear gender difference 
between male and female rabbits that was reflected in the order of agonist potencies in 
female vaginal arteries, NA = UK 14,304 = PE = Medetomidine.
Basal AR activity, either via tonic adrenergic nerve or constitutive AR activity, was 
considered to be responsible for the maintenance of endogenous tone in both male and 
female genital arteries.
Nitric Oxide-Mediated Responses
The contribution of nitric oxide (NO) to endothelium-dependent, direct smooth muscle and 
nerve mediated relaxation was investigated during the current study. Direct stimulation of 
smooth muscle by the NO donor drug, sodium nitroprusside (SNP), caused vasodilation of 
both male and female genital arteries. However, this relaxation was not potentiated by the 
phosphodiesterase type 5 (PDE-5) inhibitor, UK 343,664; which was unexpected 
considering the success of Viagi'a®, another PDE-5 inhibitor, in the treatment of male 
erectile dysfunction.
Considering the wealth of data proposing NO as the main non-adrenergic, non-cholinergic 
(NANG) neurotransmitter in male penile tissues, surprisingly little evidence was found for 
NO involvement in electrical field stimulation (EFS)-induced relaxation in male penile 
arteries. In female vaginal arteries, a greater inliibition of EPS-induced relaxation by 
blockade of nitric oxide synthase (NOS) activity using Nco-nitro-L-arginine methyl ester 
hydrochloride (L-NAME) was demonstrated than in male penile arteries. In female 
arteries, L-NAME predominantly inhibited EPS-induced responses at low frequencies 
while an L-NAME-resistant component persisted at high stimulation h'equencies.
Acetylcholine (ACh)-induced, endothelium-dependent relaxation of male and female 
genital arteries was mediated by a combination of NO and K^ chaimel activity. K^ channel 
activity was demonstrated by inhibition of K"^  channels using apamin and charybdotoxin
and was, therefore, potentially due to release of endothelial-derived hypeipolarising factor 
(EDHF). No role was demonstrated for prostacyclin in ACh-induced relaxation of male or 
female genital arteries. Relative contributions of NO and channels (EDHF-like
vasodilation) to endothelium-dependent vasodilation demonstrated significant gender 
differences. Vasodilation was predominantly mediated by NO in male dorsal arteries, 
chamiels in female EVA and a combination of both in smaller IVA and cavernous arteries. 
Contrary to previous studies, the involvement of EDHF was demonstrated to he greater in 
upstream sections of the vaginal artery (EVA) compared to smaller downstream sections 
(IVA). This study was the first to determine the relative contributions of EDHF and NO to 
endothelium-dependent relaxation of male and female genital arteries.
Vascular tone was increased in the presence of blockers or inhibitors of NOS or K"*" 
channels. Therefore, basal release of NO was found to contribute significantly to the 
maintenance of endogenous tone in both male and female genital arteries. The unique 
observation of L-NAME-sensitive, pronounced, spontaneous vasodilations in the EVA 
demonstrated the importance of NO in the maintenance of vascular tone in this artery.
Basal K’*' channel activity, thought to be due to a basal release of EDHF, contributed to the 
maintenance of endogenous tone in all genital arteries. In the IVA, NO and EDHF 
pathways showed some degree of compensation in that blockade of either pathway alone 
was significantly less effective than blockade of both pathways together.
Peptide- and Purine-Mediated Responses
L-NAME-resistant, EFS-induced vasodilation was shown not to be due to ATP in the 
female genital arteries. In contrast to published data in vaginal tissues, no direct vasodilator 
effect of ATP was demonstrated in isolated female vaginal arteries. However, functional 
P2X receptors (ATP-induced vasoconstrictions) were demonstrated; suggesting that ATP 
may be involved in sympathetic, excitatory neurotransmission. Until now, no previous 
studies have investigated this role for ATP in isolated genital arteries.
Functional VIP receptors were demonstrated in female genital arteries and the presence of 
VIPergic neurons confirmed by immunohistochemical studies. A role for VIP as a 
neurotransmitter in the EVA could not be excluded. To date no studies have managed to 
conclusively delineate the physiological function of VIP. However, an additional, 
unknown vasodilator neurotransmitter remained unidentified in both male and female 
genital arteries and identification of this compound may solve the characterisation of L- 
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Sexual Function and Dysfunction
Sexual dysfunction is an area that has been moved into the public consciousness by the 
advent of oral medications such as the PDE-5 inliibitors sildenafil citrate (Viagra®), 
tadalafil (Cialis®) and vardenafil hydrochloride (Levitra®) for the treatment of male erectile 
dysfunction. These drugs have provided some of the impetus for further scientific research 
into the underlying aetiology of sexual dysfunction. However, a large volume of basic 
research has yet to be completed before we can fully understand the mechanisms involved 
in the noimal function of the genital system and, therefore, understand the processes that 
are responsible for dysfunction.
Male Penile Anatomy
The stiTicture and function of penile arterial, venous and neiwous systems have been 
investigated in many species including rat (Fernandez et a l, 1991), rabbit (Fujimoto & 
Takeshige, 1974), monkey (Fugleholm et a l, 1989) and human (Breza et a l, 1988; Benoit 
et a l, 1999) and no major anatomical differences were found across mammalian species.
The body of the penis contains tliree cylindrical masses of erectile tissue, two paired 
corpora cavernosum and a corpus spongiosum, composed mainly of smooth muscle and 
connective tissue with endothelium, fibroblasts and nerves (Figure 1-1). The corpora 
cavernosum are positioned dorsally and divided by a septum which is incomplete in some 
species e.g. human and rabbit, allowing communication between the two bodies of tissue 
(Simopoulos et a l, 2001) but not in others e.g. dogs (Azadzoi et a l, 1995). Ventrally the 
corpus spongiosum tissue sunounds the uretlira. Each corpus is surrounded by a layer of 
tissue called the tunica albuginea composed of collagen and elastin. The tunica albuginea 
around the corpus spongiosum consists of a single layer while the paired corpora 
cavernosum are sunounded by tluee layers, an inner circular, intermediate oblique and 
outer longitudinal layer. The relative indistensibility provided by the tunica albuginea 
around the corpus cavernosum is necessary to allow this tissue to act as a blood filled 
capacitor during erection and to provide a rigid structure to the penis. Proximally in the 
root of the penis, the two corpora cavernosum separate and taper as penile crura. The crura 
are attached to the ischial and inferior pubic rami and are covered by the ischiocavernous 
muscles. Distally the corpora cavernosum end proximal to the glans penis.
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Figure 1-1: The human male genital anatomy. A cross-section of the male reproductive 
organs showing the tissues of the penis, including the corpus cavernosum, corpus 
spongiosum, and glans penis, and their positions relative to other organs in the body. 
(Adapted from Tortora & Grabowski, 2000).
Penile Circulation
The arterial blood supply to the penis originates fi*om the internal iliac (hypogastric) artery, 
which branches to give rise to the internal pudendal artery. At its terminal end this passes 
tlu'ough Alcock’s canal where it branches into the perineal and penile arteries. The penile 
artery further divides into the bulbourethral, cavernous and dorsal arteries.
The cavernous artery enters the junction of the two corpora cavernosum and is the primary 
blood supply to this tissue. A proximal branch, the crural artery, supplies blood to the 
penile crura while the cavernous artery continues distally in the centre of the corpus 
cavernosum tissue (Figure 1-2). Numerous branches, helicine resistance arteries, arise from 
the cavernous artery, connecting directly into trabecular sinuses in the corpus cavernosum 
tissue which become filled with blood during the erectile process. Shunt vessels exist, 
which are open in both flaccid and erect states and bypass the trabecular sinuses; 
connecting helicine resistance arteries directly to a venous plexus draining the corpus 
cavernosmn tissue (Fugleholm et a l, 1989).
The dorsal artery is situated along the dorsal surface of the corpora cavernosum and 
constitutes the main blood supply to the glans penis and prepuce. Circumflex arteries
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branch along the length of the dorsal artery and accompany circumflex veins around the 
lateral surfaces of the corpora cavernosum. These arteries may provide a secondary blood 
supply to the corpora cavernosum (Breza et a l, 1988).








-4 - , “ Corpus Cavernosum
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Figure 1-2: The human penile circulation. A cross-section of the penis showing the 
positions of arteries and veins relative to penile tissues. (Adapted from Tortora &
Grabowskij 2000)
The Male Sexual Response
There are three types of erection: psychogenic, reflexogenic and nocturnal (reviewed by 
Andersson & Wagner, 1995). Auditory, olfactory, visual or imaginative stimuli to the CNS 
initiate psychogenic erections while reflexogenic erections result from direct tactile 
stimulation of the genitalia. The three main events that occur during erection are increased 
penile arterial inflow, relaxation of the trabecular tissue and increased venous resistance. 
During the flaccid state cavernous arteries and smooth muscle are contracted allowing only 
a low blood flow through the tissue for nutritional purposes.
Sexual ai'ousal leads to increased parasympathetic activity causing the penile arteries and 
trabecular smooth muscle to relax. Aiterial inflow increases (Lee et a l, 1993; Azadzoi et 
al, 1995) and blood fills the corpus cavernosum, corpus spongiosum and glans penis 
erectile tissues until they become limited by the suiTounding tunica albuginea, causing 
intracavemosal pressure to rise rapidly. Veno-occlusion increases venous resistance and 
reduces outflow from the erectile tissue resulting in a relatively low flow rate to maintain 
erection. Intracavemosal pressure rises to just below systolic blood pressure values 
providing a high pressure system that gives shape and rigidity to the penis. Due to the
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relative distensibility of the tunica albuginea surrounding the corpus spongiosum and the 
glans penis these tissues have a lower pressure system than the corpus cavernosum, which 
is maintained by a high blood flow rate (Vardi & Siroky, 1990).
It is thought that full rigidity of the penile tissues may require conscious or reflexive 
stimulation of the ischiocavernous muscle (Junemann et a l, 1989). Contraction of this 
muscle causes compression of the crura of the corpora cavernosum resulting in a rise in 
intracavemosal pressure. Stimulation of the bulbocavemosal muscle is thought to be 
specifically involved in the process of ejaculation.
A decrease in parasympathetic and an increase in sympathetic activity causes the 
cavemous arteries and smooth muscle to contract followed by a gradual re-opening of 
veins draining the corpus cavernosum. Both arterial and venous blood flow return to 
normal levels and intracavemosal pressure decreases rapidly, returning the penis to the 
flaccid state.
Female Vaginal Anatomy
In 1998, the first international consensus development conference on female sexual 
dysfunction (FSD), convened by the American Foundation for Urologie Disease, identified 
the need for basic research covering the epidemiology, anatomy and biology of FSD 
concluding that FSD was an “under researched and poorly understood area” (Basson et a i,
2000). In particular, investigations of genital arterial, venous and neiwous systems and their 
role in the control of vascular smooth muscle tone, vasodilation and vaginal lubrication 
were identified as areas of study required to provide a fuller understanding of the 
physiology of the female sexual response.
The female sexual anatomy is divided into internal and external genitalia (reviewed by 
Berman & Bassuk, 2002; Munarriz et al., 2002). External genitalia are collectively temied 
as the vulva and include the labia, interlabial space, vestibular bulbs and the clitoris (Figure 
1-3). Embryologically, the clitoris and penis are derived from the same origin and, 
therefore, are composed of similar parts: a glans and two corpus cavemosum suiTounded 
by a single layer tunica albuginea. Internal genital organs include the utems, fallopian 
tubes, ovaries and the vagina. The vagina is a cylindrical organ which lies in the midline of 
the body. The vaginal wall is composed of three layers, an inner epithelial membrane 
consisting of mucous-type stratified squamous epithelial cells, a vascular muscularis layer 
composed of smooth muscle and extensive blood vessels and an outer fibrous layer. The
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vaginal wall has numerous folds allowing it to distend and increase in length and luminal 
diameter during sexual activity.









Figure 1-3: The human female genital anatomy. A cross-section of the female reproductive 
organs showing the vagina and uterus and their positions relative to other organs In the 
body. (Adapted from Tortora & Grabowski, 2000).
Vaginal Circulation
In males, many investigators have used teclmiques such as corrosion casts to provide a 
detailed knowledge of the vascular beds supplying the penile tissues. However, 
corresponding studies in the female genital tissues are limited to a single study in the rat 
(Shabsigh et a l, 1999). The vascular system in female vaginal tissues is supplied largely 
by the internal iliac artery and in part by the external iliac artery. The internal iliac artery 
branches to give the cervical and vaginal arteries. In the rat, multiple collaterals and 
serpentine vessels connect the two main vaginal arteries on the lateral sides of the vagina. 
Venous drainage is via a complex network of veins termed the vaginal venous plexus.
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The Female Sexual Response
The female sexual response, first defined by Masters & Johnson (1966) and later refined 
by Kaplan (1974), includes phases of desire, arousal, orgasm and resolution. In the basal 
state, vaginal and clitoral smooth muscles remain contracted, which is similar to coipus 
cavemosum smooth muscle in the male. During the desire phase, internal and external 
stimuli lead to a CNS response involving the hypothalamus; resulting in the release of sex 
hormones and vasoactive substances. In the female, the brain is considered to be the most 
important mediator of the sexual response and is affected by biological, e.g. hormones and 
neurotransmitters, motivational, e.g. relationship factors, and cognitive, e.g. risk and wish, 
aspects. Female sexual arousal is characterised by vasculogenic changes, including 
vasodilation, increased vaginal blood flow, increased vaginal lubrication, relaxation of the 
vaginal wall and engorgement of the clitoris with blood. Orgasm results from a rhytlimic 
contraction of the vagina, uterus and levator ani muscles. Unlike males, sexual satisfaction 
in females is not reliant on the occurrence of an orgasm response. The final phase involves 
resolution during which there is a release of muscular tension, a decrease in blood flow to 
the sexual organs and emotional satisfaction.
Genital Innervation
The innervation of male and female genital tissues is comparable and includes 
sympathetic, parasympathetic and somatic (sensory and motor) neiwes (Lue et ai, 1983; 
Andersson & Wagner, 1995; Giuliano et a l, 2002; Munarriz et a l, 2002).
In both sexes, sympathetic (thoracolumbar) preganglionic fibres synapse at the 
paravertebral sympathetic chain ganglia (Figure 1-4). Postganglionic fibres reach the 
genitalia via three possible routes; in the pudendal, pelvic (nervi erigentes) or hypogastric 
nerves. Parasympathetic preganglionic fibres travel via the pelvic nerve from the sacral 
region of the spinal cord to the pelvic plexus. Postganglionic fibres reach the genitalia via 
the cavernous and dorsal neiwes, branches of the pelvic/hypogastric and pudendal neiwes 
respectively. In the male, branches of the cavernous nerve containing sympathetic and 
parasympathetic fibres innervate the cavemous vein and uretliral, dorsal and cavernous 
arteries. Terminal neurons imiervate helicine resistance vessels and trabecular smooth 
muscle. In females, the dorsal nerve imiervates clitoral tissue while the cavernous neiwe 
provides imiervation to the vaginal tissue.
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Somatic imiervation involves afferent sensory fibres from the genitalia that reach the sacral 
region of the spinal cord thr ough the dorsal nerve in the penis and subsequently the 
pudendal nerve in both sexes. However, a difference occurs in efferent nerve pathways in 
males and females. In males, the efferent response occur s either via motor fibres in the 
pudendal neiwe to the ischiocavernous, bulbocavernous and other pelvic muscles or via 
parasympathetic pathways. In females, the efferent pathway is also via the pudendal nerve 
to the pelvic muscles but in addition the motor response is co-ordinated with sympathetic 








































Figure 1-4: Schematic overview of sympathetic, parasympathetic and somatic innervation of 
the genitalia. Sympathetic innervation originates from the thoracic and lumbar regions of 
the spinal cord and travels in the hypogastric, pelvic and pudendal nerves to the genitalia. 
Parasympathetic innervation originates In the sacral region of the spinal cord and travels in 
the pelvic nerve to the genitalia. Somatic afferent and efferent fibres relay to the sacral 
region of the spinal cord. (Adapted from Andersson & Wagner, 1995).
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Male Sexual Dysfunction
In males, sexual dysfunction can be separated into loss of libido, ejaculatory, orgasmic and 
erectile dysfunctions. The definition of the latter is an inability to attain or maintain 
erections sufficiently rigid for vaginal penetration and sexual satisfaction. Various studies 
have estimated that at any time approximately 18% to 31% of men aged 25 to 80 years 
suffer from sexual dysfunction (Laumann et ah, 1999; Johannes et a l, 2000; Maitin- 
Morales et a l, 2001; Lewis et a l, 2004; Nicolosi et a l, 2004). This dysfunction is age 
related and associated with cardiovascular risk factors, diabetes, psychiatric/psychological 
disorders and socio-demographics.
Erectile dysfunction (ED) has been classified into five types dependent upon the 
underlying cause. Of these vasculogenic ED has been estimated to account for 
approximately 75% of all ED patients (NIH Consensus Conference, 1993) and so is by far 
the most common class. Other classes include neurogenic, psychogenic, endocrinologie 
and iatrogenic ED but these were out with the scope of this study. Vasculogenic ED is 
characterised by an interruption of penile blood flow with arterial insufficiency, venous 
incompetence or both. Risk factors include diabetes mellitus, hypertension, atherosclerosis, 
hypercholesterolemia and smoking. The prevalence of ED in diabetic men, 28%, is three 
times higher than in non-diabetics, 9.6% (Feldman et a l, 1994).
Therapeutics
In the last twenty years, since the first reports of penile erections induced by 
intracavemosal agents (Virag, 1982; Brindley, 1986), pharmacological therapies have 
developed to become the most effective and reliable treatment of male ED.
Phannacological therapies generally bypass the normal psycho-neurological stimuli 
required to initiate an erection by directly activating or inhibiting central (e.g. dopamine) 
or peripheral receptors (e.g. adrenergic) and signal transduction pathways (e.g. nitric 
oxide/cGMF).
Intracavemosal injection remains a common route of administration of pharmacological 
therapies but can prove problematic due to patients’ fear of self-injection. The transurethi*al 
route can provide a less invasive altemative while oral or topical administrations aie non- 
invasive options. However, transuretliral or topical dmg administrations present a difficulty 
in dmg delivery because of the anatomy of the tunica albuginea of the corpus cavernosum. 
More recently developed oral therapies, while providing the benefit of having enhanced
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public awareness of sexual dysfunction, are also associated with more common systemic 
side effects such as flushing, headaches and visual disturbances.
Cun’ent therapeutic approaches to erectile dysfunction have been based on knowledge of 
the physiology and pharmacology of erectile tissues. Pharmacological therapies aim to 
increase vasodilation (Table 1-1), decrease vasoconstriction (Table 1-2), or act centrally 
(Table 1-3). Since most drugs target the vasodilator pathways required for erection, they 
risk causing vasodilation in the systemic circulation leading to hypotension. Systemic 
vasodilation is responsible for a common side effect of many current therapies, headache. 
Vasodilator pathways may be over stimulated by the use of drugs leading to the occurrence 
of prolonged erections (priapism). Improved results have been achieved using combination 
treatments, including reduced toxicity, priapism and adverse side effects. For example 
PGEi, phentolamine, papaverine and vasoactive intestinal polypeptide (VIP) have been 
used in two or three drug combinations with each other or with additional compounds such 
as prazosin (an a-AR antagonist) or forskolin (activates adenylate cyclase leading to 
increased cAMP, Mulhall et a l, 1997). Beneficial effects may also be achieved by 
attaching NO donors to a-AR antagonist or PDE inhibitors (Moreland et a l, 2000) to 
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Female Sexual Dysfunction
The first question many people ask when the subject of FSD arises is “does it exist?” In 
answer to this it may be put forward that no functional biological system is infallible and 
therefore will be prone to dysfunction. The question, therefore, may not be “does sexual 
dysfunction exist?” but rather “does it matter?” The primary focus of research in females 
has generally been in the field of reproduction and less in the area of sexual function, 
which has been considered passive in comparison to males. Also since sexual dysfunction 
is not life-threatening it is not always considered a high priority. However, in both males 
and females, sexual dysfunction has been shown to have a significant impact on an 
individual’s quality of life and interpersonal relationships and this point alone provides 
ample reason to strive for a treatment for sexual dysfunction in both sexes. In addition, the 
prevalence of sexual dysfunction has been shown to be greater in females than in males 
with 40% to 45% of women experiencing some form of sexual dysfunction (Laumann et 
a l, 1999; Lewis et a l, 2004; Nicolosi et a l, 2004). Therefore, FSD both exists and is a 
prevalent disorder of significant consideration for those who are affected by it.
Current definitions of FSD include sexual desire disorder, including hypo active sexual 
desire and sexual aversion, sexual arousal disorder, orgasmic disorder and sexual pain 
disorder, including vaginismus, dyspareunia and non-coital pain (Basson et, al, 2000; 
Basson et a l, 2004). Similar to erectile dysfunction in men, FSD can arise from 
vasculogenic, neurogenic, hormonal/endocrine or psychogenic aetiologies (Berman et a l , 
1999). FSD also shares common risk factors with male sexual dysfunction, including 
cardiovascular disease, smoking and hypercholesterolemia and is associated with negative 
experiences in sexual relationships and general poor health.
Female sexual arousal disorder (FSAD) is defined as the persistent or recurring inability to 
attain or maintain sufficient sexual excitement, causing personal distress. Arousal disorders 
may be characterised either by a lack of genital responses, e.g. decreased vaginal 
lubrication, decreased clitoral and labial sensation or engorgement, and a lack of vaginal 
smooth muscle relaxation, or by a lack of subjective excitement due to psychological 
factors, decreased vaginal blood flow, or as a side effect of surgery or medication (Berman 
e ta l, 1999).
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Therapeutics
Phannacological therapies for FSD have, to date, largely been based on successes in the 
male field. This is both because this provides an obvious starting point, but also because 
little is known about the physiology and pharmacology of female sexual function upon 
which to base treatment strategies. However, the lack of success of drugs such as PDE-5 
inhibitors in treating FSD highlights the inherent problems with trying to infer the function 
of one system directly from the other.
In addition, a further complication in the treatment of FSD is the multifactorial nature of 
the disorder and the greater dependence of female sexual arousal upon psychological 
stimuli. It has been found in many cases that peripheral indicators of genital arousal rarely 
con*elate to subjective feelings of sexual arousal (Laan et a l, 1995; Basson, 2002). 
However, not all FSD is psychological in origin and so a role for phannacological 
intervention remains important in the treatment of female sexual arousal disorder. Some 
drugs that have been considered include oestrogen replacement therapy, 
methyltestosterone, sildenafil, PGEi, phentolamine and apomorphine, but most therapies 
are still in the experimental stages for treatment of FSD. While the use of honnones was 
initiated largely from a secondary effect of oral contraceptives or hormone replacement 
therapy (HRT) other options, e.g. sildenafil, PGEi, phentolamine and apomorphine, have 
followed on directly from their success in males.
A greater understanding of the physiology and pharmacology of the female sexual 
response would provide a more coherent basis for the development of novel 
pharmacological therapies for the treatment of FSD.
Techniques to Study Sexual Function and Dysfunction 
Cell Cultures
Human and rabbit genital smooth muscle cells have been successfiilly cultured to provide a 
method for the investigation of biochemical and signalling pathways in both male and 
female genital tissues (Gupta et a l, 1998; Traish et a l, 1999; Sato & Kawatani, 2002). 
These cell cultures are considered to retain their metabolic functional integrity allowing the 
investigation of isolated signalling processes. Using this technique the presence of post- 
synaptic Ur, and (3-ARs in rabbit corpus cavemosum smooth muscle cells has been 
shown (Gupta et a l, 1998; Sato & Kawatani, 2002). In human and rabbit vaginal smooth
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muscle cells the action of sildenafil and zaprinast in inliibiting phosphodiesterase type 5 
activity was demonstrated. However, this method is limited in the data which it can 
provide since it includes only a single cell type.
Organ Baths
The organ bath has been used as an in vitro tool to investigate local regulatory mechanisms 
in the genital tissues. Using this technique, pharmacological responses of coipus 
cavemosum or vaginal wall strips have been investigated and this has provided the 
majority of cuiTent data on the male and female genital systems. In addition, organ baths 
can be coupled with EFS to determine responses to endogenously released transmitters, 
providing more physiologically functional infonnation. While studies have been performed 
in a variety of species, encompassing horse, human, monkey, dog, chicken, rabbit and rat, 
most data has been gained from investigations of rabbit or human genital tissues from both 
males and females.
A few studies have used the organ bath to investigate the function of isolated male genital 
vessels, but by necessity the vessels studied were from larger species since the technique is 
only suitable for vessels greater than 1 mm internal diameter. No investigators have used 
the organ bath teclinique to study isolated blood vessels from female genital tissues.
The organ bath technique has been used to demonstrate the role of VIP and NO in the 
vasodilation of human dorsal and cavernous penile arteries (Hedlund & Andersson, 1985c; 
Segarra et a l, 1999). In dorsal penile arteries from the bull, NO was shown to mediate 
NANC-induced relaxation (Liu et a l, 1991) while a combined vasodilator role of NO and 
channels was shown in the horse cavemous artery (Simonsen et a l, 1995). The 
importance of channels relative to NO-mediated vasodilations was found to be greater 
in human cavernous tissue than isolated cavemous arteries (Hedlund et a l, 1994); 
suggesting that results gained using tissue preparations may not be indicative of the 
function of isolated genital blood vessels. The same group also highlighted differences in 
the responses of human cavernous tissues and arteries to various prostanoids (PGL relaxed 
arteries but not tissues, PGEi relaxed tissues but not arteries) and adrenoceptor (AR) 
agonists (responses were mediated by ai-ARs in tissues and ui-ARs in arteries) (Hedlund 
& Andersson, 1985a, 1985b). A single study attempted to delineate the role of ai-ARs in 
the cavernous artery of the rat in an organ bath environment (Mizusawa et a l, 2002). ARs, 
endothelin and NO were also shown to be involved in active regulation of human and 
horse deep dorsal veins (Holmquist et a l, 1992; Segama et a l, 1998a; Recio et al, 2004).
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While organ baths have provided a large proportion of the current available knowledge of 
the functional pathways in genital tissues, a limitation of the method is that responses of 
isolated vessels have regularly been shown to differ from those in tissue strips. This 
indicates differences in the signal transduction pathways predominant in vascular and non- 
vascular smooth muscle and, since both muscle types are present in tissue strips, data 
gained via the organ bath method may be complicated by the presence of multiple 
pathways. A detailed study of the function of isolated genital blood vessels using a wire 
myograph should provide a more sophisticated approach to therapeutic treatments for 
sexual dysfunction.
In vivo Techniques
In vitro techniques have provided a wealth of infomiation regarding the second messenger 
pathways functionally active in genital tissues but these pathways ultimately must be also 
tested in an in vivo model where a more physiological environment is provided. In the 
investigation of sexual function, neurophysiological control of penile erection has been 
studied by stimulation of the pelvic nerve in anaesthetised animals, including dogs and 
rabbits (Andersson et a l, 1984; Vardi & Siroky, 1990; Trigo-Rocha et a l, 1993; Min et 
al, 2000). However, the pelvic nerve contains both sympathetic and parasympathetic 
fibres leading to a potentially confusing situation of mixed vasoconstrictor and vasodilator 
responses. Therefore, stimulation of cavernous and hypogastric nerves has also been used 
to study erectile responses (Holmquist et a l, 1991; Rehman et a l, 1998). The end point 
measurements that can be used in the in vivo animal model include measures of blood 
flow, luminal, wall or intracavemous pressme and dimensional measurements. Primarily, 
in vivo studies have determined the effects of drugs, such as papaverine and 
prostaglandins, on physiological indicators of sexual function in monkeys and dogs 
(Aboseif et a l, 1993; Trigo-Rocha et al., 1995) due to their larger size. However, 
techniques have now been refined such that rabbits and rats (Stief et a l, 1998; Sazova et 
al, 2002; Kim et a l, 2004) are more commonly used. A conscious animal model has also 
been developed to test potential compounds for drug development in male rabbits 
(Bischoff, 2001) and the effect of hormones in female rats (Hale et a l, 2003).
Small Vessel Wire Myography as an Experimental Tool
Small vessel wire myography is a technique developed by Mulvany & Halpem (1976) to 
study responses in isolated third order rat mesenteric arteries. Since then wire myography 
has become a well developed, reliable in vitro teclinique for the pharmacological and
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physiological characterisation of blood vessels. The wire myograph is a miniaturised 
version of an organ bath which allows investigation of the functional responses of vessels 
with an internal lumen diameter of 100 to 500 pm. Similar to larger organ baths, wire 
myography can be coupled with EFS, providing the opportunity to investigate endogenous 
factors.
In both male and female sexual function an increase in blood flow is central to the sexual 
response; making the function of blood vessels mediating this increase of gi*eat importance. 
Few investigators have previously used small vessel wire myography in the study of sexual 
function and none of these studies have involved isolated blood vessels from female 
genital tissues. Those that have used the technique, used isolated cavernous and helicine 
resistance arteries fr om larger species such as human, horse and bull to investigate genital 
vascular function. To date, studies on genital arteries in the wire myograph have primarily 
investigated vasodilator pathways. VIP, NO and sildenafil have been shown to cause 
vasodilation of human and bovine arteries (Hempelmann et a l, 1995; Simonsen et a l,
2001) while NPY caused both vasoconstriction and vasodilation (Prieto et a l, 2004). 
Endothelium-dependent relaxation was also studied in human and horse arteries (Prieto et 
a l, 1998; Angulo et a l, 2003) demonstrating that endothelium-dependent relaxation 
resulted fi'om NO release in cavemous tissue and both NO and channels in cavemous 
arteries. Similarly to studies in larger organ baths, wire myograph studies have 
demonstrated inconsistencies in the responses of isolated vessels and tissue strips.
In the current thesis, wire myogiaph and immunohistochemical teclmiques were used. This 
will add to data from cell cultures, whole tissues, in vivo systems, histological, and mRNA 
studies to provide an integrated approach to understanding the overall physiological 
system.
Rabbits as an Experimental Model
Prior to the introduction of the myograph, limitations of vessel size meant that animals 
such as the rabbit and rat could not be used to study genital blood vessels. From this 
respect, many studies have been perfomied in larger species such as horse and dog. 
However, the development of techniques and experience has led to greater use of smaller 
species such as the rabbit and rat providing, in addition, a more economic and viable 
solution. An animal showing potential for future use is the mouse, which is particularly 
attractive due to the development of genetic knockout strains, but its small size may limit 
the studies that are achievable. Initial reviews of the field of sexual function have
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concluded that both the rabbit and the rat provide systems that will help to guide future 
research in humans (Bischoff, 2001; Burnett, 2001; Min et a l, 2001; Hale et a l, 2003;
Kim et a l, 2004).
The rabbit is particularly useful since pathophysiological models for the study of sexual 
dysfunction, such as hypercholesterolaemia, diabetes and aging, can be induced. A 
disadvantage of using female rabbits is their unique endocrine physiology. Female rabbits 
remain in continuous diestrus until mounting occurs and therefore have low serum 
oestrogen levels. Therefore, the female rabbit does not provide a good system for the study 
of hormonal influences on sexual fVmction. In addition, the potency of the adrenergic 
antagonist prazosin in rabbit tissues has been demonstrated to be lower in rabbit tissues 
(Docherty, 1988; Muramatsu et a l, 1990; Naghadeh, 1996) suggesting that sensitivity of 
these tissues to adrenergic selective compounds could show species specific differences. 
While the use of animal tissue is never ideal compared to human samples the lack of 
available human tissue, in particular normal controls, makes its use inevitable. The 
relevance of data acquired from animal models must be validated where possible against 
that obtained in humans.
Male and female New Zealand White rabbits were used in the current study due to their 
multiple advantages of size, cost and comparability to previous studies. Despite the 
differences in the hormonal milieu of female rabbits, these animals were used to study 
female genital vascular function in order to provide comparable data between the sexes. In 
the cunent study no investigations were made into hormonal influences on vascular 
responses. Arteries were investigated in isolation from the in vivo environment thereby 
reducing the involvement of hoimones as far as was feasible.
Vascular R esponses In Isolated Genital Arteries 
Adrenoceptor-Mediated Responses
The involvement of ARs in genital vascular function is one of the few areas that have 
begun to be investigated in isolated male penile arteries. Using selective agonists and 
antagonists (noradrenaline, phenyleplirine, prazosin and rauwolscine) vasoconstriction of 
cavemous arteries was shown to be mediated predominantly by 02-ARs, while ai-ARs 
were shown to contribute to contraction of cavemous tissues (Hedlund & Andersson, 
1985b). In the cavernous artery of the rat, am-ARs were considered to be the predominant 
ai-AR subtype mediating noradrenaline-induced vasoconstriction (Mizusawa et a l, 2002).
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Nitric Oxide-Mediated Responses
The second area that has benefited from investigation in isolated genital arteries is the 
involvement of NO in vascular vasodilation. NO donor drugs have been shown to cause 
vasodilation in dorsal and cavemous penile arteries (Hempelmann et a l, 1995; Segarra et 
a l, 1999; Simonsen et a l, 2001), vasodilation that was increased by the PDE-5 inhibitor, 
sildenafil. The contribution of NO was investigated using selective inhibitors of NOS. In 
addition, the contribution oflL^ channels, considered to be associated with the actions of 
EDHF, were investigated using blockers of Ca^^-activated K"^  channels, e.g. apamin and 
charybdotoxin. A combination of NO and channels (EDHF-like vasodilation) mediated 
both NANC-induced relaxation in the dorsal artery (Liu et a l, 1991; Simonsen et al,
1995) and endothelium-dependent relaxation in the cavemous artery (Prieto et a l, 1998; 
Angulo et a l, 2003), while a predominance of channels (EDHF-like vasodilation) was 
suggested in the cavernous arteries (Hedlund et a l, 1994).
Peptide-Mediated Responses
An area that has received recent attention is the involvement of various peptides in the 
function of genital tissues. The contribution of some peptides, including vasoactive 
intestinal polypeptide (VIP), neuropeptide Y (NPY), substance P and vasopressin, to 
vasoconstriction and vasodilation of isolated vessels has been considered. The role of 
peptides has been investigated by determining the direct effect of these compounds on 
basal or pre-contracted tone and their effect on EFS-induced responses. Of the peptides 
tested only VIP was found to be compatible with the role of a vasodilator neurotransmitter 
(Hedlund & Andersson, 1985c). VIP-induced vasodilation was increased by sildenafil 
(Simonsen et a l, 2001) but was not found to be synergistic with NO-donor-induced 
vasodilation (Hempelmann et a l, 1995). NPY was shown to have both vasoconstrictor and 
vasodilator actions (Prieto et a l, 2004) while vasopressin also had vasoconstrictor effects 
(Segarra a/., 1998b).
A comprehensive review of the cun*ent literature in the field of adrenoceptors, NO, EDHF, 
prostaglandins and peptides in the genital tissues are provided in the relevant chapters.
Aims
In this thesis, small vessel wire myography was utilised to perform a detailed 
pharmacological analysis of isolated male and female New Zealand White rabbit genital
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arteries. The vessels chosen were the male dorsal and cavernous penile arteries. In the 
male, these vessels represented important inflow arteries to the penile tissue and were 
comparable to previous studies. The female vaginal artery was chosen for study as this 
represents the main inflow artery to vaginal tissues. No previous studies have been 
performed on any isolated arteries from female genital tissues presenting a unique 
opportunity to investigate the function of isolated vaginal arteries.
A focus of the current study was to build on preliminary findings on adrenoceptor 
pharmacology in isolated genital arteries and to define the predominant ARs. A second 
focus of the current study was to investigate the involvement of NO in neurogenic, 
endothelium-dependent and smooth muscle relaxation in both male and female genital 
arteries. In addition, the relative contributions of NO, endothelium-derived hypeipolarising 
factor (EDHF) and prostaglandins were investigated. A third focus of the cun*ent study was 
to investigate the role of peptides in neurogenic and direct vascular smooth muscle 
contraction and relaxation. The aims of the research presented herein were as follows.
• To deteimine the involvement of adrenoceptors, in particular ai- and a^-ARs, in 
vasoconstriction of male and female rabbit genital arteries. Following the 
establishment of ai-AR-mediated contractions in male penile arteries, a second aim 
was to further subtype this response.
• To investigate NO-induced vasodilator responses in male and female rabbit genital 
arteries. In addition, to characterise endothelium-dependent, direct smooth muscle 
and neurogenic NO-mediated vasodilation.
• To investigate endothelium-dependent vasodilation and determine the relative 
contributions of prostaglandins, NO and channels/EDHF in male and female 
rabbit genital arteries.
• To characterise smooth muscle and neurogenic peptide-mediated responses in 
female rabbit vaginal arteries.
• To highlight similarities or differences in the vasoconstrictor and vasodilator 
responses of male and female rabbit genital arteries.
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Isolated vaginal tissue and vaginal artery were embedded in paraffin wax, sectioned at 5 
pm thickness and mounted on polysine microscope slides in preparation for 
immunohistochemistry by J.Owen, Pfizer Global Research and Development. Vaginal 
tissue was divided distally from the vaginal opening into twelve numbered parts 
approximately 1 cm in length. Slides were prepared with two consecutive sections 
mounted on each slide to allow for control and experimental staining. The vaginal artery 
was divided into four parts and a section from each mounted on a single slide. Paraffin wax 
sections were stored at room temperature until use.
Frozen Sections
Isolated vaginal tissue was divided distally fr om the vaginal opening into nine numbered 
parts approximately 1 cm in length. Each part was snap frozen in liquid nitrogen and 
sectioned at 6  to 8 pm thickness using a cryostat (Leica CM 1900) set at -15 °C chuck 
temperature and -18 °C cryostat temperature. Two consecutive sections were mounted on 
each slide to allow for control and experimental staining. Slides were stored at -80 °C until 
use.
Techniques
Preparation of Slides for Staining
Paraffin wax sections were deparaffinised using one of two methods; either xylene, 
absolute alcohol and industrial methylated spirit (Pfizer) or tissue clear and a series of 
graded 100%, 90% and 70% alcohols (University of Glasgow) depending on location. 
Following deparaffinisation sections were fully re-hydrated in running tap water.
Frozen sections were prepared by air drying slides at room temperature before fixing in 
acetone (-20 °C). Slides were washed in phosphate buffered saline (PBS) followed by 
mnning tap water.
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Antigen Retrieval
Antigen retrieval was performed only for paraffin wax sections to improve the accessibility 
of antigens to antibodies following the wax embedding process. Re-hydrated slides were 
placed in a plastic carrying rack and dish along with a working dilution of antigen 
unmasking solution (Vector Laboratories). The solution was brought to the boil and 
simmered for either six minutes in a microwave (Pfizer) or 20 minutes in a steamer 
(University of Glasgow) depending on location. Slides were cooled in rumiing tap water.
Experimental Protocols
Sections were delineated using a hydrophobic PAP pen. To quench endogenous peroxidase 
activity paraffin wax sections were incubated for 10 minutes in peroxidase block 
(ImmunoCruz staining system - goat, Santa Cruz Biotechnology Inc.). Frozen sections 
were incubated for 30 minutes in 0.3% H2O2 in methanol to achieve an equivalent 
endogenous peroxidase block. Slides of either paraffin wax or fi'ozen sections were then 
rinsed in distilled water (dH20) followed by PBS. In some cases a step was included at this 
stage to prevent non-specific binding of secondary antibodies by incubation with protein 
block (Dako® Protein Block, semm free) for 20 minutes. Protein block was tipped off but 
slides were not rinsed prior to primary antibody incubation.
Slides were incubated with appropriately diluted primary antibodies or negative control for 
either 60 minutes at room temperatuie or overnight at 5 °C. Negative controls consisted of 
incubation with either species specific normal IgG (specific for the primary antibody 
species) where available or PBS where the correct normal IgG was unavailable. Sections 
were thoroughly rinsed in PBS prior to secondary antibody incubation. The method of 
secondary antibody incubation and staining was dependent on the required visualisation 
technique, i.e. light or fluorescence microscopy.
The majority of sections were incubated with an appropriately diluted biotinylated 
secondary antibody for 30 minutes followed by a PBS rinse. Subsequent incubation with 
HRP-streptavidin complex for 30 minutes, followed by a PBS rinse, provided an additional 
signal amplification step. Thirdly sections were incubated with peroxidase substrate 
(Vector® DAB Substrate) for 5 minutes and rinsed with dH20. Slides were counterstained 
using Vector Haematoxylin (Vector Laboratories), rinsed in tap water, 2% acetic acid 
solution, tap water a second time, incubated in Shandon Blueing Reagent (Modified Scott’s 
Tap Water) and finally rinsed in tap water for a third time. In preparation for light
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microscopy, slides were dehydrated using the appropriate re-hydration method in reverse 
and mounted using DPX and a coverslip. Sections were viewed using a light microscope. 
Positive structures were stained brown, while nuclei appeared blue.
Where sections were incubated with fluorescent-labelled secondary antibodies care was 
taken to ensure the antibody and slides were kept in dark conditions tlrroughout the 
protocol to prevent bleaching of fluorescent dyes. Sections were incubated for 30 minutes 
following which they were rinsed thoroughly in PBS followed by dH20. Slides were 
mounted using an aqueous mountant (Dako® Fluorescent Mounting Medium) and a 
coverslip. Sections were viewed using a fluorescence microscope with the appropriate 
filters for the fluorescent dye used.
A selection of slides was stained using Haematoxylin (blue nuclear stain) and Eosin (pink 
cytoplasmic stain) by J.Owen, Pfizer Global Research and Development. These slides were 
used to view the structural properties of the tissue under a light microscope.
Drugs and Solutions 
Solutions
The following solutions were used for immunohistochemical studies.
• PBS, composition (M): phosphate buffer 0.01, KCl 0.0027, NaCl 0.137, prepared 
daily using PBS tablets (Sigma®). The pH of this solution was 7.4 at 25 °C.
• Antigen Unmasking Solution (Vector Laboratories, Inc).
• Peroxidase blocking solution and donkey serum block from ImmunoCruz^ ^  
staining system, goat (Santa Cruz Biotechnology).
• Dako® Protein Block, serum-free (Dako).
Dako® Envision™ system, HRP (DAB) (Dako).
Vectastain® ABC Kit, mouse (Vector Laboratories, Inc).
Liquid DAB + Substrate Chromogen System (Vector Laboratories, Inc).
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• Haematoxylin nuclear counterstain (Vector Laboratories, Inc).
• Blueing reagent (Modified Scott’s Tap Water) (Shandon®).
• DPX (BDH/Merck®).
Primary Antibodies
Primary antibodies, used to identify nerves and endothelial cells in vaginal tissues, were 
raised in species other than the rabbit to prevent non-specific binding of secondary 
antibodies. Lists of primary antibodies, their properties and suppliers are given (Table 2-1).

















Antibody Species Mouse Goat Sheep Sheep
Supplier Biogenesis Santa Cruz SigmaAldrich Chemicon
Biotechnology Inc. International
Specificity Neuronal cell Glycoprotein Dopamine-p- Vasoactive
bodies and expressed on cell hydroxylase. intestinal
axons in the surfaces of abundant in polypeptide
CMS and PNS, monocytes, adrenergic
small nerve neutrophils, platelets neurons
fibres in PNS and some T cells
Species reactivity Human and rat Human, mouse and Human, monkey. Guinea-pig
rat bovine and rabbit
Recommended 1 :5 0 - 1:200 1:100 1:2500- 1:51
IHC Dilution
Secondary Antibodies
Secondary antibodies, selective for the appropriate primary antibody species, i.e. sheep, 
goat or mouse, were either biotin- or fluorescence-conjugated to allow visualisation of 
positive structures (Tables 2-2 and 2-3).
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Anti-Sheep IgG (H&L), 
FITC Conjugated
1:100 -  1:800
Absorption peak = 650 nm. 





1 :5 0 - 1:200
Absorption peak = 492 nm, 
Emission peak = 520 nm
Small Vessel Wire Myography
Tissues
Penile or vaginal tissues were obtained from New Zealand White rabbits (2.5-3.5 Kg) 
sacrificed by an overdose of sodium pentobarbitone (Euthatal, Rhone Merieux, UK) 
injected into the ear marginal vein. Animals were supplied by Harlan and were housed in 
the University animal holding unit. A minimum of one week was allowed between the 
arrival of animals and their use to allow acclimatisation. Gross dissection of tissue 
occurred as soon as was possible after time of euthanasia. All further tissue dissections 
were carried out in ice-cold physiological saline solution (PSS).
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Male Penile Resistance Arteries
Identification o f Suitable Vessels
An extensive review of the literature was performed to determine the most suitable genital 
blood vessels for study. Penile erection is brought about by three events; increased arterial 
inflow, relaxation of trabecular tissue and increased venous resistance. The first two of 
these processes rely on the state of vasoconstriction of the arteries supplying the penile 
tissue, making a study of genital resistance arteries worthwhile with respect to their 
importance in the erectile response. The literature review showed that in male genital tissue 
three branches of the penile artery, namely the bulbourethral, cavernous and dorsal arteries, 
compromise the blood supply to the genital tissue. The main blood supply to the penile 
tissue occurs through the cavernous artery (corpus cavernous tissue) and the dorsal artery 
(glans penis and prepuce with a secondary role supplying the coipus cavemosum). In the 
rabbit, these vessels were of a suitable size to be classified as resistance arteries, less than 
400 pm internal lumen diameter, which was to be the focus of this study.
Dissection Techniques
With the male rabbit in a supine position the skin overlying the penis was removed (Figure 
2-1). The entire penile tissue was excised from the body, up to and including a section of 
ischiocavernous muscle. In removing the penile tissues, the two corpus cavemosum were 
transected shortly after their separation into penile crura. Further dissection of penile 
arteries was performed in an agar-filled Petri dish containing ice cold PSS using a Zeiss 
dissecting microscope (Stemi 2000).
Two dorsal penile arteries, from the left and right dorsal surface of the penis, were isolated 
from beneath the overlying fascia. Lengths of each artery extending from the 
ischiocavemous muscle to a point proximal to the glans penis, approximately 1.5 cm, were 
dissected free from the penile tissue. Aiteries were pinned out and all surrounding tissue 
dissected away from the artery wall. Each artery was divided into ring segments 
approximately 2 miu in length with six or seven sections obtainable from each side. A 
single 2 cm length of 40 pm diameter wire was inserted into the lumen of each artery 
section in preparation for use on a wire myograph. The passive intemal lumen diameter of 
dorsal arteries was found to be 173.7 ± 1.1 pm (p(N) ^  155(630)).
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Corpus cavemosum tissue from the left and right sides of the dividing septum were 
isolated from penile tissue by carefully cutting around the inside edge of the tunica 
albuginea and septum. Cavemous arteries were identified within the coipus cavemosum 
tissue and all surrounding trabecular and comiective tissue carefully removed. While the 
arteries were pinned out to allow tissue removal, a length of 40 pm diameter wire was 
inserted down the entire length of each artery. This was necessary due to the convoluted 
nature and size of the cavemous artery; which meant that insertion of a wire after removal 
of the pins was more difficult and likely to cause significant damage to the vessel. Once a 
wire was successfully inserted into the vessel lumen, holding pins were removed and both 
wire and vessel cut so that each ring segment of vessel, approximately 2 mm in length, 
remained on a 2 cm length of wire. A similar number of sections as in the dorsal artery, six 
or seven, were obtainable. Cavernous arteries were generally smaller than dorsal arteries 
with a passive internal lumen diameter of 138.3 ±1.2 pm ixi(N) = 152(610)).
Arteries prepared in this way for use on a wire myograph were stored in PSS at 5 °C and 
used within 48 hours of dissection. Arteries from the left and right sides of the corpus 
cavemosum or dorsal surface and from different positions along the length of the penis 













Dorsal artery, vein & 
connective tissue
Figure 2-1: Location of the male rabbit penile arteries. A: Genital tissues in situ showing 
position of the penile dorsal arteries. B: Isolated penile tissue showing dissected dorsal and 
cavernous arteries and opened corpus cavemosum.
Female Vaginal Resistance Arteries
Idenliflcalion o f Suitable Vessels
A review of the current literature in females revealed that although female sexual arousal is 
known to be a vasocongestive and neuromuscular event (Giuliano et al., 2002) very few 
studies have been performed to investigate vaginal or clitoral anatomy and vasculature. 
Sexual stimulation in females is characterised by an increase in vaginal blood flow and 
smooth muscle relaxation as in male penile tissues. However, studies measuring increased 
vaginal blood flow have relied on techniques, such as laser Doppler flowmetry, laser 
oximetry or heated oxygen electrodes, to provide a measure of vaginal tissue perfusion. In 
an attempt to identify suitable blood vessels for isolation from vaginal tissues investigative 
dissections were carried out in collaboration with colleagues (Pfizer Global Research and 
Development) and based on anatomical illustrations (Barone, 1973; Popesko et al., 1990). 
The main vaginal artery was identified as a branch of the intemal iliac artery, which was
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traced towards the vaginal tissue and found to form a close association with the vaginal 
wall. This artery was considered to be the main blood supply for vaginal tissues and hence 
important in sexual vascular responses. The vaginal artery corresponds well to the male 
penile arteries chosen for study since both originate as branches of the intemal iliac artery.
Dissection Techniques
To remove vaginal tissues, the female rabbit was placed in a supine position. Skin 
overlying the abdomen was dissected back towards the hindlimbs and the exposed 
abdominal muscles excised down the midline towards the vaginal opening. Since the 
vagina lies beneath the symphysis pubis in this position it was necessary to remove a 
section of pelvic bone to expose the vaginal vestibule. The vaginal aitery, left and right 
branches of the intemal iliac artery, was identified and the entire vaginal tissue excised 
fi'om the animal taking care to preserve a good length of vaginal artery (Figure 2-2).
Further dissection of the vaginal artery was performed in ice-cold PSS, under a Zeiss 
dissecting microscope (Stemi 2000), in an agar-filled Petri dish.
The vaginal artery was identified prior to joining with the vaginal wall. A length of artery 
approximately 5 cm long, mnning from out with the vaginal wall to a point proximal to the 
vaginal opening, was dissected free from both left and right sides of the vaginal tissue. The 
vaginal artery branches extensively within 2 cm of the vaginal opening and as many as 
possible of these branches were included in the dissection. Surrounding tissue was 
removed from the artery walls whilst the vessels were pinned.
In the isolated vaginal artery, the point at which the vessel originally met the vaginal wall 
in situ could be identified by the presence of a single branch point neai' the beginning of 
the isolated section, followed by a significant length of vessel devoid of branches. Ring 
segments of artery approximately 2 mm in length were taken hom the vaginal artery 
proximal to this identifying branch point. These sections were referred to as the ‘extra’ 
vaginal artery (EVA) since they originated from a section of artery not closely associated 
with the vaginal wall. The passive intemal lumen diameter was found to be 270.0 ±3.5 pm 
{n(N) = 66(254)) and as such was the largest artery investigated. In preparation for wire 
myography, 40 pm diameter wires were inserted into the artery lumens and the vessels 
were stored in PSS at 5 °C and used within 48 hours of dissection.
Further ring segments of a similar length were taken from the distal end of the vaginal 
artery; at a point where the vaginal artery branches extensively. Primary branches were
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chosen for dissection and ail smaller branches removed. Ring segments were taken down 
to a point where vessel lumens became too narrow for use on a wire myograph. Due to the 
requirement to insert two 40 pm diameter wires into the artery lumen, see Vessel Mounting 
Procedure, this equated to around 90 to 100 pm intemal lumen diameter. These artery 
sections were referred to as the intra’ vaginal artery (IVA) since they were found in close 
association with the vaginal wall. The mean passive intemal lumen diameter was found to 
be 148.4 ± 1.5 pm (n(N) = 69(269)). As with the cavemous artery, the size of these vessels 
required the insertion of a length of wire into the entire artery before subsequent separation 
into approximately 2 mm lengths. This helped to prevent undue damage occurring to 
endothelial cells and vessel walls. Arteries were stored in PSS at 5 °C and were used 




Figure 2-1: Dissection of the female rabbit genital arteries. A: Isolated vaginal tissues 
showing the position of the vaginal artery (EVA and IVA). B: Isolated vaginal artery showing 
the branch point from above which the artery was termed ‘EVA’ and smaller downstream 
branches termed IVA’. C: B’ shown to scale against the Isolated rabbit vagina.
Techniques
The equipment used to carry out pharmacological evaluation of vessel function was the 
small vessel wire myograph (DMT, Aarhus, Denmark). The particular models used were 
the multi myograph 600M or 610M, which consist of a set of four baths mounted on a heat
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block set to heat the baths to 37 °C. Each bath had provision for a supply of gas and 
suction fluid removal (Figure 2-3). Within each bath a set of two detachable stainless steel 
heads were positioned to form a vice-like set of jaws. One head was attached to a 
micrometer and could be adjusted to allow alignment and application of circumferential 
tension to the vessel. The second head was attached to a force transducer measming the 
tension generated by stretch or vascular activity as force in mN. Output was transmitted via 
a myograph interface and PowerLab 4/20 data acquisition system to a computer display 
calibrated in grams force, Chart v4.1.2 (PowerLab ADInstruments Ltd, UK). Myographs 
were regularly calibrated using a two gram weight and ‘T’ bar, which exerted a force 















Figure 2-3: Top and side views of a wire myograph bath showing micrometer and 
transducer heads, gas supply and suction.
Vessel Mounting Procedure
Prior to setting up tissue, the myograph was first rinsed with dHiO and cold PSS. Each 
bath could accommodate a single 2 mm section of vessel and was filled with 5 ml of PSS. 
Prepared arteries were mounted in the baths as follows (Figure 2-4). A vessel with a single
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wire thi'ough the lumen was placed between the myograph heads and held by closing the 
jaws together. The wire was then secured to the micrometer head using two small screws. 
Once in place the heads were separated and a second 40 pm diameter wire inserted through 
the vessel lumen. In larger vessels this did not present a problem but in smaller vessels the 
potential for causing endothelial damage was more significant and care was taken to 
minimise damage. The second wire was secured to the transducer head using two small 
screws. The heads were positioned with the two wires parallel and adjacent. Excess wire 
was removed to prevent interference with gas bubbles. A Perspex lid and funnel were fitted 
to the bath to assist temperature regulation and the regular replacement of PSS. Each bath 
was bubbled with 95% O2, 5% CO2 to minimise changes in pH and maintain the viability 
of the blood vessels.
b.
Figure 2-4: Procedure for mounting a biood vessei in a wire myograph bath. a. Positioning 
of vessei with a singie wire through lumen between myograph heads using forceps, b. 
Ciosure of heads, c. Attachment to micrometer head. d. Insertion of second wire through 
iumen. e. Ciosure of heads, f. Attachment to transducer head.
Protocols
Optimal Isometric Tension
Active-tension experiments were performed to determine the optimal isometric tension for 
each vessel. Maximal contractions in response to phenylephrine (PE, 10 pM) were 
determined using a range of resting tensions fi'om zero to one gram force (Figure 2-5). 
Resting tension was set at 0.25 grams force for all experiments involving cavemous and 
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Wake-Up Protocol
Vessels were allowed to equilibrate under resting tension for 30 minutes, following which 
a reproducible maximal contraction to noradrenaline (NA, 10 pM) was determined. 
Between each addition of NA responses were allowed to plateau, given two washes over a 
period of eight to ten minutes and allowed to re-equilibrate for a further ten minutes. Each 
wash, whether during wake-up or experimental protocols, consisted of four total changes 
of PSS. The mean NA maximal contraction was used as a standard response (sighting 
response), specific for each vessel, with which to compare experimental responses. 
Endothelium integrity was confirmed by assessing the ability of acetylcholine (ACh, 3 
pM) to relax NA (10 pM) pre-contracted vessels. Vessels were allowed to equilibrate for 
30 minutes prior to the commencement of experimental protocols.
Experimental Protocols
To assess the properties of vasoconstrictor agonists, concentration response curves (CRCs) 
were constructed by cumulative addition of agonists in half log increments from 0.1 nM to 
300 pM. During the evaluation of antagonists, first curves to agonists were performed with 
an absence of antagonist in all preparations. Following a wash out period, vessels were 
incubated with antagonist (1 iiM to 100 pM) for 30 to 40 minutes prior to second agonist 
CRCs. This procedure was repeated to establish third or fourth CRCs when necessary. All 
protocols included a parallel control vessel with an absence of antagonist during each 
curve, hi some cases where a subsequent agonist cuiwe was found to be significantly 
desensitised pre-incubation of antagonists occurred before single CRCs were constmcted. 
hi this situation responses in the presence of antagonist were compared to parallel control 
vessels.
An alternative protocol was used to determine receptor subtypes involved in responses to 
the agonist UK 14,304. In this protocol a cumulative CRC to UK 14,304 (either 0.1 nM to 
30 nM or 0.1 iiM to 30 pM) was constructed in the absence of antagonists. Following the 
completion of these curves, and before responses were washed out, CRCs to antagonists 
were constructed on the backgi'ound of UK 14,304-induced vasoconstriction.
To investigate agonist-induced vasodilation tone was raised using NA. Following the 
establishment of a plateau, agonists were added cumulatively in half log increments from 
0.1 nM to 30 pM. As with contractile agonists first cui’ves were performed with an absence 
of antagonist. After a wash out period preparations were incubated with antagonists (0.001
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to 100 pM) for 30 to 40 minutes prior to second agonist CRCs. Wliere responses to 
vasoactive intestinal polypeptide (VIP) were investigated a total of two hours was allowed 
between curves to prevent desensitisation of the response, hi a parallel control vessel 
cuiwes were constmcted in the absence of antagonists.
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Electrical Field Stimulation
Techniques Additional to Small Vessel Wire Myography
To perform EPS of blood vessels, tissues were dissected and prepared for small vessel wire 
myography as previously described in this chapter. However, to allow electrical 
stimulation the stainless steel myograph heads were replaced with Perspex heads, each 
containing a stimulating electrode. The stimulating electrodes were situated alongside and 
parallel to the blood vessel. A current stimulator, model CS200 (DMT, Aarhus, Denmark) 
was used to pass a current thi'ough the vessel and cause stimulation of nerves within the 
vessel walls. The current stimulator could be programmed to generate bipolar pulses of a 
specified frequency, duration and current (Figure 2-6). The equipment could also generate 






Figure 2-6: Pulses generated by the CS200 electrical field stimulator with a bipolar output, 
pulse duration ms (a.), current mA (b.), train duration ms (c.) and train delay ms (d.)
Protocols
Dissection and setting up of tissues, application of baseline tension and wake-up protocols 
proceeded as for general wire myography (see section Small Vessel Wire Myography). 
Initial experiments were performed using varying cuiTents and frequencies to determine 
whether stimulation-induced responses could be blocked by tetrodotoxin (TTX), a Na"^  
channel blocker that blocks the conduction of nerve impulses. Following initial 
investigatory experiments stimulation parameters were set at pulse duration 0.3 ms, current 
35 mA, train duration 15 s with a delay of five minutes between trains.
Vasoconstrictor responses were investigated from baseline tone. To study vasodilator 
responses vessels were incubated with 10 pM guanethidine for 1 hour 30 minutes to
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prevent adrenergic-induced contraction. Baseline tone was raised using NA (10 pM) and 
was allowed to plateau before stimulation began. For both vasoconstrictor and vasodilator 
responses initial frequency-response curves were constructed using frequencies from 0.5 
Hz to 64 Hz increasing two-fold with each step. Following a wash out period vessels were 
incubated with an antagonist (10 nM to 100 pM) for 30 to 40 minutes prior to the 
construction of a second CRC. This was repeated for third or fourth CRCs where 
appropriate.
Data Analysis
Data was recorded using Chart v4.1.2 (PowerLab ADInstruments Ltd, UK) and analysed 
using Prism v3.0 (GraphPad Software Inc, U.S.A.) or Excel (Microsoft® Office Excel 
2003) software. Data were expressed using mean, standard error (s.e.mean) and 95% 
confidence intervals (95% Cl) where appropriate. Contractions were expressed either as 
force in grams, a percentage of the sighting response to NA (10 pM) or a percentage of the 
maximum contraction achieved during a CRC (E^ax). Vasodilations were expressed as a 
percentage relaxation from pre-contracted baseline tone. CRCs were fitted with a 
sigmoidal cui-ve of variable slope using the non-linear regression capabilities of Prism. 
Agonist responses were expressed using pECso values; the inverse log of the effective 
concentration producing 50% of maximum contraction. Where shown n indicates the 
number of animals used while N  indicates the total number of vessel sections. Data were 
compared using a one-way analysis of variance (ANOVA) with a Bonferroni post-test or a 
Student’s t-test where appropriate. Statistical significance was taken as R < 0.05.
hi cases where three or more antagonist concentrations caused a parallel shift of an agonist 
curve in the same tissue a Schild plot of log(dose ratio -  1) vs log(antagonist 
concentration) was constructed. In circumstances where linear regression of this plot gave 
a slope that was not significantly different from unity, the antagonist could be considered 
competitive and the x-intercept of this plot as an estimate of the log Kb. A pAg was 
calculated as the inverse log Ke. The pAi is defined as the inverse log of the concentration 
of antagonist required to shift an agonist response curve by two-fold compared to the 
control. Where less than three antagonist concentrations were available for analysis pKg 
values were calculated for single antagonist concentrations. The pKg is defined as the 
inverse log of the concentration of antagonist that occupies 50% of available receptors. 
Both pA2 and pKe values were used to describe receptor/dmg interactions and to allow the 
potency of antagonists to be quantified.
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Drugs and Solutions 
Solutions
PSS composition (mM): NaCl 119, KCl 4.7, CaCh 2.5, MgS0 4 -H2 0  1.2, KH2PO4 1.2, 
NaHCOs 24.9, glucose 11.1, EDTA 0.023 was prepared daily. The pH was 7.3 at room 
temperature.
Drugs
All drugs used were of analytical grade and purchased from Sigma-Aldrich™ (ACh, 
apamin, ATP, a,(3,mATP, BMY 7378, corticosterone, 5-MeU, NA, phentolamine, PE, 
prazosin, SNP, TNP-ATP), Roche Bioscience™, Palo Alto, CA (RS 100329), 
Calbiochem™ (VIP), Bachem (UK) Ltd™ (VIP, VIP (6-28)), Tocris™ (BRL 44408, 
rauwolscine, UK 14,304) or manufactured in house (Rec 15/2615, UK 343,664). Stock 
solutions were made from powder foim using de-ionised H2O (unless otherwise stated) and 
all fui-ther dilutions were made in de-ionised H2O. Some drugs required sonication to assist 
the formation of a solution, hi the preparation of ATP, solutions were tested for pH and 
found to be approximately pH 7.2 at the highest dilutions used for small vessel wire 
myography protocols.
Drugs included:
• ACh (acetylcholine): 10 mM
• ATP (adenosine 5 triphosphate disodium salt): 10 mM
• a,p,mATP (a,/3,methyleneadenosine 5 ’ triphosphate)'. 100 mM
• Apa, Apamin: 1 mM
• BMY 7378 (8-[2-[4-(2-methyoxyphenyl)-l-piperazinyl]ethyl]~8~ 
azaspirol[4,5]decane-7,9-dione dihydro-chloride)'. 1 mM
• BRL 44408 (2-[(4,5-dihydro-lH-imidazol-2-yl)methyl]-2,3-dihydro-l-methyl-lH- 
isoindole maleate)'. lOmM
• ChTX, Charybdotoxin: 100 pM
• Cocaine (cocaine hydrochloride)'. 10 mM
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Corticosterone (4-pregnene-l 1 ( ,^21 -diol-3,20-dione 21-acetate): 30 in 
physiological saline solution
Guanethidine (guanethidine sulphate): 100 mM
• Indomethacin: 10 mM in DMSO (dimethylsulphoxide)
• L-NAME (Nco-nitro-L-arginine methyl ester hydrochloride): 100 mM
• Medetomidine: 1 mM
• 5"MeU, 5-methyliu'apidil (5-methyl-6[[3-[4-(2-methoxy-phenyl)-l- 
piperaziny I] -propyl] -amino] ~1,3-dimethyl-uracil): 100 nM
• MRS 2179 (2'-Deoxy-N^-methyl adenosine 3',5'-diphosphate Diammonium salt): 1 
mM
• NA, noradrenaline ((-)-norepinephrine (+)-bitartrate salt hydrate): 100 mM in 23 
pm EDTA (diaminoethanetetraacetic acid disodium salt)
• Phentolamine (2-(N-[m-hydroxyphenyl]-p-toluidinomethyl) imidazoline): 10 mM
• PE, phenylephrine ((R)-(-)-phenylephrine hydrochloride): 100 mM
• Prazosin (1 -(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl) 
piperazine): 1 mM
• Rauwolscine (17a-Hydroxy-20a-yohimban-16/l-carboxylic acid methyl ester): 1 
mM
• Rec 15/2615 (l-(4-amino-6,7-dimethoxy-2-guinazolinil)-4-[2-[2-metoxy-6-(l- 
methylethyl)phenoxy]acetyl]piperazine hydrochloride): 1 mM in DMSO 
(dimethylsulphoxide)
• RS 100329 (N-[(2-trifluoroethoxy)phenyl],N'-(3-thyminylpropyl) piperazine 
hydrochloride): ImM
• SNP, sodium nitroprusside (sodium nitroferricyanide): 100 mM
• TNP-ATP (2',3'-0-(2,4,6-trinitrophenyl) adenosine 5 '-triphosphate monolithium 
trisodium salt): 10 mM
• UK 14,304 (5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline): 10 mM in DMSO 
(dimethylsulphoxide)
• UK 343,664: 10 mM in DMSO (dimethylsulphoxide)
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VIP, vasoactive intestinal polypeptide (vasoactive intestinal peptide acetate salt):
10 mM
VIP (6-28), VIP fragment 6-28: 1 mM
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Introduction
Adrenoceptors
Adrenoceptors (ARs) belong to the G-protein coupled receptor family. Since their initial 
conception over a century ago, following the demonstration of an adrenaline-induced 
pressor effect in 1896 by Oliver & Schafer (Rang et al., 2002), ARs have been through 
many changing definitions. After an intensive bout of scientific research in the 1980s, the 
current classification of nine, plus a potential further two, subtypes was reached (Bylund et 
a l, 1994).
The cuiTent nine AR subtypes have been characterised both pharmacologically and using 
molecular techniques. Three major classes exist, namely ai, Uz and (3, defined by their drug 
affinities, second messenger and physiological responses. Post-junctionally, cti-ARs are 
coupled to Gq/n-proteins, which cause contraction of vascular smooth muscle by activation 
of the inositol trisphosphate (IP3) pathway. Post-junctional a2-ARs may inliibit relaxation 
by coupling to Gi~proteins that in turn inhibit the adenylate cyclase (AC)/cyclic adenosine 
monophosphate (cAMP) pathway. Pre-junctionally, U2-ARs have been shown to inhibit 
release of neurotransmitters from adrenergic, cholinergic and non-adrenergic, non- 
cholinergic (NANG) nerve tenninals in penile tissues (Saenz de Tejada et a l, 1989; 
Simonsen et a l, 1997b). p-ARs are coupled to Gg-proteins and cause stimulation of the 
AC/cAMP pathway leading to smooth muscle relaxation.
Each class of AR, ai, «2 and p, has been further subdivided. The ui-ARs are divided into 
aiA, cciB and uid subtypes, the missing 1C reflects the fluxes and discrepancies arising from 
various methods of characterising and classifying ai receptors. Classification of Ui-AR 
subtypes originally included only two groups: the uia- and uib-ARs (McGrath, 1982).
Later definitions accounted for low (œil) and high (um) affinities for prazosin (Flavahan & 
Vanhoutte, 1986). The cuiTent classification into Uia, and uid subtypes includes tlu’ee 
subtypes, which all demonstrate a high affinity for prazosin, leaving the uil-AR subtype 
currently unaccounted for. Further research in the late 1990s proposed the uil-AR as a 
fourth, distinct subtype (Docheify, 1998). Flowever since the uil-AR has not been 
successfully cloned it has been suggested that the Uil-AR may represent an alternative 
affinity state of the uia-AR (Ford et a l, 1997).
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The a2-ARs are divided into U2a, ct2B and azc subtypes. While most research to detennine 
U2-AR subtypes has shown a good coiTelation between pharmacological and cloning 
methods, the only discrepancy was the a2o-AR, which has been proposed as a species 
variant of the U2A-AR found in rodents.
The P-ARs are divided into pi, p2 and p3 subtypes (reviewed by Guimaraes & Moura, 
2001). Pi-ARs are foimd in the heart where they mediate chronotropic and ionotropic 
effects. p2-ARs cause relaxation of vascular smooth muscle via stimulation of the 
AC/cAMP pathway. The third subtype, the Ps-AR, mediates lipolysis and thermogenesis in 
skeletal muscle and adipose tissue. A fourth p-AR has been proposed, the P4-AR (Bylund 
et a l, 1994; Oriowo, 1995). However, the results of this study may also be explained 
thi'ough an atypical action of a P3-AR agonist on the Pi-AR.
Adrenergic Pathways In Male Genital Tissues
Cavernous trabecular smooth muscle and penile arteries are innervated by adrenergic 
nerves (Tamura et a l, 1995). The neurotransmitter NA is released from these nerves and 
causes contraction of the smooth muscle of trabecular tissue and vasculature leading to 
detumescence of the penis. It has also been suggested that tonic sympathetic activity may 
maintain flaccidity of the penis in the resting state. Support of this theory is based on 
erections induced by injection of a-AR antagonists and the association of priapism and 
prolonged erection following treatment with ai-AR selective antagonists (Brindley, 1986; 
Saenz de Tejada et a l, 1991; Munoz et a l, 1994; Zorgniotti, 1994; Becker et a l, 1998; 
Marquer & Bressolle, 1998).
NA-induced contraction of penile erectile tissue is considered to be predominantly 
mediated by ai-ARs. Sato & Kawatani (2002) have shown that NA-induced increase in 
cytosolic Ca^ "^  concentration in rabbit corpus cavernosum cells was largely mediated by ai- 
ARs with a small decrease due to p-ARs. Expression of mRNA for aiA, uib and am 
subtypes has been demonstrated in coipus cavernosum tissue in the human (Dausse et a l , 
1998; Goepel et a l, 1999), rabbit (Peng et a l, 1998) and rat (Veronneau-Longueville et 
a l, 1998). However, Goepel et al (1999) showed that only Uia- and am-AR mRNA was 
further translated into protein with no protein expression for the am-AR detected.
Functional studies have demonstrated the presence of ai-ARs in the corpus cavernosum 
tissue of the horse (Recio et a l, 1997; Simonsen et al, 1997a), rat and dog (Sironi et a l,
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2000; Mizusawa et a i, 2002), human and rabbit (Saenz de Tejada et a l, 1989; Traish et 
a l, 1995; Furukawa et a l, 1996; Peng et a l, 1998; Sato & Kawatani, 2002). In the rabbit 
corpus cavernosum, despite showing a major mRNA expression of am-ARs, Peng et al 
(1998) attributed the main functional receptor to be the aia-AR using the selective 
antagonist 5-methylurapidil. The ai A-AR was also concluded to be the main functional AR 
in the rat coipus cavernosum by Tong & Cheng (1997) using an alternative Uia-AR 
selective antagonist, WB4101. Fuiukawa et al (1996), suggested that functional 
characteristics in the rabbit corpus cavernosum represented an am-AR response based on 
the sensitivity of PE contractions to chloroethylclonidine (CEC) and a low pA% (8.05) to 
WB4101. However, Hirasawa et al (1997) have shown that CEC is not ai-AR subtype- 
selective and, therefore, cannot be relied on as an am-AR selective antagonist as 
previously believed. Both am- (Rec 15/2841) and am-AR (Rec 15/2615) antagonists, but 
not am-AR antagonists (Rec 15/3039), have been shown to have pro-erectile properties in 
rats and dogs (Sironi et a l, 2000). In conti'ast, Mizusawa et al (2002) demonstrated that 
am-ARs had only a minor role in NA-induced contraction of rat corpus cavernosum and 
cavernous arteries with a major am-AR component based on a putative am-AR selective 
compound, A-119637. However, the concentrations of A-119637 used during the study 
could be acting at all three ai-AR subtypes (Carroll et a l, 2001).
Functional post-junctional a2-ARs have been shown to be present in rabbit trabecular 
smooth muscle cells (Gupta et a l, 1998) and in human corpus cavernosum and cavernous 
arteries (Hedlund & Andersson, 1985). Pre-junctional a2-ARs have been demonstrated in 
horse cavemosal arteries (Simonsen et a l, 1997b). hi the penile tissues, pre-j unctional a2- 
ARs are thought to modulate both adrenergic neurons, an autoregulatory function 
inhibiting further NA release (Saenz de Tejada et a l, 1989) and NANC neurons, an 
inhibition of nitric oxide (NO) release (Simonsen et al, 1997b).
Endogenous NA and adrenaline may also act at (3-ARs. The presence of functional |3-ARs 
has been demonstrated in horse corpus cavernosum (Pi- and P2-AR subtypes, Recio et a l, 
1997) and cultured rabbit corpus cavernosum cells (Sato & Kawatani, 2002). It is thought 
that the P2-AR subtype may be important in mediating relaxation of trabecular smooth 
muscle and penile arteries (Carati et a l, 1985; Simonsen et a l, 1997a). Evaluation of 
mRNA expression has shown that p-ARs are outnumbered approximately 10:1 by a-ARs 
(Levin & Wein, 1980) and, therefore, may not exert a significant vasodilator effect in 
response to NA (reviewed by Lemer et a l, 1993). However, Simonsen et al (2002) have 
suggested that p-ARs are highly sensitive to adrenaline and that elevated plasma levels of
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adrenaline during erection, demonstrated by Becker et al. (2000), may contribute to 
vasodilation of penile arteries.
Adrenergic Pathways in Female Genital Tissues
Human female vaginal tissue has been shown to be densely innervated (Hilliges et al., 
1995) and in the pig both adrenergic and cholinergic neiwes were present (Lakomy et al, 
1987). Similar to the male, sympathetic imieiwation in females originates from the 
hypogastric nerve (Liu et a l, 2001) and nervous control of sexual function is thought to be 
comparable in males and females (Giuliano et a l, 2001). However unlike males, in 
females the adrenergic agonist ephedrine, administered in vivo to activate the sympathetic 
nervous system, facilitates the initial stages of sexual arousal, demonstrated by an increase 
in both subjective and physiological sexual responses (Meston & Heiman, 1998; Meston, 
2000).
The presence of ai- and a^-ARs in female genital tissues has been demonstrated both by 
expression of mRNA (Munamz et a l, 2003) and by the action of ai- and uz-AR agonists 
and antagonists. In contrast to the reported actions of ephedrine in facilitating sexual 
arousal, the ai-AR agonist clonidine was shown to inhibit female sexual arousal (Meston et 
a l, 1997) and a non-selective a-AR antagonist, phentolamine, increased vaginal blood 
flow and pressure in rabbits in vivo (Park et a l, 1997). A comprehensive in vitro study by 
Kim et a l (2002) demonstrated functional ai- and az-ARs in rabbit vaginal and clitoral 
tissues using the non-selective antagonist phentolamine, the ai-AR selective antagonists 
prazosin, tamsulosin and Rec 15/2615 and the ai-AR antagonist delequamine. In addition, 
P-ARs have been shown to be present in vaginal and clitoral smooth muscle cell cultures 
(Traish et a l, 1999).
Alms
Significantly more data is available on adrenergic mechanisms in males than in females.
All of the major AR classes, ai, a2 and p, have been demonstrated to be present and 
functionally active within male genital tissues. However, even in this relatively well 
researched area there exist discrepancies and gaps in the cuiTent knowledge. The ai-AR 
has been attributed as the predominant AR mediating smooth muscle contraction in the 
genital tissues. However, no consensus of opinion has been reached as to the subtype/s that 
may he responsible for this action; studies exist to support each of the three candidates, 
aiA-, ctiB- and am-ARs. In addition, most cunent research has been performed in genital
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tissues with few studies considering the function of isolated genital arteries. Studies in 
whole tissues may be complicated by the presence of many, potentially conflicting, 
pathways, while the study of isolated vessels may provide additional information about 
mechanisms involved in the function of the tissue circulation.
In female genital tissues, considerably more research is required to understand the basic 
physiology and phannacology of vascular function. The involvement of the adrenergic 
system in female sexual function has been suggested but little mechanistic data has been 
acquired.
The aims of this chapter were as follows.
• To determine the involvement of a r  and a2-ARs in the function of male and female 
rabbit genital arteries.
• To subtype the ai-AR mediated response in male rabbit genital arteries.
• To compare AR mediated responses in male and female rabbit genital arteries.
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Results
Adrenergic Innervation
During this study, immunohistocheinistry techniques were used to make preliminary 
investigations into the innervation of female rabbit vaginal tissues. While it would have 
been interesting to have also carried out these studies in male penile tissues much of that 
work has been previously carried out by other investigators and constraints of time did not 
allow for it in the present study.
Pan-Neuronal Antibody
The initial primary antibody used was a mouse monoclonal antibody specific for protein 
gene product 9.5 (PGP 9.5, 1:200). PGP 9.5 is present in neuronal cell bodies and axons in 
the central and peripheral neiwous systems and in small neiwe fibres in the peripheral 
nervous system. Therefore, this antibody would be expected to bind to all neurons present 
in the tissue studied, a pan-neuronal antibody. In negative controls, primary antibody was 
omitted and replaced with normal mouse IgG.
Following primary antibody incubation, slides were stained for visualisation using the 
Dako® EnVision™ system (Dako) to label positive stmctures with horseradish peroxidase 
(HRP) followed by DAB. Using this system, negative stmctures were stained blue using a 
haematoxylin nuclear counterstain, while positive structures stained brown and were 
visualised under a light microscope. A second series of slides were stained using PGP 9.5 
primary antibody (1:200) followed by FITC conjugated secondary antibody (1:50).
Positive structures stained fluorescent green and were visualised under a fluorescence 
microscope using a HQ525/40nm (chroma technology) filter. Secondary antibodies or 
stains were included in all experimental and control slides.
During the preparation of isolated vaginal artery slides, nearby surrounding tissues and 
vessels were included in the sections. On staining these sections it could be seen that 
surrounding tissues included nerve ganglia, veins and arterioles in addition to the main 
vaginal artery. Arteries were identified by their structure, comprising a circular shape with 
thick walls and a smaller lumen (Figures 3-1 and 3-2). Veins were identified by a thiimer 
wall stmcture in addition to a collapsed circular formation and larger lumen (Figure 3-3).
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All nerve ganglia in vaginal artery sections were stained positive using PGP 9.5 and were 
numerous and in close proximity to the vaginal artery (Figure 3-1). In addition, PGP 9.5 
staining demonstrated a layer of positive neurons surroimding arteries (Figures 3-1 and 3- 
2) but not veins (Figiue 3-3). This layer, or plexus, of neurons was positioned external to 
vascular smooth muscle cells; around the media-adventitia border. Positive neiwe 
structures were also demonstrated in close proximity to arterioles (Figure 3-3). Neurons, 
ganglia and the nei*ve plexus surrounding blood vessels were additionally visualised by 
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Figure 3-1: PGP 9.5 (1:200 dilution) staining in female vaginal tissue. A: Control, B: Brown
staining positive for PGP 9.5 seen in a layer surrounding the arterial smooth muscle, close
to an arteriole and in numerous nerve ganglia. Scale bar = 100 pm.
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Figure 3-2: PGP 9.5 (1:200 dilution) staining in female vaginal tissue. A: Control, B: Brown
staining positive for PGP 9.5 seen in a layer surrounding the arterial smooth muscle, close
to an arteriole and in numerous nerve ganglia. Scale bar = 100 pm.
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Figure 3-3: PGP 9.5 (1:200 dilution) staining in female vaginal tissue. A: Control, B: Brown
staining positive for PGP 9.5 seen close to an arteriole, in nerve ganglia but not inassociation with a vein. Scale bar = 100 pm.
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Figure 3-4: PGP 9.5 (1:200 dilution) staining in female vaginal tissue. A: Control 
demonstrating autofluorescence in red blood ceils. Positive green fluorescent staining 
(FITC 1:50) demonstrating B: A plexus of nerves surrounding a blood vessel, C: A neuron
and D: A nerve ganglion.
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Adrenergic Neurons
To determine the presence or absence of adrenergic neurons in female genital tissues a 
primary sheep polyclonal antibody specific for dopamine (3-hydroxylase (D(3H, 1:1000) 
was chosen. The secondary antibody used was a donkey anti-sheep antibody conjugated to 
FITC at a concentration of 1:50, within the manufacturers’ guidelines of 1:50 to 1:200. 
Negative controls consisted of slides where the primary antibody was replaced with PBS 
since normal sheep IgG was not available. These slides were incubated with secondary 
antibody as for experimental slides. Using these antibodies, positive structures were 
stained fluorescent green and were visualised under a fluorescence microscope using a 
HQ525/40nm (cliroma technology) filter.
Positive fluorescent staining for D(3H was observed in vaginal tissue sections in an area 
surrounding arteries that was similar to the plexus of nerves visualised using PGP 9.5 
(Figure 3-5). However, no ganglia or veins within the genital tissues were observed as 
positive for DpH. A large amount of non-specific staining was obseiwed in connective 
tissues and in the endothelial layer of arteries.
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Figure 3-5: D^H (1:1000 dilution) staining the female vaginal tissue. A: Control, B: Green 
fluorescent staining (FITC 1:50) positive for DpH seen in a layer surrounding the arterial 
smooth muscle (arrow). Scale bar = 50 pm.
Chapter 3, 89
Jude S Morton, 2006
Adrenoceptor-Mediated Responses 
Noradrenaline -  Non-Selective Adrenoceptor Agonist
The non-selective AR agonist NA caused vasoconstriction of all four arterial preparations 
(Figure 3-6, Table 3-1). Maximal contractions were greatest in EVA > dorsal = IVA > 
cavernous arteries and were of magnitude EVA: 2.88 ± 0.25 g {n(N) = \2(14J), dorsal: 1.87 
± 0.12 g (ji(N) = \6(27)), IVA: 1.81 ± 0.12 g (n(N) = l\(12)) and cavernous: 1.08 ±0.11 g 
{n(N) = 1^(24)). In all arterial preparations, NA responses demonstrated similar potencies 
{P > 0.05) and Hill slopes close to unity.
Nitric Oxide Synthase Inhibition
Incubation with the nitric oxide synthase (NOS) inhibitor, Nco-nitro-L-arginine methyl 
ester hydrochloride (L-NAME, 100 pM), caused a significant increase in NA Emax in EVA 
and dorsal arteries {P < 0.05, Figure 3-7, Table 3-2). In the dorsal artery, maximal NA 
contractions were increased approximately 37% from 1.76 ± 0.32 g to 2.78 ± 0.16 g (nfTV)
= 6(6)). The increase in the EVA was of approximately 38% from 3.17 ± 0.25 g to 4.39 ± 
0.35 g {n(N) = ^(10)). In the female EVA, NA potency was significantly increased fiom 
pECso 5.86 ± 0.06 to 6.33 ± 0.14 {P < 0.01). L-NAME had no significant effect on NA- 
induced vasoconstriction in the IVA and cavernous arteries {P > 0.05).
Noradrenaline Uptake Block
Incubation with cocaine (3 pM) and corticosterone (30 pM) to block uptake 1 (neuronal 
reuptake) and uptake 2 (extra-neuronal uptake) mechanisms respectively, caused a 
significant increase in the sensitivity of all preparations to NA (Figure 3-8, Table 3-3). In 
male arteries, NA potency increased from pEC^o cavernous artery; 6.22 ± 0.14 to 7.20 ± 
0.21, (nfTV) = 5(6), P < 0.01) and dorsal artery; 5.66 ± 0.13 to 6.86 ± 0.12, (y(N) = 5(6), P < 
0.001). In female vessels, NA potency increased from pECso IVA; 5.90 ± 0.19 to 6.62 ± 
0.14, {n(N) = 6(6), P < 0.05) and EVA; 5.85 ± 0.08 to 6.67 ± 0.09, {n(N) = 5(6), P <
0.001). NA uptake blockers had no effect on overall NA Emax during a CRC in any artery 
but decreased responses to the highest concentrations in EVA and dorsal arteries {P <
0.05). At 300 pM, NA-induced vasoconstriction was decreased by 24.1 ± 9.0% (nfTV) = 5 
(6)) and 43.7 ± 14.5% (n(7V) = 6(7)) in EVA and dorsal arteries respectively.
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Figure 3-6; NA-induced vasoconstriction in the genital arteries expressed as grams tension
± s.e.mean.
Table 3-1: Comparison of NA-induced vasoconstriction between vessels.
n(N) Emax grams (s.e.mean) Hill Slope (95% Cl) pECso (s.e.mean)
Cavernous ^8(24) 1.08 (0.11) 1.22 (1.04 to 1.39) 6.27 (0.07)
Dorsal ^6(27) 1.87 (0.12) 1.23 (0.83 to 1.63) 5.92 (0.08)
IVA 11 (12) 1.81 (0.12) 1.36 (0.84 to 1.88) 5.81 (0.19)
EVA 12 (14) 2.88 (0.25) 1.33 (0.99 to 1.67) 5.94 (0.10)
Cl: confidence interval
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Alphai-Adrenoceptor-Mediated Responses 
Phenylephrine -  Alphai-Adrenoceptor Selective Agonist
All preparations responded to the Ui-AR selective agonist, PE, with concentration- 
dependent vasoconstriction (Figure 3-9, Tahle 3-4). Maximal vasoconstriction to PE 
demonstrated the equivalent order of magnitude to NA-induced vasoconstriction, namely 
EVA > dorsal = IVA > cavernous arteries. The potency of PE-induced vasoconstriction 
was similar in EVA; 5.84 ± 0.19 (nfTV) = 12(12)), IVA; 5.73 ± 0.18 (n(N) = 13(13)) and 
dorsal; 5.74 ± 0.05 (n(N) = 35(37)) arteries, while cavernous arteries; 6.28 ± 0.04 (n(N) = 
3S(39)) demonstrated a significantly greater sensitivity to PE than all other preparations {P 
< 0.001).
Vasoconstrictions to PE were reproducible with no change in potency fi'om 1®^ to 2"  ^CRCs 
in any arterial preparation (P >0.05, Figure 3-10, Table 3-5). However, IVA and dorsal 
artery preparations demonstrated a significant decrease in maximal contraction to PE of 
approximately 13% and 18% respectively on repetition of the PE CRC (P < 0.05).
Maximal responses decreased from 2.02 ± 0.07 g to 1.75 ± 0.06 g (n(N) = 7(7)) in IVA and 
1.85 ± 0.10 g to 1.52 ± 0.09 g (n(N) = 35(37)) in dorsal arteries. No decrease in Emax was 
observed from 1®^ to 2"  ^CRCs in either the EVA or cavernous arteries {P > 0.05).
Nitric Oxide Synthase Inhibition
Incubation with the NOS inhibitor L-NAME significantly increased maximal contractions 
to PE in IVA, EVA and dorsal arteries {P < 0.05), by approximately 24%, 54% and 56% 
respectively with no effect on potency {P > 0.05, Figure 3-11, Table 3-6). PE Emax 
increased in the IVA from 1.31 ± 0.23 g to 1.63 ± 0.15 g {n(N) = 6(6)), in the EVA from 
1.96 ±0.31 g to 3.02 ± 0.42 g (n(N) = 5(5)) and in the dorsal artery from 1.48 ± 0.25 g to 
2.31 ± 0.14 g (n(N) = 5(5)). PE-induced vasoconstrictions in cavernous arteries were not 
significantly affected by incubation with L-NAME {P > 0.05).
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Figure 3-9: PE-induced vasoconstriction In the genital arteries expressed as grams tension
± s.e.mean.
Table 3-4: Comparison of PE-induced vasoconstriction between vessels.
n(N) Emax grams (s.e.mean)
Emax % NA Sighting 
(s.e.mean) Hill Slope (95% Cl)
pECso
(s.e.mean)
Cavernous 38 (39) 0.97 (0.08) 102.32 (2.07) 1.28 (1.15 to 1.41) 6.28 (0.04)
Dorsal 35 (37) 1.85 (0.10) 87.64 (2.01) 1.31 (1.08 to 1.53) 5.74 (0.05)
IVA n ( 1 3 ) 1.Q9(0.15) 101.43 (8.08) 1.36 (1.28 to 1.45) 5.73 (0.18)
EVA ^2(12) 2.55 (0.23) 91.97 (4.77) 1.19 (1.07 to 1.31) 5.84 (0.19)
Cl : confidence interval
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Phentolamine -  Non-Selective Alpha-Adrenoceptor Antagonist
Phentolamine (0.001 to 1 pM), a non-selective a-AR antagonist, was tested against PE- 
induced vasoconstrictions (Figure 3-12, Table 3-7) in male penile arteries.
In the cavernous artery, vasoconstrictions were significantly antagonised by phentolamine 
{P < 0.001) resulting in a parallel rightward shift of the PE ciuwe. A mean pKe of 8.33 ± 
0.09 {n(N) = ^(18)) was calculated and a Schild plot of the data described a linear 
relationship with a slope not significantly different from unity, 0.81 ± 0.08, allowing an 
estimated pA] of 8.55, 95% Cl 8.09 to 9.12, to be calculated (Figure 3-13).
In the dorsal artery, PE-induced vasoconstrictions were significantly antagonised by 
phentolamine (0.1 to 1 pM, P < 0.001, Figure 3-12, Table 3-7). Analysis of the data gave a 
mean pKe of 8.00 ±0.16 {n(N) = 8(75j). The corresponding Schild plot demonstrated a 
slope not significantly different fi'om unity, 0,72 ± 0.19 and a pA% of 8.32, 95% Cl 7.34 to 
10.31, (Figure 3-13).
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Figure 3-12: PE-induced vasoconstriction in the maie genital arteries in the absence (• )  or 
presence of phentolamine, 1 nM (o), 10 nM (■), 100 nM (o) or 1 pM (f),expressed as a 







Figure 3-13: Schild plot of PE vs phentolamine in the maie genital arteries. Each point 
shows a single result at a given antagonist concentration. Linear regression ± 95% Ci
shown.
Table 3-7: PE-induced vasoconstriction in the absence or presence of phentolamine In the
maie genital arteries.
Dorsal
n (N) Emax grams (s.e.mean)
Emax % NA Sighting 
(s.e.mean) Hill Slope (95% Cl)
pECso
(s.e.mean)
Control 8(8) O.QO (0.13) 90.61 (5.82) 1.02 (0.87 to 1.17) 6.34  (0.08)
1 nM 8(3) 0 .90  (0.05) 78 .98  (4.51) 0 .79  (0.71 to 0.87) 6.14  (0.09)
10 nM 5(5) 0 .74  (0.14) 83 .03  (7.13) 0 .92  (0.83 to 1.00) 5.62  (0.07)
100 nM 6(6) 1.27 (0.26) 101.21 (6.78) 1.27 (1.15 to 1.38) 5.02  (0.07)
1 pM 4(4) 0 .90  (0.14) 85 .75  (7.08) 1.55 (1.35 to 1.76) 4 .3 9  (0.12)
Control 8(8) 1.39(0.20) 71 .33  (4.89) 1.19 (1.05 to 1.33) 5 .63  (0.19)
1 nM 6(7) 1.46 (0.18) 75 .36  (6.06) 1.21 (1.00 to 1.43) 5.59 (0.14)
10 nM 8(8) 1.58 (0.16) 79.92  (5.99) 0 .99  (0.85 to 1.14) 5.43  (0.16)
100 nM 8(8) 1.54 (0.27) 7 3 .27  (4.27) 1.23 (1.12 to 1.35) 4 .6 6  (0.10)
1 pM 6(7) 1.58(0.20) 6 4 .48  (6.17) 1.20 (1.11 to 1.29) 4.33  (0.09)
Cl: confidence interval
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Prazosin -  Non-Subtype-Selective Alphai-Adrenoceptor Antagonist
Prazosin (1 to 100 nM), anon-subtype-selective oi-AR antagonist, caused a parallel 
rightward shift of the PE CRC in the cavernous artery {P < 0.001, Figure 3-14, Table 3-8). 
The mean pKs was calculated to be 8.41 ±0.15 (nfTV) = 8(76)). Schild analysis 
demonstrated a slope equal to unity, 0.99 ± 0.25, allowing an estimated pA] of 8.42, 95% 
Cl 7.66 to 9.85, to be calculated (Figure 3-15).
In the dorsal artery, prazosin (10 to 100 nM) caused a significant rightward shift of the PE 
CRC {P < 0.01, Figure 3-14, Table 3-8). The mean pKp was 8.60 ± 0.16 {n(N) = 1(18)) in 
these arteries. Plotting a Schild plot of the data revealed a linear regiession with a shallow 
slope, 0.41 ±0.16. Re-analysis of calculated pKes demonstrated decreasing affinity with 
increasing concentrations of prazosin: pKe 9.34 ± 0.29 at 1 nM, 8.64 ± 0.23 at 10 nM and 
8.14 ± 0.17 at 100 nM (Figure 3-15).
In the IVA, prazosin (100 nM) significantly inhibited PE-induced vasoconstrictions (P < 
0.001, Figure 3-14, Table 3-8). The mean affinity of prazosin inhibition in these arteries 
was pKb 8.35 ± 0.11 {n(N) ^1(16)). A  Schild plot of the data showed a linear regi'ession 
with a shallow slope, 0.61 ± 0.09. Analysis of the pKeS demonstrated decreasing affinity 
with increasing concentrations of prazosin: pKe 8.85 ± 0.20 at 1 nM, 8.21 ± 0.12 at 10 nM 
and 8.05 ± 0.05 at 100 nM (Figure 3-15).
Prazosin (10 to 100 nM) significantly inhibited PE responses in the EVA {P < 0.05, Figure 
3-14, Table 3-8) with a mean pKs of 8.44 ± 0.09 (y(N) = 1(19)). Schild analysis 
demonstrated a linear regression with a slope close to unity, 0.78 ±0.10. The estimated 
pA% from this data was 8.58, 95% Cl 8.03 to 9.22 (Figure 3-15).
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R S 100329 and 5-Methylurapidil -  Alphaia-Adrenoceptor Selective Antagonists
In the cavernous arteries RS 100329 (1 to 100 nM), an uia-AR selective antagonist, 
potently inhibited PE-induced vasoconstrictions with a mean pKe of 8.80 ± 0.09 in(N) = 
6(13), Figui'e 3-16, Table 3-9). Schild analysis of the data demonstrated a linear 
relationship with a slope not significantly different from unity, 0.83 ±0.10, allowing a pA% 
estimate of 8.98, 95% Cl 8.51 to 9.61, to be calculated (Figure 3-17). A second uia-AR 
selective antagonist, 5-methylurapidil (10 to 100 nM), inhibited PE vasoconstrictions with 
variable affinity (P < 0.05, Figure 3-18, Table 3-10). The mean pKe estimate was 8.65 ± 
0.21 (nfTV) = 5(16)). A Schild plot gave a pA% of 9.07, 95% Cl 7.05 to 17.22, with a slope 
not significantly different from unity, 0.65 ± 0.26 (Figure 3-19).
PE vasoconstrictions in the dorsal ailery were significantly inhibited by RS 100329 at 10 
nM, but no further rightward shift was obseiwed at the higher concentration of 100 nM 
(Figure 3-16, Table 3-9). An estimate of the mean pKe based on 1 nM and 10 nM data was 
found to be 9.03 ± 0.07 {n(N) = 6(12)). A Schild plot of all data demonstrated a linear 
relationship with a shallow slope, 0.43 ±0.11, which was skewed by data obtained at 100 
nM. Excluding this data and re-evaluating the Schild plot resulted in a slope not 
significantly different from unity, 0.74 ± 0.11, with an apparent pA^ of 9.22, 95% Cl 8.82 
to 9.84, (Figure 3-17). Responses to PE were inhibited by 5-methylurapidil with highly 
variable affinity (Figure 3-18, Table 3-10). A mean pKs estimate was 8.45 ± 0.22 {n(N) = 
6(14)). Schild analysis of the data demonstrated a slope significantly shallower than unity, 
0.25 ± 0.17 (Figure 3-19).
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Figure 3-16: PE-induced vasoconstriction in the male genital arteries in the absence (• )  or 
presence of RS 100329,1 nM (o), 10 nM (■), or 100 nM (□) expressed as a percentage of the










Figure 3-17: Schild plot of PE vs RS 100329 in the male genital arteries. Each point shows a 
single result at a given antagonist concentration. Linear regression ± 95% Cl shown. Dorsal 
artery plot shows dotted line: linear regression on 1,10 and 100 nM data, solid line: linear
regression on 1 and 10 nM data.
Table 3-9: PE-induced vasoconstriction in the male genital arteries in the absence or
presence of RS 100329.
n(N) Emax grams (s.e.mean)
Emax % NA Sighting 
(s.e.mean) Hill Slope (95% Cl)
pECgo
(s.e.mean)
Cavernous Control Q(6) 0 .58  (0.09) 8 8 .99  (5.13) 0.95(0.92 to 0.99) 6 .15  (0.06)
1 nM 5(5) 0 .44  (0.13) 9 5 .27  (4.28) 0.70(0.63 to 0.76) 5 .66  (0.21)
10 nM s r s ; 0 .72  (0.28) 8 7 .48  (13.42) 0 .73  (0.62 to 0.84) 5.17 (0.17)
100 nM 5(5) 0 .74  (0.15) 6 8 .70  (6.16) 0 .68  (0.62 to 0.73) 4 .5 0  (0.11)
Dorsal Control 4(6) 1.54(0.11) 82.14(2.62) 1.13 (0.98 to 1.28) 5.70(0.13)
1 nM Q(6) 1.31 (0.18) 7 7 .46  (7.07) 1.03 (0.97 to 1.09) 5.36 (0.14)
10 nM 6(6) 0 .98  (0.14) 6 8 .40  (9.36) 0 .9 4  (0.85 to 1.04) 4.72 (0.15)
100 nM 6(6) 1.32 (0.27) 6 4 .99  (11.96) 0.85 (0.77 to 0.92) 4 .63  (0.14)
Cl: confidence interval
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Figure 3-18: PE-Induced vasoconstriction in the male genital arteries in the absence (• )  or 
presence of 5-methylurapidil, 1 nM (o), 10 nM (■), or 100 nM {□) expressed as a percentage 







Figure 3-19: Schild plot of PE vs 5-methylurapidil in the male genital arteries. Each point 
shows a single result at a given antagonist concentration. Linear regression ± 95% Cl is 
shown only when slope was not significantly different from unity.
Table 3-10: PE-induced vasoconstriction in the male genital arteries in the absence or
presence of 5-methylurapidil.
Dorsal
n (N) ^max grams (s.e.mean)
Emax % NA Sighting 
(s.e.mean) Hill Slope (95% Cl)
pECso
(s.e.mean)
Control 5(5) 1.03 (0.25) 9 5 .1 8 (3 .0 4 ; 1.00 (0.86 to 1.14) 6 .62  (0.26)
1 nM 5(5) 1 .1 9 (0 .3 3 ; 89 .76  (5.28) 1.07 (0.84 to 1.30) 6.16(0.16)
10 nM Q(6) 1.20 (0.18) 88 .27  (3.97) 0.81 (0.69 to 0.93) 5.90  (0.07;
100 nM 6(6) 1.26 (0.18) 97 .66  (6.94) 1.08 (0.89 to 1.27) 5 .24  (0.06)
Control 6(6) 1.78 (0.25) 7 0 .22  (6.80) 1.13 (0.98 to 1.29) 5.62 (0.24)
1 nM 6(6) 1.26 (0.23) 6 2 .28  (10.16) 1.19 (0.94 to 1.43) 5.29  (0.16)
10 nM 6(6) 1.88 (0.12) 7 5 .99  (4.06) 1.19 (0.95 to 1.42) 5.31 (0.15)
100 nM 6(6; 1.70 (0.18) 66 .92  (5.80) 0 .8 4  (0 .73  to 0.95) 4.67 (0.18)
Cl: confidence interval
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Rec 15/2615 ~ AlphaiB-Adrenoceptor Selective Antagonist
Rec 15/2615 (1 to 100 nM), an am-AR selective antagonist, did not affect PE-induced 
vasoconstriction in the cavernous arteries (P > 0.05, Figure 3-20, Table 3-11). 
Concentration ratios at 1 nM, 10 nM and 100 nM were 1.06 ± 0.47, 2.14 ± 0.72 and 3.00 ± 
2.06 (j\(N) = A(4)) respectively; demonstrating that Rec 15/2615 had no effect in these 
arteries (Figure 3-21).
In the dorsal arteries, Rec 15/2615 (1 to 100 nM) did not significantly affect PE-induced 
vasoconstriction {P > 0.05, Figure 3-20, Table 3-11). Concentration ratios were 1.03 ± 0.28 
at 1 nM, 1.50 ± 1.18 at 10 nM and 1.01 ± 0.19 at 100 nM {n(N) = 6(6), Figure 3-21).
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Figure 3-20: PE-induced vasoconstriction in the male genital arteries In the absence (• )  or 
presence of Rec 15/2615,1 nM (o), 10 nM (■), or 100 nM {□) expressed as a percentage of the
NA (10 pM) sighting response ± s.e.mean.
10 .0-1 
7 .5 - 







P 0.0oga  05-
§  -1.0- 
-1 .5- 
-2.0- log [Rec 15/2615]
Figure 3-21: Schild plot of PE vs Rec 15/2615 in the male genital arteries. Each point 
represents a single result at a given concentration. Linear regression not shown since slope
was significantly different from unity.
Table 3-11: PE-induced vasoconstriction in the male genital arteries in the absence or








n (N) Emax grams (s.e.mean)
Emax % NA Sighting 
(s.e.mean) Hill Slope (95% Cl)
pECso
(s.e.mean)
3(3) 0.69  (0.39) 73 .92  (7.38) 0.92  (0.76 to 1.08) 6.12  (0.19)
4(4) 0.78  (0.32) 7 3 .60  (10.78) 0.77  (0.61 to 0.93) 6.36  (0.18)
4(4) 0.78(0.14) 80 .30  (8.64) 0.79  (0.62 to 0.96) 5.98  (0.14)
4(4) 0.97  (0.12) 79 .75  (11.34) 0.83  (0.71 to 0.95) 5.97  (0.16)
4(4) 1.20 (0.03) 64 .08  (1.45) 1.27 (0.96 to 1.59) 5.49  (0.18)
4(4) 1.31 (0.02) 59 .78  (0.69) 1.48 (1.25 to 1.70) 5.56  (0.18)
4(4) 1.52 (0.03) 68.31 (1.50) 0 .95  (0.74 to 1.16) 5 .78  (0.28)
4(4) 1.43 (0.02) 6 9 .69  (1.31) 1.38 (1.08 to 1.68) 5.51 (0.13)
Cl: confidence interval
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BMY 7378 -  AlphttiD-Adrenoceptor Selective Antagonist
In the cavernous arteries BMY 7378 (1 to 100 nM), an aio-AR selective antagonist, caused 
no inhibition of PE-induced vasoconstriction (P > 0.05, Figure 3-22, Table 3-12). The 
concentration ratios of responses at 1 nM, 10 nM and 100 nM were 0.86 ± 0.33, 1.83 ±
0.69 and 1.30 ± 0.53 respectively (r\(N) = 6(7), Figure 3-23).
In the dorsal arteries BMY 7378(1 to 100 nM) also had no effect on PE-induced 
vasoconstriction (P > 0.05, Figure 3-22, Table 3-12) with concentration ratios at 1 nM, 10 
nM and 100 nM of 1.91 ± 0.67, 1.02 ± 0.38 and 1.30 ± 0.53 respectively (nfTV) = 6(6), 
Figure 3-23).
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Figure 3-22: PE-induced vasoconstriction in the male genital arteries in the absence (•)  or 
presence of BMY 7378,1 nM (o), 10 nM (■), or 100 nM (□) expressed as a percentage of the
NA (10 pM) sighting response ± s.e.mean.









Figure 3-23: Schild plot of PE vs BMY 7378 in the male genital arteries. Each point 
represents a single result at a given concentration. Linear regression not shown since slope
was significantly different from unity.
Table 3-12: PE-induced vasoconstriction in the male genital arteries in the absence or
presence of BMY 7378.




Control Q ( 7 ) 0.83  ( 0 .1 5 ) 88 .06  ( 1 0 .6 2 ) 0 .87  ( 0 . 7 3  to  1 .0 0 ) 6 .47  ( 0 .1 6 )
1 nM Q ( 7 ) 1.12 ( 0 .1 9 ) 85 .84  ( 1 1 .9 4 ) 0 . 7 0  ( 0 . 5 4  to  0 .8 5 ) 6 .46  ( 0 .1 6 )
10 nM 6 ( 7 ) 0.93  ( 0 .2 8 ) 6 4 . 1 7  ( 1 1 .1 7 ) 1.00 ( 0 . 8 6  to  1 .1 4 ) 6 .25  ( 0 .1 4 )
100 nM 6 ( 6 ) 0.92  ( 0 .2 3 ) 92.11 ( 6 .8 1 ) 0 .95  ( 0 . 7 6  to  1 .1 4 ) 6 .55  ( 0 .3 6 )
Control 6 ( 6 ) 1.51 ( 0 .2 4 ) 6 7 .79  ( 8 .0 4 ) 1.09 ( 0 . 9 7  to  1 .2 1 ) 5.81 ( 0 .1 4 )
1 nM 6 ( 6 ) 1.52 ( 0 .1 4 ) 6 7 .20  ( 4 .5 8 ) 1.27 ( 1 . 1 2  to  1 .4 3 ) 5 . 6 9 ( 0 . 1 5 )
10 nM 6 ( 6 ) 1.70 ( 0 .0 6 ) 7 0 .88  ( 3 .5 8 ) 1.24 ( 1 . 0 8  to  1 .3 9 ) 5.92  ( 0 .0 8 )
100 nM 6 ( 6 ) 1.64 ( 0 .1 7 ) 71.21 ( 6 .0 5 ) 1.16 ( 1 . 0 7  to  1 .2 6 ) 5.81 ( 0 .1 7 )
Cl: confidence interval
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Alpha2“Adrenoceptor-Mediated Responses 
UK 14,304 -  Alpha2-Adrenoceptor Selective Agonist
The U2-AR selective agonist UK 14,304 caused concentration-dependent vasoconstrictions 
in all four genital arterial preparations (Figure 3-24, Table 3-13). Maximal responses to 
UK 14,304 in male genital arteries were approximately 50% smaller in magnitude than 
those induced by NA or PE. Maximal vasoconstrictions were cavernous artery 0.43 ± 0.01 
g {n(N) = 24(24)) and dorsal artery 0.88 ± 0.02 g {n(N) = 16(J6)). In female genital 
arteries, contractions to UK 14,304 did not reach a plateau at the highest concentration 
used during a CRC (30 pM) precluding the calculation of a pECso. Maximal responses to 
UK 14,304 at 30 pM were TVA, 0.98 ± 0.08 g (n(N) = 6(22)) and EVA 0.92 ± 0.13 g {n(N) 
= 6(24)). Responses to UK 14,304 in all preparations demonstrated Hill slopes 
significantly shallower than unity: cavernous 0.42 ±0.17, dorsal 0.59 ± 0.29, IVA 0.48 ± 
0.15 and EVA 0.54 ±0.22.
UK 14,304 CRCs in male genital arteries were not reproducible (Figure 3-25, Table 3-14). 
While the maximal responses did not change from to 2"^  CRCs {P > 0.05), a significant 
leftward shift was observed in both cavernous and dorsal arteries demonstrating a decrease 
in sensitivity to UK 14,304 (P < 0.05). In cavernous arteries the pECso was changed by 
approximately a half log step from 7.78 ± 0.15 (n(N) = 2(4)) to 7.18 ± 0.11 {n(N) ^  2(4)), 
while in dorsal arteries the shift was gi'eater than one log step from 7.09 ± 0.28 (n(N) = 
4(6)) to 6.25 ± 0.21 (n(7V; -  4(6)).
In female arteries, although a plateau was not reached, responses were reproducible. No 
change was observed in maximal vasoconstriction to UK 14,304 at 30 pM. In the IVA, the 
pEC calculated at approximately half of the UK 14,304 non-plateaued maximal response, 
equivalent to 35% NA sighting, was not significantly different from 6.33 ± 0.72 (nfTV)
= 2(3)), to 2"^ 6.15 ± 0.05 (n(N) = 2(3)), CRCs. Similarly in the EVA, the pEC at 20% NA 
sighting was not significantly different from 5.39 ±0.18 (n(N) = 2(3)), to 2""^ , 5.04 ± 
0.68 (n(N) = 2(3)), CRCs.
Partial Agonism
In the IVA, NA (10 pM) induced tone, 1.25 ± 0.15 g (n(N) = 1(4)), was decreased by UK 
14,304 (Figure 3-26). Relaxation of NA-induced tone amounted to -0.70 ± 0.10 g (-56%) at 
30 pM UK 14,304. However, 5-hydroxytryptamine (3 pM) induced tone, 0.28 ± 0.08 g
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{n(N) = \ (4)), was not decreased by UK 14,304. In the IVA, UK 14,304 (30 pM) caused 
vasoconstriction from baseline, 0.12 ± 0.07 g {n.(N) ~ 1(4)), and from 5- 
hydroxytryptamine-induced, 0.30 ± 0.10 g {n(N) = 1(4)), tone.
Similarly, in the EVA, UK 14,304 caused relaxation of NA (10 pM) but not 5- 
hydroxytryptamine (3 pM) pre-contracted vessels (Figure 3-27). Relaxation of NA- 
induced tone, 1.53 ± 0.05 g {n(N) -  1(4)), amounted to -1.00 ± 0.12 g (-65%) at 30 pM UK 
14,304. UK 14,304 caused vasoconstriction from baseline, 0.17 ± 0.03 g (n(N) = 1(4)), and 
from 5-hydroxytryptamine-induced, 0.09 ± 0.06 g (n(N) = 1(4)), tone.
Nitric Oxide Synthase Inhibition
The NOS inhibitor L-NAME (100 pM) caused no change in the magnitude or potency of 
responses to UK 14,304 in the cavernous artery {P > 0.05, Figure 3-28, Table 3-15). In the 
dorsal artery, L-NAME significantly increased the magnitude of UK 14,304-induced 
vasoconstrictions {P < 0.05) from 0.81 ± 0.18 g to 1.78 ± 0.18 g (n(7V) = 6(6)) with no 
change in potency (P > 0.05).
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Figure 3-24: UK 14,304-lnduced vasoconstriction in the genital arteries expressed as grams
tension ± s.e.mean.
Table 3-13: Comparison of UK 14,304-induced vasoconstriction between vessels.





24(24) 0.43(0.01) 60.79 (1.39) 0.42 (0.31 to 0.53) 7.86 (0.16)
^6 (16) 0.88 (0.02) 52.26 (1.08) 0.59 (0.45 to 0.73) 7.^8 (0.07)
8(22) 0.98(0.08) 53.25 (3.88) 0.48 (0.37 to 0.58) nd
8 (24) 0.92 (0.13) 27.97 (3.53) 0.54 (0.41 to 0.67) nd
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Figure 3-26: Partial agonism of UK 14,304 relative to NA in the IVA expressed as a change in 
grams tension from NA (10 pM)-induced tone (o) or 5-hydroxytryptamine (3 pM)-induced
tone (•).
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Figure 3-27: Partial agonism of UK 14,304 relative to NA in the EVA expressed as a change 
in grams tension from NA (10 pM)~induced tone (o) or 5-hydroxytryptamine (3 pM)-induced
tone (•).
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Figure 3-28: UK 14,304-induced vasoconstriction in the maie genital arteries In the absence 
(• )  or presence (o) of L-NAME (100 pM) expressed as a percentage of the NA (10 pM)
sighting response ± s.e.mean.
Table 3-15: UK 14,304-induced vasoconstriction in the maie genital arteries in the absence
or presence of L-NAME (100 pM).
n(N) Emax grams (s.e.mean)
Emax % NA Sighting 
(s.e.mean) Hill Slope (95% Cl)
pECso
(s.e.mean)
Cavernous Control 1 ( 7 ) 0 .44  ( 0 .0 7 ) 4 7 .8 9  ( 3 .1 7 ) 0 .79  ( 0 .6 1  to  0 .9 6 ) 8 .04  ( 0 .0 6 )
L-NAME Q ( 6 ) 0 .53  ( 0 .1 3 ) 56 .29  ( 1 3 .3 4 ) 0 .72  ( 0 .5 1  to  0 .9 3 ) 8 .00  ( 0 .0 9 )
Dorsal Control 6 (5; 0.81 ( 0 .1 8 ) 52 .58  (6 .8 6 ) 1.07 ( 0 . 5 5  to  1 .6 0 ) 8 .14  ( 0 .1 0 )
L-NAME 6 (5 ; 1.78 ( 0 .1 8 ) 103 .24  ( 2 7 .1 6 ) 1 . 3 7  ( 0 . 2 7  to  2 .4 6 ) 8.01 ( 0 .1 3 )
Cl: confidence interval
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Rauwolscine -  Non-Subtype-Selective Alpha2 -Adrenoceptor Antagonist
Due to the desensitisation of control UK 14,304 curves in male arteries, a protocol was 
used whereby antagonist (0.001 to 1 pM) was added cumulatively in log steps following 
the construction of a partial (0.1 nM to 30 nM) or full (0.1 nM to 30 pM) UK 14,304 CRC.
In the cavernous artery, rauwolscine (0.001 to 1 pM) reversed UK 14,304-induced tone 
following a partial CRC (Figure 3-29, Table 3-16). However, this reversal of tone was not 
significant when compared to the loss of tone with time {P > 0.05). Rauwolscine (1 pM) 
caused 102.1 ± 3.0% (n(N) = S(6)) relaxation of UK 14,304-induced tone compared to a 
76.0 ± 10.6% (n(N) = 5(5)) loss of tone with time. In the cavernous artery, rauwolscine- 
induced relaxation following a full CRC, 64.5 ± 4.6% {n(N) = 5(5)), was not significantly 
different to the loss of tone with time, 54.0 ± 9.5% (n(N) ^  5(6), P > 0.05, Figure 3-30, 
Table 3-16).
In the dorsal artery, addition of rauwolscine (0.001 to 1 pM) following the constmction of 
a partial CRC significantly reversed UK 14,304-induced vasoconstriction; 97.3 ±6.1% 
(n(N) = 5(5)), compared to a 37.4 ± 5.3% (n(7V) = 4(6)) loss of tone with time (P < 0.001, 
Figure 3-29, Table 3-16). Rauwolscine (1 pM) did not significantly decrease UK 14,304- 
induced tone following a full CRC; 56.1 ± 9.0% (n(N) = 1(7)) compared to 52.8 ± 8.5% 
(nfTV) = 6(9)) loss of tone with time {P > 0.05, Figure 3-30, Table 3-16).
In female arteries, control UK 14,304 CRCs were reproducible allowing the traditional 
protocol of pre-incubating vessels with antagonist prior to an agonist CRC to be used.
In the IVA, rauwolscine (10 nM) did not significantly inhibit UK 14,304-induced 
vasoconstriction {P > 0.05, Figure 3-31, Table 3-17). However, a small parallel rightward 
shift of the CRC was observed from a pEC, calculated at 35% NA sighting, of 6.15 ± 0.05 
(nfTV) = 5(3)) to 5.70 ± 0.26 iri(N) = 6(6)) with a coneentration-ratio at 10 nM rauwolscine 
of 7.79 ± 2.83. The calculated pKg was 8.67 ± 0.31 (n(N) = 3(3)) suggesting that there was 
an effect of rauwolscine at this concentration.
Rauwolscine (10 nM) had no effect on UK 14,304-induced vasoconstriction in the EVA (P 
> 0.05, Figure 3-31, Table 3-17). The pEC, calculated at 20% NA sighting, was 5.74 ±
0.10 (n(N) = 4(4)), compared to control pEC 5.04 ± 0.68 (nfTV) = 6(6)), while the 
concentration-ratio was 0.92 ±0.10 (n(N) = 3(3)).
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Figure 3-29: Inhibition of a partial UK 14,304 CRC by rauwolscine, 1 nM to 1 pM, (o) 
compared to a decrease of tone with time {•) in the male genital arteries expressed as a 
percentage of a vessels own maximum ± s.e.mean.
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Figure 3-30: Inhibition of a full UK 14,304 CRC by rauwolscine, 1 nM to 1 pM, (o) compared 
to a decrease of tone with time (•)  in the male genital arteries expressed as a percentage of
a vessels’ own maximum ± s.e.mean.
Table 3-16: Maximum percentage decrease in UK 14,304 tone with time (control) or in 
response to rauwolscine, 1 nM to 1 pM, following either a full or partial UK 14,304 CRC.
Cavernous
Dorsal
UK 14,304 CRC Protocol n(N) % Maximum Relaxation (s.e.mean)
Partial Control 5(6) 76.02 (10.57)
Rauwolscine 5(5) 102.12 (3.04)
Full Control 5(7) 53.98 (9.48)
Rauwolscine 5(5) 64.46 (4.64)
Partial Control 4 (6) 37.37 (5.34)
Rauwolscine 5 (5 ) 97.28 (6.11)
Full Control 6 (9 ) 52.76 (8.53)
Rauwolscine 7 (7 ) 56.10 (8.97)
CRC: concenttration response curve
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Figure 3-31: UK 14,304-induced vasoconstriction in the female genital arteries in the 
absence (•)  or presence of rauwolscine, 10 nWI (o) expressed as a percentage of the NA (10
pM) sighting response ± s.e.mean.
Table 3-17: UK 14,304-induced vasoconstriction in the female genital arteries in the absence
or presence of rauwolscine.
n(N) Emax grams (s.e.mean)
Emax % NA Sighting 
(s.e.mean) Hill Slope (95% Cf)
IVA Control 3(3) 1.05(0.15) QQ.72 (12.15)
10 nM Q(6) 0.QQ(0.17) 47.18(15.08)




0.71 (-0.22 to 1.64) nd
0.97 (-0.13 to 2.07) nd
1.09 (0.19) 36.87 (10.15) 0.60 (-0.17 to 1.36) nd
1.15(0.35) 32.23(6.74) 1.38 (-0.03 to 2.79) nd
Cl; confidence interval, nd: not determined
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BRL 44408 ~ Alpha2 A~^drenoceptor Selective Antagonist
The subtype-selective azA-AR antagonist, BRL 44408, did not significantly reverse UK
14,304-induced tone in the cavernous artery following the construction of either a partial or 
full CRC (P > 0.05). Following the constmction of a partial CRC (Figure 3-32, Table 3- 
18), a trend was observed whereby BRL 44408 caused reversal of UK 14,304-induced 
tone; 120.2 ± 17.8% (n(N) = 1(7)) compared to a 76.0 ± 10.6% (n(N) = 5(6J) loss in the 
time control. However, due to the variability of responses in cavernous arteries to UK 
14,304 this effect was not significant. No significant effect of BRL 44408 was observed 
following the constmction of a full UK 14,304 CRC (P > 0.05, Figure 3-33, Table 3-18).
In the dorsal artery, following the constmction of a partial UK 14,304 CRC, BRL 44408 
significantly reversed UK 14,304-induced tone by 97.4 ± 7.5% (n(N) = ^(10)) compared to 
a 37.4 ± 5.3 (nfTV) = 4(6)) loss of tone with time (P < 0.01, Figure 3-32, Table 3-18). BRL 
44408 had no significant effect on UK 14,304-induced tone following a full UK 14,304 
CRC, 59.9 ± 6.8% (n(7V) =  9(10)) compared to 52.8 ± 8.5% (nfTV) = 6(9)) with time (P > 
0.05, Figure 3-33, Table 3-18).
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Figure 3-32: Inhibition of a partial UK 14,304 CRC by BRL 44408,1 nM to 1 pM, (o) compared 
to a decrease of tone with time (• )  in the male genital arteries expressed as a percentage of
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Figure 3-33: Inhibition of a full UK 14,304 CRC by BRL 44408,1 nM to 1 pM, (o) compared to 
a decrease of tone with time {•) in the male genital arteries expressed as a percentage of a
vessels own maximum ± s.e.mean.
Table 3-18: Maximum percentage decrease in UK 14,304 tone with time (control) or in 
response to BRL 44408,1 nM to 1 pM, following either a full or partial UK 14,304 CRC.
Cavernous
Dorsal
UK 14,304 CRC Protocol n(N) % Maximum Relaxation (s.e.mean)
Partial Control 5(6) 76.02(10.57)
BRL 44408 7(7) 120.15(17.82)
Full Control 5(7) 53.98(9.48)
BRL 44408 7(8) 66.93 (8.45)
Partial Control 4 (6 ) 37.37 (5.34)
BRL 44408 8(10) 97.36 (7.46)
Full Control 6(9) 52.76 (8.53)
BRL 44408 9 (10) 59.89 (6.82)
CRC: concentration response curve
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Prazosin -  Non-Subtype-Selective Alphaj-Adrenoceptor Antagonist
In the cavernous artery, addition of prazosin following the construction of a partial (Figure 
3-34, Table 3-19) or full (Figure 3-35, Table 3-19) CRC was ineffective at causing any 
significant reversal of UK 14,304-indueed tone (P > 0.05). A trend was observed following 
a full UK 14,304 curve whereby prazosin caused 78.5 ± 9.5% (n(7V) = S(5)) reversal of 
tone compared to 54.0 ± 9.5% (n(N) = 5(7)) with time.
Following the construction of a partial UK 14,304 CRC in the dorsal artery, prazosin 
demonstrated a non-significant trend towards reversal of UK 14,304 tone; 67.2 ± 6.3% 
(n(N) = 5(6)) compared to 37.4 ± 5.3% (nfTV) = 4(6)) with time (P > 0.05, Figure 3-34, 
Table 3-19). Prazosin (1 pM) significantly reversed UK 14,304-induced tone following the 
construction of a full CRC; 96.1 ± 3.3% (n(N) = 7(8)) compared to 52.8 ± 8.5% (n(N) = 
6(9)) with time (P < 0.01, Figure 3-35, Table 3-19).
In the IVA, pre-incubation with prazosin (10 nM) significantly (P < 0.05) shifted the UK
14,304-induced response from pEC, calculated at 25% NA sighting, of 6.17 ± 0.04 (n(N) = 
3(3)) to 5.01 ±0.17 (n(N) = 6(6), Figure 3-36, Table 3-20). The mean pKs was 8.98 ± 0.56. 
A combination of prazosin (10 nM) and rauwolscine (10 nM) produced a similar shift, pEC 
4.67 ± 0.27 (n(N) = 6(7), P < 0.05), while rauwolscine (10 nM) alone had no significant 
effect (see previous section, UK 14,340 vs rauwolscine).
Pre-incubation with prazosin in the EVA followed a similar pattern to that observed in the 
IVA (Figure 3-36, Table 3-20). Prazosin (10 nM) significantly shifted the UK 14,304- 
induced response from a pEC, calculated at 15% NA sighting, of 5.74 ± 0.07 {i\(N) = 4(4)) 
to 4.69 ± 0.29 {n(N) = 5(5), P < 0.05). A similar significant shift occurred using a 
combination of prazosin (10 nM) and rauwolscine (10 nM); pEC, calculated at 15% NA 
sighting, 4.46 ± 0.29 (n(N) = 5(5), P < 0.05), while 10 nM rauwolscine alone had no 
significant effect (see previous section, UK 14,340 vs rauwolscine). The mean pKe of 
prazosin in this tissue was 8.55 ± 0.05 (nfTV) = 2(2)), while that of the combination was 
8.56 ± 0.05 (y.(N) = 3(3)) and of rauwolscine alone was 6.76 (p(N) = 1(1)).
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Figure 3-34: Inhibition of a partial UK 14,304 CRC by prazosin, 1 nM to 1 pM, (o) compared to 
a decrease of tone with time (• )  in the male genital arteries expressed as a percentage of a
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Figure 3-35: Inhibition of a full UK 14,304 CRC by prazosin, 1 nM to 1 pM, (o) compared to a 
decrease of tone with time (• )  in the male genital arteries expressed as a percentage of a
vessels own maximum ± s.e.mean.
Table 3-19: Maximum percentage decrease in UK 14,304 tone with time (control) or in 
response to prazosin, 1 nM to 1 pM, following either a full or partial UK 14,304 CRC.
Cavernous
Dorsal
UK 14,304 CRC Protocol n(N) % Maximum Relaxation (s.e.mean)
Partial Control 5(6) 76.02 (10.57)
Prazosin 5(5) 65.92 (12.50)
Full Control 5(7) 53.98(9.48)
Prazosin 5(5) 78.46 (9.52)
Partial Control 4 (6 ) 37.37 (5.34)
Prazosin 5(6) 67.18 (6.25)
Full Control 6(9) 52.76 (8.53)
Prazosin 7(8) 96.09 (3.34)
CRC: concentration response curve
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Figure 3-36: UK 14,304-1nduced vasoconstriction in the femaie genital arteries in the 
absence {•) or presence of prazosin 10 nM (o), or a combination of prazosin 10 nM pius 
rauwoiscine 10 nM (□) expressed as a percentage of the NA (10 pM) sighting response ±
s.e.mean.
Tabie 3-20; UK 14,304-induced vasoconstriction in the female genital arteries in the absence 
or presence of prazosin or prazosin plus rauwoiscine.
IVA
n(N) Emax grams (s.e.mean)
Emax % NA Sighting 
(s.e.mean) Hill Slope (95% Cl)
pECso
(s.e.mean)
Control 3(3) 1.05 (0.15) 66.72 (12.15) 0.71 (-0.22 to 1.64) nd
10 nM 6(6) 0.86 (0.18) 37.18 (7.15) 0.65 (-0.31 to 1.61) nd
Prazosin + 
Rauwoiscine 6(7) 0.79 (0.18) 38.77 (10.73) 0.53 (-0.83 to 1.90) nd
Control 4(4) 1.09 (0.19) 36.87 (10.15) 0.60 (-0.17 to 1.36) nd
10 nM 6(6) 0.59 (0.28) 14.99 (5.42) 1.77 (-0.75 to 4.29) nd
Prazosin + 
Rauwoiscine 5(6) 0.62 (0.24) 18.87 (7.91) 1.50 (-3.94 to 6.93) nd
Cl: confidence interval, nd: not determined
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Medetomidine -  Alpha2-Adrenoceptor Selective Agonist
In addition to UK 14,304, a second non-subtype-selective tt2-AR agonist was tested in 
genital arterial preparations to determine if less variable results could be obtained.
Medetomidine caused concentration-dependent vasoconstriction in all genital arterial 
preparations (Figure 3-37, Table 3-21). Maximal responses to medetomidine in the male 
genital arteries, similar to UK 14,304, were approximately 50% smaller in magnitude than 
those induced by NA or PE. Medetomidine demonstrated a similar potency in male 
cavernous, pECso 6.43 ± 0.10 (n(N) = 10(34)), and dorsal arteries, pECso 6.47 ± 0.14 (n(N) 
= 9(37)) that was significantly less than UK 14,304 (P < 0.01). Responses to medetomidine 
in the female genital aiteries did not reach a plateau at the highest concentration used 
during a CRC (30 pM), similar to UK 14,304, precluding the calculation of a pECso-
Medetomidine responses were reproducible in male arteries; no change in either maximal 
response or potency was observed between and 2"^  CRCs (P > 0.05, Figure 3-38, Table 
3-22). As with UK 14,304, vasoconstrictions were smaller in magnitude than NA-induced 
vasoconstriction and were approximately 50% to 70% of NA responses. In contrast to UK 
14,304, responses to medetomidine demonstrated Hill slopes that were not significantly 
different from unity: cavernous 0.98 ± 0.21, dorsal 0.75 ± 0.18, IVA 0.89 ± 0.19 and EVA 
1.02 ±0.14.
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Figure 3-37: Medetomidlne-lnduced vasoconstriction in the genital arteries expressed as
grams tension ± s.e.mean.






N (N) Emax grams (s.e.mean)
Emax % NA S ig h t in g  
(s.e.mean) Hill Slope (95% Cl) (s.e.mean)
^0 (34) 0.55(0.06)
9 (37) 1.28 (0.11)
7(26) 1.13(0.11)
7(27) 1.39(0.10)
60 .93  (2.81) 0 .98  (0.57 to 1.40) 6.43  (0.10)
56.41 (3.81) 0 .7 5  (0.40 to 1.10) 6 .47  (0.14)
71 .20 (5.02) 0 .89  (0.51 to 1.26) nd
5 3 .05  (2.99) 1.02 (0.74 to 1.30) nd
Cl: confidence intei-val, nd: not determined
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Rauwoiscine -  Non-Subtype-Selective Alphuj-Adrenoceptor Antagonist
Pre-incubation with the non-subtype-selective U2-AR antagonist rauwoiscine (0.01 to 1 
pM) had no effect on responses to medetomidine in the cavernous artery {P > 0.05, Figure 
3-39, Table 3-23). Concentration ratios were 0.57 ± 0.27 {n(N) == 4(^), 0.99 ± 0.21 {n(N) = 
3(3)) and 1.32 ± 0.31 (nf7\  ^= 3(3)) at 10 nM, 100 nM and 1 pM respectively (Figure 3-40).
In the dorsal artery responses to medetomidine were significantly shifted by pre-incubation 
with rauwoiscine {P < 0.05, Figure 3-39, Table 3-23). Analysis of the data gave a mean 
PKb of 6.96 ± 0.23 (n(2V) = 5(12)). The corresponding Schild plot demonstrated a slope not 
significantly different fi’om unity, 0.56 ± 0.24 with an estimated pAz of 6.87, 95% Cl -3.29 
to 11.00 (Figure 3-40).
Rauwoiscine (10 nM) did not significantly inhibit vasoconstriction to medetomidine in the 
IVA (P > 0.05, Figure 3-39, Table 3-23). The pEC calculated at 30% NA sighting was 5.16 
± 0.38 (n(N) = 6(10)) in controls and 5.48 ± 0.31 (n(N) = 6(7)) in the presence of 
rauwoiscine (10 nM) while the concentration-ratio was 0.86 ± 0.19 (n(N) = 7(7)).
Vasoconstriction to medetomidine in the EVA was also not affected by rauwoiscine (10 
nM, P > 0.05, Figure 3-39, Table 3-23). The pEC calculated at 30% NA sighting was 5.92 
±0.13 (n(N) = 6(10)) in controls and 5.87 ± 0,12 (n(N) = 6(6)) in the presence of 
rauwoiscine (10 nM), while in this artery the concentration-ratio was 2.86 ±1.15 (n(N) = 
6(^).
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Prazosin -  Non-Subtype-Selective Alphai-Adrenoceptor Antagonist
Prazosin (10 nM), a non-subtype-selective ai-AR antagonist, did not significantly inliibit 
medetomidine-induced vasoconstriction in cavernous arteries (P > 0.05, Figure 3-41, Table 
3-24). The concentration-ratio was 0.42 ± 0.32 (n(N) = 2(2)).
In the dorsal artery, responses to medetomidine were significantly inliibited (P < 0.01, 
Figure 3-41, Table 3-24) by prazosin (10 nM) shifting the CRC from a pECso of 6.28 ±
0.15 (n(N) = 8(75)) to 5.48 ± 0.14 {n(N) = 4(7)). The mean pKs was calculated as 8.24 ± 
0.54 (n(N) = 3(3)).
Vasoconstriction to medetomidine in the IVA was unaffected by prazosin (10 nM, P  >
0.05, Figure 3-41, Table 3-24). The pEC, calculated at 25% NA sighting, was 5.17 ± 0.37 
(n(N) = 6(10)) in control and 4.71 ± 0.32 (n(N) = 5(5) in the presence of prazosin (10 nM) 
with a concentration-ratio of 1.49 ± 0.17 (n(N) = 4(4)).
In the EVA, medetomidine-induced vasoconstriction was significantly inliibited by 
prazosin (10 nM, P  < 0.001, Figure 3-41, Table 3-24). The pEC, calculated at 25% NA 
sighting, decreased from 5.94 ±0.13 {n(N) = 6(10)) to 5.02 ± 0.06 (n(N) = 6(7)). The 
calculated mean pKe was found to be 9.00 ± 0.23 (n(7V) = 6(7)).
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E/ectrical Field Stimulation
To demonstrate the presence of physiologically functional adi*energic neurons in the 
genital tissues, small vessel wire myography was coupled with EFS. Adrenoceptor 
antagonists were tested against responses induced by electrical stimulation of endogenous 
nerves and the release of endogenous neurotransmitters.
Control Responses
To compare EFS responses in the presence or absence of inhibitors, ffequency-response 
curves were constructed to frequencies of 0.5 to 64 Hz, increasing two-fold with each step. 
EFS parameters were pulse duration 0.3 ms, current 35 mA, train duration 15 s with a 
delay of 5 minutes between trains.
TTX, a Na^ channel blocker, was tested against various EFS parameters, including 
different currents, frequencies and pulse widths. However, variable results were obseiwed 
with no experiments achieving complete abolition of EFS-induced responses by TTX (1 
pM). Following a review of the literature, it was noted that experimenters investigating 
EFS-induced responses in genital tissues from both males and females used a range of 
parameters. EFS parameters used by these investigators included frequency 0.5 to 64 Hz, 
ciUTent 35 to 75 mA or voltage 4 to 70 V, pulse width 0.1 to 1.0 ms and train duration 1 to 
120 s. In many of these experiments EFS-induced responses were abolished by TTX (0.1 
to 1 pM). The tissues studied included vaginal wall tissue, corpus cavernosum tissue, 
dorsal and cavernous arteries from species such as mouse, rat, rabbit, monkey, bull, horse 
and human (Saenz de Tejada et a l, 1988; Simonsen et a l, 1997a; Okamma et a l, 1998; 
Recio et a l, 1998; Hedlund et a l, 1999; Segarra et a l, 1999; Hedlund et a l, 2000; 
Simonsen et a l, 2001; Ziessen et a l, 2002; Prieto et a l, 2004). From this literature review 
it was concluded that a set of parameters at the lower end of the range used to obtain 
published data would be suitable for investigations in the current study. The chosen 
parameters were those previously quoted (frequency 0.5 to 64 Hz, current 35 mA, pulse 
width 0.3 ms, train duration 15 s, train delay 5 minutes) and were similar to those used by 
Prieto et al (2004) in horse cavernous arteries.
Further experiments were performed to determine the extent to which chosen EFS 
parameters could be inhibited by TTX in the genital arteries being studied. Responses to 
EFS during a frequency-response curve were inhibited, but not abolished, in all genital 
artery preparations (Figure 3-42). The magnitude of this inhibition amounted to 12.3%
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{n(N) = 1(1)), 12.5 ± 1.2% {n(N) = ?>(4)), 69.0% (n(2V; = \(1)) and 13.0 ± 2.4% {n(N) = 
2(3)) in the cavernous artery, dorsal artery, IVA and EVA respectively. Since the same 
parameters were used for both EFS-induced vasoconstriction and vasodilation and EFS- 
induced vasodilation was variable, TTX was not further tested against vasodilation 
responses.
In male and female genital artery preparations, vasoconstrictions in response to ffequency- 
response curves were found to be highly reproducible (Figures 3-43 and 3-44, Table 3-25). 
No changes were observed in the magnitude of EFS-induced vasoconstriction at any 
frequency (0.5 to 64 Hz, P > 0.05).
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Figure 3-42: EFS-induced responses in the genital arteries in the absence (a.) or presence 
(b.) of 1 pM TTX. Raw traces obtained with the EFS parameters frequency 0.5 to 64 Hz 
(arrows), current 35 mA, pulse width 0.3 ms, train duration 15 s and train delay 5 minutes.
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Figure 3-43: Frequency-response curves (arrows, 0.5 to 64 Hz) in the genital arteries, 1®* (a.) 
and 2"  ^ (b.) controls. Raw traces obtained with the EFS parameters current 35 mA, pulse 
width 0.3 ms, train duration 15 s and train delay 5 minutes.
Chapter 3, 135
CO If) (N O) (O M
(suiejB) uoisua;
(O If) (N G) <0 (O
(suiej6) uojsus;
00 if) CN O) CD CO
(su ie jB ) u o is u a ;
ï .s-
I
CO lO CN CF) CD fOT— T~ ^  O O O















































































T - CO : :
CD
CD











00 00 CD T -g  g





































































































































Jude S Morton, 2006
Adrenoceptor Inhibition
A combination of prazosin (10 nM) and rauwoiscine (10 nM), inhibitors of aj- and az-ARs 
respectively, were tested against ffequency-response curves to detennine the involvement 
of adrenergic neurons in EFS-induced responses.
In cavernous arteries, maximal vasoconstrictions were reduced by AR inliibition (prazosin 
plus rauwoiscine) by 41.8 ± 3.4% (n(N) = 4(4)) at the highest frequency, 64 Hz (Figure 3- 
45). In dorsal arteries, the reduction in maximum vasoconstriction was less, 16.2 ± 2.2% 
(n(7V) = 6(6)) at the highest frequency. Inhibition of ARs reduced EFS-induced 
vasoconstriction in IVA by 33.7 ± 4.9% (n(N) = 4(4)), and in EVA by 48.7 ± 11.4% (n(N)
= 3(3)). While responses in individual vessels were visibly decreased by adrenergic 
inhibition, statistical analysis of mean data did not prove any effects to be significant (P > 
0.05, Figure 3-46, Table 3-26).
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Figure 3-45: Frequency-response curves (arrows, 0.5 to 64 Hz) in the genital arteries In the 
absence (a.) or presence (b.) of prazosin (10 nM) pius rauwoiscine (10 nM). Raw traces 
obtained with the EFS parameters current 35 mA, pulse width 0.3 ms, train duration 15 s and
train delay 5 minutes.
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Discussion 
Adrenergic Neurons
Male erectile tissues have been extensively studied and as a result both sympathetic and 
parasympathetic pathways, including adrenergic, cholinergic and NANC neurons, have 
been demonstrated and localised to the cavernous trabecular smooth muscle and penile 
arteries (McComiell et a i, 1972; Lue et a l, 1983; Sathananthan et a l, 1991; Tamura et al, 
1995; Segarra et a l, 1998).
Female genital tissues have been far less extensively investigated and while vaginal tissue 
has been shown to be densely imiervated (Hilliges et al, 1995) and iimervation to include 
adrenergic, cholinergic neurons and NANC neurons (Lakomy et a l, 1987; Yucel et al, 
2004), few studies have been perfoimed to localise or characterise neurons within female 
genital tissues. In this study, sections of vaginal tissue and isolated vaginal artery were 
prepared for immunohistochemical analysis to further investigate innervation of these 
tissues.
Initial studies were carried out using a pan-neuronal antibody to deteimine the general 
density and location of neurons within rabbit vaginal tissues. Many nei*ve ganglia were 
observed, which is consistent with Hilliges et a l (1995) who reported a dense imiervation 
of human vaginal tissues. These neiwe ganglia are likely to be parasympathetic due to their 
location in the peripheral tissues, hr addition, this study showed nerves aiTanged in a 
plexus sun'ounding the vascular smooth muscle of larger arteries, while arterioles also 
appeared to be closely innervated. Veins, however, were lacking in any imreiwation 
indicating that vaginal veins are not directly regulated by neurogenic stimuli. This is an 
interesting point since it has been postulated that active regulation, in addition to the 
passive veno-occlusive mechanism, is responsible for decreased venous outflow during the 
erectile response in males (Kirkeby et a l, 1991; Holmquist et a l, 1992; SegaiTa et al, 
1998). However, the vaginal tissue does not act as a capacitor; unlike male penile tissues 
that retain blood to achieve rigidity. Therefore, increased vaginal blood flow may be 
adequate for sexual arousal in females without controlled venous outflow.
DpH was used in this study to determine the location of adrenergic neurons. D^H is an 
enzyme involved in catecholamine synthesis (Figure 3-47). It is present in adrenergic 
neurons and synthesises the conversion of dopamine to the neurotransmitter NA. Tyrosine 
hydroxylase, another enzyme involved in catecholamine synthesis, has previously been
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used to locate adrenergic neurons. However, tyrosine hydroxylase is common to the 
synthesis of dopamine, NA and adrenaline and will be present in additional locations 
including dopaminergic neurons. Therefore, DpiT has become more commonly used for the 











Figure 3-47; Catecholamine biosynthetic pathway.
DpH-positive staining was observed in a similar location to the nerve plexus sun’ounding 
vaginal arteries, previously demonstrated by PGP 9.5 staining. This indicates a likely 
adrenergic involvement in the vasoconstriction of vaginal arteries. DpH was not identified 
in any nerve ganglia in vaginal tissues, further confirming that these structm’es were not 
sympathetic ganglia. The presence of non-specific background staining in the endothelium 
and connective tissues of vaginal tissue could be removed by using lower concentrations of 
primary or secondary antibodies. Further experiments ar'e required to refine the technique 
and further investigate co-localisation of DpH-positive staining with PGP 9.5 to determine 
a percentage representation of sympathetic innervation.
Dense innervation of both male and female genital tissues includes adrenergic iimeiwation, 
which in this study was shown to be located in close association with genital arteries. 
Electrical stimulation of genital arterial preparations caused frequency-dependent 
vasoconstriction which could be inliibited by a combination of prazosin and rauwoiscine in 
all vessels studied. Therefore, it is likely that sympathetic adrenergic innervation, of both 
penile and vaginal arteries, has an important physiological role in the vascular function of 
genital tissues. However, while individual vasoconstriction responses could be inhibited by
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up to 69% using prazosin plus rauwoiscine, in all arteries a resistant component remained 
following AR antagonism. This suggested the presence of additional vasoconstrictor 
mechanisms.
An interesting point was that EFS-induced vasoconstriction could not be abolished by TTX 
in any arterial preparation. TTX is a powerful neurotoxin from puffer fish which prevents 
the propagation of nerve impulses along an axon by blocking Na"*" channels and would, 
therefore, be expected to abolish any nerve-induced responses. EFS parameters are 
normally chosen such that direct stimulation of the smooth muscle does not occur and it 
might be implicated that responses observed during the cuixent study were as a result of 
direct activation of arterial smooth muscle cells. However, if responses were due to direct 
smooth muscle stimulation no inhibition of EFS-induced vasoconstriction could be 
achieved by inhibition of receptors, which could only be activated by transmitter release. 
When compared to TTX inhibition, which amounted to approximately 13% in most 
arteries, adrenergic inhibition was much gi'eater, approximately 40%. In addition, 
responses gained via direct activation of smooth muscle would be expected to be longer in 
duration than the transient, EFS-induced responses observed during the current study.
TTX-resistant, EFS-induced responses were also noted in the rabbit pulmonary artery 
(Jackson et ah, 2002). The authors of this study suggested that electrical stimulation of 
blood vessels could cause direct depolarisation of nerve varicosities leading to 
neurotransmitter release, an action which would be TTX-resistant since TTX blocks only 
the conduction of an action potential. In addition, some neurons have been shown to 
contain TTX-resistant Na^ channels (Campbell, 1993; Ikeda et a l, 2005).
In summary, inhibition of EFS-induced responses by AR inhibition with prazosin and 
rauwoiscine provides a good indication of the involvement of sympathetic adrenergic 
neurotransmission in the control of genital arteries. The lack of total inhibition of EFS- 
induced responses by TTX is a phenomenon that requires further investigation to 
deteimine whether it was due to experimental method, depolarisation of nerve varicosities, 
TTX-resistant Na^ channels or Na^-independent neurotransmission. This would be a novel 
finding if indeed a TTX-resistant neiTe-mediated response could be proven. To investigate 
this area further, alternative methods could be used to either remove neurons, e.g. 
sympathetic denervation with 6-hydroxydopamine, or inliibit nerve transmission, e.g. by 
removal of Na"^  from the bathing media.
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Adrenoceptor-Mediated Mechanisms
Ail four genital arteries responded to the non-selective adrenergic agonist NA with sizable 
contractions. These responses were relatively insensitive compared to other rabbit blood 
vessels including aorta, renal vein, saphenous artery and vein, plantaris vein, ear artery and 
vein, but similar to the rabbit renal artery and vena cava (Dumi et a l, 1991 ; Naghadeh,
1996). Responses to NA were of greatest magnitude in EVA, of equivalent size in IVA and 
dorsal arteries, and smallest in cavernous arteries. This may reflect either differences in AR 
density or the relative size and stmcture of the genital arteries.
In EVA and dorsal arteries, maximal responses to NA were increased by incubation with 
the NOS inhibitor, L-NAME, suggesting that either a basal release of NO occurs in these 
arteries, that would normally oppose adrenergic contractile responses, or that NA induces 
NO release. The involvement of NO and other vasodilator mechanisms are considered in 
further detail in later chapters.
All vessels studied demonstrated up to a ten-fold increase in NA potency in the presence of 
NA uptake blockers cocaine and corticosterone, demonstrating active NA uptake 
mechanisms. Interestingly, in EVA and dorsal arteries at the highest NA concentrations (10 
to 300 pM) vasoconstrictions reached a maximum and then decreased instead of 
maintaining a plateau. In the presence of uptake blockers, NA removal from the vicinity of 
receptors was prevented, amplifying the effective NA concentration compared to the 
application of NA in the absence of uptake blockers. The explanation for the observed 
suppression of responses to supra-maximal NA concentrations may be due to a 
desensitisation of ARs in the presence of increased concentrations of NA. Alternatively, an 
increased presence of NA may act at p-ARs, reputed to be present in horse and rabbit 
penile tissues (Recio et a l, 1997; Sato & Kawatani, 2002).
These experiments demonstrated that NA responses could be increased both in sensitivity 
(all vessels) and size (EVA and dorsal arteries) using uptake blockers or NOS inhibition 
respectively. However, blockers or inliibitors were not included routinely throughout 
experimental protocols and so responses obtained to NA could be expected to be sub- 
maximal. The advantage of not routinely including these inhibitors was to avoid the use of 
a cocktail of antagonists and blockers during experimental protocols; the potential complex 
interactions of which would be unknown.
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Alphai-Adrenoceptors
To characterise adrenergic mechanisms in the genital arteries, both non-subtype- and 
subtype-selective antagonists were tested against responses to the ai-AR-selective agonist 
PE. Responses to PE were found to be similar in characteristics to NA responses and, as 
with NA, maximal PE vasoconstrictions in EVA and dorsal arteries were increased by 
incubation with L-NAME; further confirming evidence of a basal and/or AR-induced 
release of NO in these vessels. Although a minimal, approximately 13% to 18%, decrease 
in PE Emax was obseiwed between and 2"  ^control curves in IVA and dorsal arteries, no 
change in potency was observed. It was therefore considered reasonable to compare 2"^  
curves to determine the effect of antagonists on PE responses.
In male dorsal and cavernous arteries, vasoconstrictions to PE were inhibited by both 
phentolamine and prazosin, while responses in female IVA and EVA were inliibited by 
prazosin (phentolamine not tested). Prazosin would be expected to inhibit responses at all 
ai-AR subtypes with approximately ten-fold greater affinity than phentolamine (Leonard! 
et a l, 1997). However, in the dorsal artery and IVA, prazosin did not demonstrate typical 
antagonism of PE responses; affinity estimates decreased with increasing concentrations of 
prazosin and the coixesponding Schild plot demonstrated a shallow slope. Both NA and, to 
a lesser extent, PE can act at tt2-ARs. Additionally, phentolamine has been shown to inhibit 
responses at U2-ARs; receptors at which prazosin has little effect (Leonard! et a l, 1997). 
Rabbit genital tissues, specifically corpus cavernosum strips (Gupta et a l, 1998) and 
vaginal tissues (Kim et a l, 2002), have been demonstrated to possess functional U2-ARs in 
addition to ai-ARs. In the present study, antagonism of PE by prazosin in IVA and dorsal 
arteries may be complicated at higher PE concentrations where responses are due to a 
mixed receptor population of ai- and U2-ARs. At these concentrations, both ai- and U2-AR 
mediated responses would be inhibited by phentolamine but only ai-AR responses would 
be inhibited by prazosin, reducing the apparent affinity of prazosin in these tissues. 
Naghadeh (1996) similarly demonstrated that in the rabbit saphenous vein, shown to have a 
mixed receptor population of ai- and a2-ARs (Daly et a l, 1988a; Naghadeh, 1996), PE 
responses were inliibited by prazosin with a low pA2 of 8 . The presence of functional (%2- 
ARs in the genital arteries is discussed in more detail in later sections.
Prazosin inhibition in EVA and cavernous arteries was, however, more straightforward and 
demonstrated parallel shifts of CRCs with pKgS of 8.44 and 8.41 respectively. These 
affinities are relatively low for prazosin, which normally demonstrates subnanomolar
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affinities at ai-ARs (Hieble et a l, 1995). However, low affinity estimates for prazosin have 
been demonstrated in other rabbit tissues (Daly et a l, 1988b; Muramatsu et a l, 1990; Van 
der Graaf et a l, 1997; Kava et a l, 1998) and this may either represent a mixed receptor 
population, a species-specific effect or be indicative of a distinct AR subtype with a low 
affinity for prazosin (Flavahan & Vanhoutte, 1986; Ford et a l, 1997).
Alphai-Adrenoceptor Subtypes in Male Genital Arteries
To characterise ai-AR subtype/s involved in PE-induced vasoconstriction in male genital 
arteries, four subtype-selective antagonists were tested. RS 100329 and 5-methylurapidil 
are both selective for the uia-AR subtype (Hanft & Gross, 1989; Williams et a l, 1999). RS 
100329 was shown to potently inhibit PE responses in both dorsal and cavernous arteries 
with pKes of 9.03 and 8.80 respectively. Responses in the dorsal artery were atypical in 
that PE-induced vasoconstriction was not further inhibited by the highest concentration of 
RS 100329 (100 nM). This may represent a maximum rightward shift of the PE curve; at 
this point the pECso was 4.63 ± 0.14. At high concentrations of agonist, selectivity may be 
reduced; as previously mentioned PE may act at both ai- and a 2-ARs and it may equally 
be possible for non-AR mediated responses to occur. Further support for this hypothesis 
was demonstrated by the failure of any antagonist used during the study to shift the dorsal 
PE curve significantly further to the right; 1 pM phentolamine pECso 4.33 ± 0.09, 100 nM 
prazosin pECso 4.40 ± 0.08, 100 nM 5-methylurapidil pECso 4.67 ±0.18.
PE-induced vasoconstriction in the presence of 5-methylurapidil was found to be highly 
variable, particularly in the dorsal artery. Despite this variability, in the cavernous artery 
PE responses were shown to be significantly inhibited by 5-methylurapidil with a pKs of 
8.65. This further confirmed evidence, indicated by RS 100329 inhibition of PE-induced 
vasoconstriction, of the presence of functional uia-ARs in the cavernous arteries. The 
variability of 5-methylurapidil data in the dorsal artery prevented calculation of a pA2 but 
an estimated pKs of 8.45 ± 0.22 was deteiinined. Taken together, results for both 5- 
methylurapidil and RS 100329 confirmed the presence of functional ai a-ARs in both 
dorsal and cavernous male penile arteries. In addition, vessels from various species, 
including rabbit, rat, dog and human, have demonstrated a relative insensitivity to NA (pA2 
5.7 to 6 .8) in tissues possessing the Uia-AR subtype compared to those with either the am­
or aiD-AR subtypes (pA2 7.1 to 8.4) (Buckner et a l, 1996; Smith et a l, 1997; Ai'gyle & 
McGrath, 2000; Jarajapu et a l, 2001; Deighan et a l, 2005; Hosoda et a l, 2005). The 
relative insensitivity to NA, previously mentioned, in all arterial preparations would 
provide further support for the presence of the qia-AR subtype in these vessels. The
Chapter 3, 145
Jude S Morton, 2006
presence of am-ARs in erectile tissue is also supported by two studies in rabbit and rat 
corpus cavernosum tissue (Tong & Cheng, 1997; Peng et a l, 1998) and by an in vivo 
investigation of the effects of ai-AR antagonists on erections in rats and dogs (Sironi et a l,
2000). However, this is the first study to demonstrate the presence of functional am-ARs in 
isolated male genital arteries.
Two antagonists, selective for the am-AR subtype (Rec 15/2615) and the am-AR subtype 
(BMY 7378), were ineffective when tested against PE-induced vasoconstriction in both 
male arteries. Evidence for the am-AR subtype in corpus cavernosum tissue has been put 
forward only by one group (Furukawa et a l , 1996) whose results were largely based on the 
sensitivity of PE responses to CEO. However, a study by Hirasawa et al (1997) has shown 
that CEC is not subtype-selective for ai-ARs and cannot be relied on as an am-AR- 
selective antagonist as previously believed. Rec 15/2615 has been shown to be selective for 
the aiB-AR subtype (Testa et a l, 1997) and has been used in two recent in vivo studies of 
adrenoceptor pharmacology (Sironi et a l, 2000; Kim et a l, 2002) in rabbits, rats and dogs. 
The lack of effect of Rec 15/2615 in dorsal and cavernous arteries argues against an 
involvement of the am-AR subtype in these vessels.
Mizusawa et al (2002) previously proposed the am-AR as the predominant subtype in rat 
corpus cavernosum and cavernous artery but based this conclusion on a relatively untested 
antagonist. A-119637. A-119637 has been shown to possess only a small selectivity for 
aiD-ARs over am-ARs and at the concentrations used during the study, A-119637 could 
act at all three a%-AR subtypes (CaiToll et a l, 2001). The antagonist used during the 
present study, BMY 7378, is a widely used am-AR antagonist used at concentrations of 1 
nM to 100 nM; covering its known affinity at the am-AR (pKg ~ 8.7, Kermy et a l, 1995; 
Satoh et a l, 1999; Daly et a l, 2002; Tanoue et a l, 2002; Deighan et a l, 2005), while 
avoiding its affinity at the am-AR (pKs ~ 6 .6 , Lachnit et a l, 1997; Zacharia et a l, 2004; 
Deighan et a l, 2005). Since no effect on PE-induced vasoconstriction was observed over 
this concentration range it would be reasonable to conclude that the am-AR subtype is not 
a predominant functional subtype in either dorsal or cavernous penile arteries.
A Ip ha 2-A drenoceptors
All four genital arterial preparations studied responded to UK 14,304 with 
vasoconstrictions that were 28% to 61% of those induced by NA (10 pM). UK 14,304 was 
significantly more potent than NA or PE in male, but not female, arteries. Rank order of 
agonist potency was UK 14,304 > NA > PE in the cavernous and dorsal arteries and NA =
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PE = UK 14,304 in the IVA and EVA. In female arteries UK 14,304 was shown to be a 
partial agonist in comparison to NA. In these arteries, UK 14,304 caused relaxation of NA- 
induced, but not 5-hydroxytrptamine-induced, tone demonstrating that receptor occupancy 
by UK 14,304 resulted in a lesser vasoconstriction than that resulting from NA. In the male 
dorsal artery, responses to UK 14,304 were significantly increased by incubation with L- 
NAME, which was also shown for responses to both NA and PE in this artery.
Since UK 14,304 is considered to be an a2-AR-selective agonist (Turner et a l, 1985), UK
14.304-induced vasoconstriction would suggest that functional, post-junctional 02-ARs are 
present and contribute to AR mediated vasoconstriction in the genital arteries. However, 
responses to UK 14,304 in all preparations demonstrated Hill slopes that were significantly 
shallower than unity. Potential explanations for shallow Hill slopes include the activation 
of more than one receptor by the agonist in use. In this case it may be possible that while 
UK 14,304 is considered to be an (%2-AR-selective agonist, in the genital arteries being 
studied it was acting at both ai- and a2-ARs. To investigate the actions of UK 14,304 
further, both ai- and a2-AR-selective antagonists were tested against agonist responses.
In male genital arteries an alternative protocol was used to test antagonists against UK 
14,304 responses during curves. In these protocols, antagonists were added 
cumulatively following the induction of tone by a partial (0.1 nM to 30 nM) or full (0.1 nM 
to 30 pM) UK 14,304 CRC. Responses to UK 14,304 were not significantly reversed by 
the addition of rauwoiscine following the construction of a full CRC in either male penile 
artery, hiterestingly, addition of rauwoiscine following a partial CRC did affect UK
14.304-induced tone. In the dorsal and cavernous arteries, rauwoiscine completely 
abolished UK 14,304-induced tone. However, due to the poor maintenance of UK 14,304- 
induced tone in time controls, the effect of rauwoiscine in cavernous arteries was not found 
to be significant. These results suggest that at low concentrations, UK 14,304 acts at az~ 
ARs, present in both male genital arteries. At high concentrations, UK 14,304-induced 
responses were due to a mixed population of receptors, which may include both tt2- and ai- 
ARs.
In female arteries, UK 14,304 CRCs were not significantly desensitised from E‘ to 2"  ^
curves allowing pre-incubation with antagonists prior to a 2"  ^CRC. Rauwoiscine did not 
significantly affect UK 14,304-induced vasoconstriction in the IVA. However, the 
presence of U2-ARs could not be excluded since the coixesponding concentration-ratio was 
greater than one; demonstrating that rauwoiscine antagonised UK 14,304-induced
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responses in this artery. In the EVA, there was no evidence using pre-incubation with 
rauwolscine (10 nM) of an a2-AR mediated response.
A second ai-AR-selective antagonist, BRL 44408, which is claimed to be selective for the 
a2A-AR subtype (Uhlen et a l, 1995), was tested against UK 14,304-induced 
vasoconstriction in male genital arteries. Addition of BRL 44408 following the 
construction of a full CRC did not have any effect on UK 14,304 tone. However, the 
addition of BRL 44408 following a partial UK 14,304 CRC had a striking effect in dorsal 
arteries; completely abolishing UK 14,304-induced tone as previously obseiwed using the 
Œ2-AR antagonist rauwolscine. BRL 44408 also completely abolished UK 14,304 tone in 
cavernous arteries but, again, this effect was not significant due to the considerable loss of 
tone with time in these vessels. The results gained using the a2A"AR-selective antagonist 
BRL 44408 confirm those demonstrated by rauwolscine and suggest that UK 14,304 
responses in male genital arteries are mediated predominantly by a2-ARs at low 
concentrations of UK 14,304 but by a mixed receptor population at high concentrations of 
UK 14,304. In addition, since responses to low concentrations of UK 14,304 were 
completely abolished by BRL 44408, a subtype-selective antagonist, it is likely that the 02- 
AR subtype involved in these responses is the Œ2A-AR subtype.
UK 14,304 has been previously shown to be a partial agonist at am-ARs in the rat carotid 
artery by Naghadeh (1996). Therefore, to test whether responses to high concentrations of 
UK 14,304 could be mediated by a mixed receptor population involving both a2- and ot]- 
ARs, experiments were repeated using the ai-AR-selective antagonist prazosin.
Tone induced during a partial UK 14,304 CRC was not significantly reduced by prazosin 
in the cavernous artery. Following the construction of a full UK 14,304 CRC prazosin 
reduced UK 14,304-induced tone but, due to the variability of UK 14,304 responses in the 
cavernous arteries, this effect was not significant. The indication was, however, that 
prazosin may be inhibiting an ai-AR mediated response at high concentrations of UK 
14,304; a result which would complement those obtained with the a2-AR-selective 
antagonist rauwolscine.
In the dorsal artery, prazosin completely abolished UK 14,304 tone induced during a full 
CRC and showed a trend towards reversing UK 14,304 tone resulting from a partial CRC. 
This indicates that in the dorsal artery, UK 14,304-induced vasoconstrictions are mediated 
in part by ai-ARs at high concentrations of UK 14,304.
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In both female genital arteries, pre-incubation with prazosin (10 nM) significantly inhibited 
the UK 14,304 CRC. In addition, inhibition by a combination of rauwolscine (10 nM) and 
prazosin (10 nM) had no further effect than that of prazosin alone. Since the effect of pre­
incubation with rauwolscine (10 nM) alone was also non-significant, this would suggest 
that rauwolscine has no effect in either artery. Therefore, UK 14,304 responses in the 
female arteries are predominantly meditated via ai-ARs and, if functional uz-AR are 
present, their contribution is likely to be minimal.
In an attempt to clarify the adrenergic mechanisms functionally active in genital tissues, a 
second proposed ai-AR-selective agonist medetomidine (Bryant et a l, 1998) was 
investigated. This agonist caused concentration-dependent vasoconstriction in all four 
preparations and was less potent than UK 14,304 in male genital arteries. UK 14,304 
responses demonstrated shallow Hill slopes suggesting that vasoconstrictions were 
mediated by more than one receptor, however. Hill slopes of medetomidine responses were 
not significantly different from unity.
Pre-incubation with the aa-AR-selective antagonist rauwolscine was ineffective at 
inhibiting medetomidine-induced vasoconstriction in IVA, EVA and cavernous arteries. In 
the dorsal artery, medetomidine CRCs were significantly shifted to the right by 
rauwolscine. The mean pKB/pA2 of rauwolscine in the dorsal arteries was low, 6.96/6.87. 
Maximal responses to medetomidine were also significantly increased by 100 nM and 1 
pM rauwolscine (P < 0.001, n(N) = 3(3)) demonstrating that antagonism of medetomidine 
responses by rauwolscine was atypical.
Prazosin (10 nM) was also ineffective at inhibiting medetomidine-induced vasoconstriction 
in IVA and cavernous arteries. However, medetomidine-induced vasoconstriction in EVA 
and dorsal arteries was significantly inhibited by 10 nM prazosin with a pKe of 9.00 and 
8.24 respectively.
The evidence, therefore, suggests that far from being an a2-AR-selective agonist, 
medetomidine appears to mediate contractile responses in male and female genital arteries 
predominantly via the ai-AR. While responses in IVA and cavernous ai'teries were 
inhibited by neither rauwolscine nor prazosin, inliibition of responses may have been 
achieved using higher antagonist concentrations. It was clear, however, that medetomidine 
would not prove to be a more selective agonist than UK 14,304 and so this avenue of 
investigation was not pursued further.
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Physiologically, in male erectile tissues, increased sympathetic activity and concomitant 
release of NA during the flaccid state would lead to activation of ai-, and potentially 02- 
ARs, with the predominant functional receptor being the Uia-AR. Vasoconstriction of 
cavernous arteries, mediated via uia-ARs, would prevent an increased arterial inflow that 
is the first stage of an erectile response. During this study it was demonstrated that dorsal 
arteries had a lower sensitivity to NA than cavernous arteries. This difference in sensitivity 
may allow dorsal arteries to remain dilated during the flaccid state, allowing a continued 
blood supply to penile tissues when cavernous arteries are occluded by vasoconstriction.
During this study, dorsal arteries demonstrated increased basal tone and maximal 
contractions to NA, PE and UK 14,304 in the presence of L-NAME (100 pM) suggesting a 
basal or AR-induced level of NO release, an effect which was not obseiwed in cavernous 
arteries. Dorsal arteries also demonstrated a higher incidence of rhytlimic activity that may 
result from spontaneous or agonist-induced NO release. Decreased sensitivity to adrenergic 
transmitters and increased levels of NO release would provide a two-pronged approach to 
maintaining blood flow, via the dorsal arteries, to the penile tissues during the flaccid state. 
The occurrence of spontaneous activity in all genital artery preparations is considered in 
more detail in later chapters.
Little is known about the physiology of female genital tissues. However, increased vaginal 
blood flow, a marker of sexual arousal, has been previously shown to be caused by a-AR- 
selective antagonists, such as phentolamine (Park et a l, 1997). This indicates that the 
female adrenergic system may act in a similar fashion to the male adrenergic system; by 
maintaining blood vessels in a contracted state during periods of quiescence. However, 
unlike male genital tissues, where sympathetic activity has been shown to inhibit the onset 
of erection, sympathetic activity in the female has been shown to facilitate the first stages 
of sexual arousal. The vascular function of female genital tissues is, therefore, more 
complex than first anticipated and cannot be directly inferred from findings in male tissues. 
In the current study it was demonstrated that U2-ARs may be of significantly less 
importance in female than in male genital arteries, while ai-ARs appear to mediate the 
main functions of the adrenergic system in females.
Summary
In summary, evidence was found supporting the presence of functional adrenergic 
mechanisms and active NA uptake mechanisms in both male and female genital arteries. In 
male penile arteries PE responses obtained in the presence of the non-selective antagonists
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phento lamine and prazosin suggested that dorsal arteries may have a mixed receptor 
population composed of a\ - and a2-ARs. Using subtype-selective antagonists, the ai-AR 
mediated response was shown to be due to the uia-AR subtype in both dorsal and 
cavernous arteries. No evidence was found for functional am- or am-AR subtypes in these 
vessels (Tables 3-27 and 3-28).
Further investigations using the agonist UK 14,304 demonstrated that at low 
concentrations of UK 14,304, contractions in both dorsal and cavernous arteries were 
mediated by a2-ARs, while conti'actions in response to high concentrations of UK 14,304 
were mediated by a mixed population of ai- and a2-ARs. In dorsal arteries in particular, a2- 
ARs contributed significantly to adrenergic mediated vasoconstiiction. On the basis of 
BRL 44408 effects, the predominant a2-AR subtype was likely to be the a2A-AR. These 
results were further supported by the rank order of agonist potency. In the cavernous artery 
this was UK 14,304 > Medetomidine = NA = PE, demonstrating that the a2-AR agonists 
were more potent than the non-selective NA and the ai-AR-selective PE. A similar rank 
order was observed in dorsal arteries, UK 14,304 > Medetomidine > NA = PE, with the 
notable difference of both a2-AR~selective agonists being significantly more potent than 
NA; confirming the significant contribution of a2-ARs in this artery. The presence of 
functional a2-ARs in penile tissues may provide the basis for the use of yohimbine, an a2- 
AR antagonist, for over 100 years in the treatment of erectile dysfunction with variable 
results (Susset et a i, 1989; Vick et a l, 2002).
In female vaginal arteries no evidence was found to support the presence of functional ai- 
ARs in the larger EVA while a possible role for the a2-AR in the downstream IVA 
remained. Results supported the presence of functional ai-ARs although the predominant 
subtype was not investigated. The lack of a2-AR contribution to vasoconstriction in these 
vessels was reflected in the rank order of agonist potencies, which was NA = UK 14,304 = 
PE = Medetomidine in both IVA and EVA. Previously, the presence of functional ai- and 
a2-ARs has only been demonstrated by a single study in vaginal tissues (Kim et a l , 2002) 
making this study the first investigation of AR pharmacology in isolated vaginal arteries. 
The additional finding made during the current study was the lack of significance of an a2- 
AR mediated response in isolated vaginal arteries.
Over the course of experiments, both UK 14,304 and medetomidine were shown to be now- 
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Introduction
Nitric Oxide as a NANC Neurotransmitter in Genital Tissues
Since the 1970’s, when a NANC inhibitory neurotransmission was first described by 
Gillespie (1972) and Klinge & Sjostrand (1974), a large volume of work has been cairied 
out to uncover the transmitters and pathways responsible. In the following years various 
candidates, including ACh, VIP, calcitonin gene related peptide (CGRP) and pituitary 
adenylate cyclase-activating polypeptide (PACAP), among others, were investigated to 
determine the identity of the NANC neurotransmitter in male penile erection. Many studies 
indicated a role for NO: NANC relaxation was inhibited by NOS inhibitors (Gillespie et 
ah, 1989; Holmquist et a l, 1991, 1992; Raj fer et a l, 1992; Finberg et a l, 1993; Trigo- 
Rocha et a l, 1993a; Kim et a l, 1994), the NO scavenger oxyhaemoglobin (Bowman et al, 
1982; Ignano et a l, 1990; Simonsen et a l, 1995) and sulphydryl inactivating compounds 
(Liu et a l, 1994).
The functional significance of NO release in penile tissue was shown in vivo by 
administration of NO donors which increased intracavemosal pressure and caused erection 
in male monlcey, dog, cat, rat and rabbit (Trigo-Rocha et a l, 1993a, 1995; Hellstrom et a l, 
1994; Wang et a l, 1994; Bivalaqua et a l, 1999b; Champion et a l, 1999; Sazova et a l, 
2002). In vitro, NO, nitrosothiols and NO donors caused relaxation of corpus cavemosum 
strips (Heaton, 1989; Bush et a l, 1992a; Rajfer et al, 1992; Holmquist et al, 1993). In 
addition, levels of NO (Escrig et a l, 1999) and NO breakdown products nitrate and nitrite 
(Ignarro et al, 1990; Bush et a l, 1992b; Leone et al, 1994) were increased following EFS 
of corpus cavemosum tissue. NO is now widely accepted as the main inhibitory 
neurotransmitter mediating penile smooth muscle and vascular relaxation.
Female genital tissues have also been shown to be innervated by NOS immunoreactive 
neurons (Grozdanovic et a l, 1994; Majewski et a l, 1995; Hoyle et a l, 1996; Costagliola 
et a l, 1997; Uckert et a l, 2005b). In vivo, vaginal blood flow in rats, an indicator of sexual 
function, was increased by NO donors (Pacher et a l , 2003) and decreased by the NOS 
inhibitor L-NAME (Kim et a l, 2004). In female genital tissues in vitro, the NO donors 
nitroglycerin and SNP induced relaxation of human, rabbit and chicken vaginal tissue 
accompanied by an increase in cyclic guanosine monophosphate (cGMP) (Traish et a l , 
1999; Costagliola et a l, 2004; Uckert et a l, 2005a). The PDE-5 inhibitors sildenafil and 
vardenafil were also shown to cause relaxation of vaginal tissues via an increase in cGMP
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(Uckert et al., 2005a). In addition, NANC neurotransmission was inhibited by NOS 
inliibitors (Al-Hijji et a l, 2000; Ziessen et a l, 2002; Oh et a l, 2003; Costagliola et a l, 
2004; Kim et a l, 2004). However, only a partial inhibition of NANC relaxation was 
achieved in vaginal tissues. Therefore, while NO has been widely accepted to be the main 
NANC neurotransmitter in female clitoral tissue, in vaginal tissues NO is thought to have 
only a partial role (reviewed by Traish et a l, 2002 and Munaniz et a l, 2003).
Nitric Oxide Pathways
NO and citrulline are produced through the oxidation of L-arginine in a reaction catalysed 
by NOS and which requires the presence of the prosthetic gioups flavin, haem, reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) and tetrahydrobiopterin (BH4).
The reaction also requires the presence of calmodulin as a cofactor in promoting electron 
transfer (reviewed by Moore & Handy, 1997). Both constitutive isoforms of the enzyme, 
neuronal NOS (nNOS) and endothelial NOS (eNOS), have been demonstrated in penile 
erectile tissue. In addition, nNOS and eNOS have been demonstrated in female human, rat 
and rabbit vaginal tissues (Chatteijee et a l, 1996; Batra & Al-Hijji, 1998; Yoon et al, 
2001; Uckert et al, 2005b).
NO causes smooth muscle relaxation through activation of soluble guanylate cyclase 
(sGC), which catalyses the conversion of guanosine triphosphate (GTP) to cGMP, leading 
finally to a decrease in intracellular Ca^ '*' concentration and relaxation. Intracellular 
concentrations of cGMP, but not cAMP, increase in response to nitrergic stimulation and 
NO donors (Bowman & Drummond, 1984; Ignarro et a l, 1990; Mirzazadeh et a l, 1991; 
Bush et a l, 1992a; Dahiya et a l, 1993; Jeremy et al, 1997; Vanhatalo et al., 2000). 
Inhibition of sGC by methylene blue or 1H-[1,2,4] oxadiazolo [4,3,-a] quinoxalin-l-one 
(ODQ) decreased both EFS- and NO-induced relaxation in erectile tissues (Simonsen et 
al, 1995; Recio et a l, 1998; Simonsen et a l, 2001) and vaginal tissues (Ziessen et a l, 
2002; Kim et a l, 2003).
The mechanisms of signal transduction from cGMP to smooth muscle relaxation are 
cun'ently imcertain but many pathways have been suggested, which all result in a 
decreased intracellular concentration of Ca^  ^(Figure 4-1). cGMP may inliibit voltage- 
dependent Ca^  ^channels preventing entry of Ca^ "^  into the cell (Lincoln et a l, 1988; Clapp 
& Gumey, 1991). Alternative pathways involve activation of cGMP-dependent protein 
kinase (PKG, Cornwell & Lincoln, 1989). Genetic disruption of PKG in mice abolishes 
relaxation responses to EFS in corpus cavemosum tissues (Hedlund et al, 2000). PKG
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may have a number of different actions on smooth muscle cells. Voltage dependent Ca^  ^
channels may be indirectly inhibited by PKG through activation of Ca^^-sensitive K^ 
channels, leading to hyperpolarisation of the plasma membrane (Hampl et a l, 1995; 
Simonsen et a l, 1995). PKG may activate Ca^ "^  ATPase (Yoshida et a l, 1991) or the 
NaVCa^’*' exchanger (Furukawa et a l, 1991) on the plasma membrane resulting in net Ca^ "^  
efflux from the cell. Agonist-induced production of IP3 by phospholipase C may be 
inhibited by PKG (Flirata et a l, 1990), while the action of IP3 on the sarcoplasmic 
reticulum (SR) may also be inhibited by PKG phosphorylation of the SRIP3 receptor 
(Komalavilas & Lincoln, 1994). PKG may cause phosphorylation of SR phospholamban 
resulting in activation of SR Ca^  ^ATPase and uptake of Ca^  ^into the internal stores 
(Cornwell et a l, 1991; Cohen et a l, 1999). These potential pathways may not be mutually 
exclusive and may act in either an independent or synergistic mamier.
Voltage-dep’ Ca^'^-sensitive Ca^  ^ATPase NaVCa^'^ 










PLC: phospholipase 0  
NO: nitric oxide
sGC: soluble guanylate cyclase 
PKG: protein kinase G 
- : inhibition





Figure 4-1: Summary of potential NO signal transduction mechanisms in smooth muscle
cells.
The actions of cGMP are curtailed by PDE hydrolysis. Currently 11 families of PDE 
containing greater than 40 isoforms have been characterised (reviewed by Andersson,
2 0 0 1 ), of which 13 isoforms have been isolated from human corpus cavemosum tissue 
(Kuthe et a l, 2001, Figure 4-2). Of these, PDE-3A and PDE-5 A are thought to be the most 
functionally relevant isoforms in erectile tissues (Ballard et a l, 1998; Stief et a l, 1998; 
Bivalaqua et a l, 1999a; Kuthe et a l, 2000, 2001). PDE-5 inhibitors have been shown to 
increase cGMP levels in rabbit, rat and mouse corpus cavemosum (Bowman &
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Drummond, 1984; Gibson & Mirzazadeh, 1989; Mirzazadeh et a l, 1991; Jeremy et al,
1997), increase nitrergic-induced relaxation in human corpus cavemosum (Rajfer et al, 
1992; Ballard et a l, 1998) and enhance EFS-induced intracavemosal pressure increases 
(Trigo-Rocha et a l, 1993b; Boolell et a l, 1996; Bivalaqua et a l, 1999a). In female vaginal 
tissues, PDE-4, PDE-5 and PDE-10 have been demonstrated to be present (D'Amati et al, 
2002; Uckert et a l, 2005b). PDE-5 inhibitors decreased EFS-induced contractions and 
caused concentration-dependent relaxation of pre-contracted vaginal strips in vitro (Giraldi 
et a l, 2002; Uckeit et a l , 2005b). In vivo, inhibition of PDE-5 increased vaginal blood 
flow and lubrication in rats and rabbits (Min et a l, 2000; Kim et a l, 2003, 2004).
GTP A PDE-1A, 18. 1C 
cGMP PDE-2A




sGC: soluble guanylate cyclase AC: adenylate cyclase
GTP: guanosine triphosphate ATP: adenosine triphosphate
GMP: guanosine monophosphate AMP: adenosine monophosphate
cGMP: cyclic guanosine monophosphate cAMP: cyclic adenosine monophosphate
Figure 4-2: Summary of the formation and breakdown by phosphodiesterases of cGMP and 
cAMP in male erectile tissues. (Adapted from Kuthe etal., 2001).
Aims
Male and female genital tissues have been demonstrated to be abundantly innervated by 
NOS-IR neurons. Nitrergic neurons have been accepted as the main inliibitory 
neurotransmission in penile and clitoral, but not vaginal, tissues. Therefore, the aims of this 
chapter were as follows.
• To characterise responses of male and female rabbit genital ai’teries to a NO donor, 
SNP.
# To confirm the presence of functional nitrergic neurotransmission in male and 
female rabbit genital arteries.
The involvement of NO in endothelium-dependent relaxation of genital ai'teries is 
considered in detail alongside other endothelial factors in later chapters.
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Results
Nitric Oxide Mediated Responses
Noradrenaline-Induced Vasoconstriction
NA (10 |iM) was used to induce tone in all preparations. Sufficient time was allowed for 
tone to reach a stable plateau before experimental protocols were begun. Responses were 
found to be most stable in the cavemous artery. In all other preparations NA-induced 
vasoconstriction demonstrated an initial transient phase followed by a significant loss of 
tone before a sustained level was reached (P < 0.001, Figure 4-3, Table 4-1). Sustained 
tone was measured and vasodilation responses taken as a decrease from this level of tone.
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Cavernous








Figure 4-3: NA-induced vasoconstriction in the genital arteries (10 pM, arrows). Raw traces 
from typical experiments demonstrating an initial loss of tone prior to the establishment of a 
stable plateau in the dorsal artery, EVA and iVA compared to maintained tone In the
cavernous artery.
Table 4-1: Comparison of NA-induced (10 pM) vasoconstriction between vessels.
Sustained Tone gramsn (N) Emax grams (s.e.mean) (s.e.mean)
Cavernous 11 (29) 0.92 (0.07) 0.92 (0.08)
Dorsal ^3(34) 2.01 (0.09) 1.51 (0.09)
IVA ^5(30) .^7Q (0.13) 1.03 (0.10)
EVA 16 (30) 2.88 (0.13) 2.15(0.14)
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Sodium Nitroprusside -  Nitric Oxide Donor
The nitric oxide donor, SNP, caused a concentration-dependent vasodilation in all genital 
arterial preparations (Figure 4-4, Table 4-2). Maximal relaxations were greatest in IVA = 
dorsal ~ cavemous > EVA and were of magnitude IVA: 97.9 ± 1.3% {n(N) = 3(29)), 
dorsal: 95.8 ± 2.6% {n(N) = 4C7d )^, cavernous: 81.8 ± 3.8% (n(N) = 2(11)) and EVA: 65.5 
± 4.7% (n(N) = 8(30)). The potency of SNP was greater in IVA, pECso 6.21 ± 0.12, and 
dorsal, pECso 6.24 ± 0.06, arteries than EVA, pECso 5.52 ± 0.17, and cavemous, pECgo 
5.46 ± 0.08, arteries (F < 0.01).
CRCs to SNP were reproducible and showed no significant changes in either potency or 
maximal responses (Figure 4-5, Table 4-3) Ifom to 2"*^  curves (F > 0.05).
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Figure 4-4: SNP-lnduced vasodilation In the genital arteries expressed as a percentage of 
NA (10 pM) induced baseline tone ± s.e.mean.
Table 4-2: Comparison of SNP-induced vasodilation between vessels. 
% Maximumn(N) Relaxation (s.e.mean) -Hill Slope (95% Cl) pECso (s.e.mean)
Cavernous 3(11) 81.79 (3.76) 0.66 (0.54 to 0.78) 5.46 (0.08)
Dorsal 4(16) 95.82 (2.55) 1.09 (0.82 to 1.36) 6.21 (0.12)
IVA 8 (29) 97.88 (1.28) 1.16 (0.84 to 1.48) 6.24 (0.06)
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UK 343,664 -  PDE-5 Inhibitor
A  30 minute incubation with the PDE-5 inhibitor, UK 343,664 (3 to 30 nM) did not 
significantly potentiate or inhibit SNP-induced vasodilation in any genital arterial 
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Electrical Field Stimulation
To demonstrate the presence of functional nitrergic neurons in the genital tissues, EFS 
protocols were perfonned on vessels mounted on a small vessel wire myograph. NOS 
inhibitors were tested against vasodilations induced by electrical stimulation of nerves and 
the consequent release of endogenous neurotransmitters.
Control Responses
To allow the study of EFS-induced vasodilation, vessels were incubated with guanethidine 
(10 pM) for 1.5 hours to inhibit adrenergic neurons. NA (10 pM) was used to raise tone in 
all preparations. Sufficient time was allowed for tone to reach a stable plateau before 
experimental protocols were begim. Following the establisliment of stable tone, ffequency- 
response curves were constructed using frequencies from 0.5 to 64 Hz, increasing two-fold 
with each step. EFS parameters were pulse duration 0.3 ms, current 35 mA, train duration 
15 s with a delay of 5 minutes between trains. As previously described in Chapter 3 -  
Adrenergic Mechanisms, TTX was tested against the EFS parameters chosen for these 
studies and was found to inhibit, but not abolish, EFS-induced responses.
In many experiments involving EFS protocols, tone was found to decrease substantially 
over the course of a frequency-response curve, making comparisons of EFS-induced 
relaxation difficult (Figure 4-7). Incubation with a combination of cyclooxygenase 
inliibitor, indomethacin (1 pM), and channel blockers, apamin (Apa, 100 nM) and 
charybdotoxin (ChTX, 100 nM), was found to maintain the stability of NA-induced tone 
over the course of a frequency-response cuiwe without affecting EFS-induced relaxations 
(Figure 4-8). Therefore, during some EFS protocols, controls were performed both with 
and without cyclooxygenase and channel blockers before the effects of other inliibitors 
were determined.
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Figure 4-7: Frequency-response curves (arrows, 0.5 to 64 Hz) In the genital arteries 
following incubation with guanethidine (10 pM) and tone raised with NA (10 pM), 1®* (a.) and 
2"** (b.) controls. Raw traces obtained with the EFS parameters current 35 mA, pulse width 
0.3 ms, train duration 15 s and train delay 5 minutes.
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Figure 4-8: Frequency-response curves (arrows, 0.5 to 64 Hz) in the genital arteries 
following Incubation with guanethidine (10 pM) and tone raised with NA (10 pM), In the 
absence (a.) or presence (b.) of Indomethacin (1 pM), Apa (100 nM) plus ChTX (100 nM). Raw 
traces obtained with the EFS parameters current 35 mA, pulse width 0.3 ms, train duration
15 s and train delay 5 minutes.
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Nitric Oxide Synthase Inhibition
To determine the effect of incubation with L-NAME (100 |iM) on EFS-induced responses 
a preliminary exploratory experiment was performed in male genital arteries. Initial 
experiments were carried out early in the study, prior to the establishment of EFS 
parameters and so a different set had been used: frequency 0.5 Hz, pulse width 0.1 ms, 
current 150 mA, train duration 30 s. In this experiment, EFS-induced contractions in male 






Figure 4-S : EFS-induced contraction in male genital arteries in the absence (black line) or 
presence (blue line) of L-NAME (100 pM). Hatched areas Indicate change in responses, 
stimulation period indicated by bar under traces. Raw traces obtained with the EFS 
parameters frequency 0.5 Hz, current 150 mA, pulse width 0.1 ms and train duration 30 s.
Further experiments were performed to investigate the effect of NOS inliibition on EFS- 
induced vasodilation using an established set of EFS parameters, see section Control 
Responses. To maintain NA-induced tone, all responses were measured in the presence of 
cyclooxygenase (indomethacin) and channel (Apa and ChTX) blockers.
In cavernous arteries, L-NAME (100 pM) had veiy little effect on EFS-induced 
vasodilation (Figure 4-10). In tlnee o f five vessels the magnitude of EFS-induced 
relaxations remained unchanged, while in two of five vessels, relaxations in response to 
low (0.5 to 4 Hz) frequencies were increased. Mean data demonstrated no significant 
changes in maximal vasodilations at any frequency {P > 0.05, Figure 4-12, Table 4-5).
Vasodilation in the dorsal arteries was reduced by L-NAME (100 pM) in three of seven 
vessels, particularly to low (0.5 to 4 Hz) frequencies (Figure 4-10). In a further three of 
seven vessels L-NAME had no effect on responses. In a single vessel EFS-induced
Chapter 4, 178
Jude S Morton, 2006
vasodilation was increased by incubation with L-NAME. Mean data demonstrated no 
significant changes in EFS-induced vasodilation at any frequency (P > 0.05, Figure 4-12, 
Table 4-5).
In the IVA, vasodilation was decreased by incubation with L-NAME (100 pM), 
particularly to low fi-equencies (1 to 4 Hz), in six of seven vessels (Figure 4-11). However, 
the overall effect was complicated by changes in both baseline tone and contractile 
components of the response. At low frequencies (1 to 4 Hz) maximal relaxations were 
significantly decreased by L-NAME (P < 0.05, n(N) = 3(3), Figure 4-12, Table 4-5) but 
maximal relaxations to higher frequencies (8 to 64 Hz) were not affected {P > 0.05).
In all EVA preparations, six of six vessels, EFS-induced vasodilations were decreased by 
incubation with L-NAME (100 pM, Figure 4-11). At low (0.5 to 4 Hz) frequencies, 
relaxations were almost abolished with less than 9% relaxation remaining after incubation 
with NOS inhibitor. At fi-equencies of 2 Hz to 64 Hz, EFS-induced relaxation was 
significantly inhibited by L-NAME {P < 0.05, n(N) = 3(3), Figure 4-12, Table 4-5) but an 
L-NAME resistant relaxation of approximately 35% remained.
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Figure 4-10: Frequency-response curves (arrows, 0.5 to 64 Hz) In the male genital arteries 
following Incubation with guanethidine (10 pM), indomethacin (1 pM), Apa (100 nM) plus 
ChTX (100 nM) and tone raised with NA (10 pM). Curves in the absence (a.) or presence (b.) 
of L-NAME (100 pM). Raw traces obtained with the EFS parameters current 35 mA, pulse 
width 0.3 ms, train duration 15 s and train delay 5 minutes.
IVA







Figure 4-11: Frequency-response curves (arrows, 0.5 to 64 Hz) in the female genital arteries 
following incubation with guanethidine (10 pM) and tone raised with NA (10 pM), in the 
absence (a.) or presence (b.) of L-NAME (100 pM). Raw traces obtained with the EFS 
parameters current 35 mA, pulse width 0.3 ms, train duration 15 s and train delay 5 minutes.
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Discussion
In all genital arterial preparations, inhibitory neurotransmission was demonstrated which 
was greater in female (approximately 62% and 70% relaxation in IVA and EVA 
respectively) than male (approximately 40% and 45% relaxation in cavernous and dorsal 
arteries respectively) genital arteries.
Nitrergic neurotransmission has been well described in male penile tissues and NO is 
considered to be the main inhibitory neurotransmitter in erectile tissues. Using the NO 
donor SNP to directly stimulate vascular smooth muscle, male penile arteries demonstrated 
NO-induced vasodilations that were greater both in magnitude and potency in dorsal 
arteries. However, it is not known whether the physiological source of NO in male penile 
arteries is via activation of nNOS or eNOS.
In contrast to accepted knowledge, in the current study EFS-induced vasodilation was less 
successfully blocked by L-NAME in male than female genital arteries. Dorsal arteries 
demonstrated a degree of nitrergic inliibition at low frequencies (0.5 to 2 Hz); an inhibition 
that was not found to be significant in mean data. However, vasodilation in male penile 
ai'teries was generally found to be poor in comparison to vasodilation in female arteries. In 
addition, without the inclusion of indomethacin, Apa and ChTX, responses in IVA, EVA 
and dorsal arteries demonstrated a substantial loss of baseline tone and particularly variable 
EFS-induced responses complicating the analysis of EFS-induced relaxation. It was found 
that using cyclooxygenase (indomethacin) and channel (Apa and ChTX) blockers, both 
considered to be inhibitors of endothelium-derived relaxing factors (EDRPs), gave a 
maintained baseline from which to compare EFS-induced vasodilations. Further analysis of 
these experiments continued to give no significant evidence for nitrergic vasodilation in 
male genital arteries. EFS-induced relaxation of cavernous arteries was largely unaffected 
by L-NAME but in two cases was actually increased by NOS inliibition. This suggests that 
NO pathways may have other, perhaps modulatory effects, on neurogenic vasodilator 
mechanisms in male penile arteries.
Nitrergic neurotransmission has been less extensively studied in female genital tissues. 
Following a particular study by Ziessen et al (2002), which showed that NANC 
neurotransmission in female rabbit vaginal tissues could not be completely blocked by 
NOS inliibitors, the opinion was formed that NO has only a partial role in the relaxation of 
vaginal tissues.
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This study represents the first investigation of EFS-induced relaxation in isolated vaginal 
arteries. EFS-induced vasodilation in female vaginal arteries was significantly reduced by 
L-NAME in both IVA and EVA. Experiments in both vaginal artery preparations 
demonstrated a greater inliibition of low frequency responses; in the EVA responses were 
virtually abolished by L-NAME. Similarly, Ziessen et al. (2002) demonstrated that 
inhibition of NANC vasodilations in vaginal tissues by L-NAME or the sGC inhibitor IH- 
[l,2,4]oxadiazolo[4,3,-a]quinoxalin-l-one (ODQ) was more effective at low frequencies. 
Oh et a l (2003) demonstrated that partial inhibition of TTX-sensitive, EFS-induced 
relaxation of female rabbit vaginal tissue could be achieved using either L-NAME or d- 
VIP, a VIP receptor antagonist. In addition, neuronal NO and VIP were co-localised in 
bovine, porcine and avian vaginal tissues by Majewski et al (1995) and Costagliola et al
(1997). Further investigations would be warranted to determine whether the remaining 
vasodilation to high frequencies in female vaginal arteries were due to a neuropeptide, 
potentially VIP.
While inhibition of EFS-induced responses by L-NAME in female genital arteries was 
greater in EVA than IVA, responses to the NO donor SNP were both of greater magnitude 
and potency in IVA than EVA. hr accordance with these findings, Traish et al (2003) 
suggested that NOS activity in rabbit vaginal tissue was greater in proximal 
(approximating to the IVA) than distal (approximating to the EVA) vaginal regions. 
However, in the same year Kim et a l (2003) found no significant difference in NOS 
activity in proximal or distal regions of the rabbit vagina. This discrepancy between the 
relative predominance of L-NAME-sensitive EFS-induced vasodilation in IVA and EVA 
compared to their relative sensitivity to the NO donor, SNP, may be due to differences in 
nitrergic imiervation. If EVA were closely innervated by nitrergic neurons, resulting in 
regular NO-induced smooth muscle relaxation, NO mechanisms may become down- 
regulated or less sensitive to subsequent activation, hr contrast, IVA, which demonstrated a 
smaller L-NAME-sensitive component of EFS-induced vasodilation, may be less 
frequently exposed to NO and remain more sensitive to NO activation.
Curiously, despite the demonstration in both male coipus cavemosum (Gibson & 
Mirzazadeh, 1989; Mirzazadeh et a l, 1991; Raj fer et a l, 1992; Jeremy et a l, 1997;
Ballard et a l, 1998) and female vaginal tissues (Giraldi et a l, 2002; Uckert et a l, 2005a) 
o f a PDE-5-induced increase in cGMP and EFS-induced vasodilations, this study 
demonstrated no inhibition of SNP-induced vasodilation in any isolated genital artery 
preparation by the PDE-5 inhibitor UK 343,664 (3 to 30 nM, Wareing et a l, 2004). This 
area requires fiiither investigation to determine the effect of PDE-5 inhibitors on EFS-
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induced vasodilation, ACli-induced vasodilation and directly on genital arteries. Little or 
no PDE-5 involvement in the NO pathway in female genital arteries may explain the lack 
of success of PDE-5 inhibitors in the treatment of FSD; sildenafil citrate has proven to 
have a very limited effect on general FSD (Kaplan et a l, 1999; Basson et al., 2002), 
despite the demonstration in this study of substantial L-NAME-sensitive, EFS-induced 
vasodilation.
It was interesting to note that in comparing responses to SNP between the genital arteries, 
parallels were seen between IVA and dorsal arteries, EVA and cavernous arteries. During 
further investigations it would be worthwhile to observe whether these parallels remain 
consistent. If this is the case, parallels in the treatment of male and female sexual 
dysfunction may be indicated.
Summary
In summary, both male and female genital arteries displayed concentration-dependent 
vasodilation in response to the NO donor, SNP, which was not inhibited by the PDE-5 
inhibitor UK 343,664 (Table 4-6). Female genital vessels alone demonstrated significant 
inhibition of EFS-induced responses by L-NAME, suggesting a greater nitrergic 
innervation in female than male genital arteries. This is interesting since the use of PDE-5 
inhibitors has been shown to be ineffective in the treatment of FSD but is widely used in 
the treatment of male ED. EFS-induced relaxation of female vaginal arteries demonstrated 
an L-NAME resistant component at high frequencies. Therefore, inhibitoiy innervation of 
male and female genital arteries may be due to a combination of nitrergic and an unknown 
neurotransmitter, potentially cholinergic, such as ACh, or peptidergic, for example VIP.
The lack of L-NAME-sensitive EFS-induced vasodilation in male arteries could be due to 
experimental conditions, which gave relatively poor and variable responses in controls. 
However, since good responses, which could be significantly inhibited by L-NAME were 
achieved in female arteries under the same conditions, this suggests that nitrergic 
relaxation of male genital arteries was poorer than would be expected from previous 
studies in corpus cavemosum strips. This may reflect a genuine difference in the relaxation 
of whole tissues and isolated arteries. If an alternative inhibitory neurotransmission is 
found to be of more importance than nitrergic neurotransmission in male penile arteries, 
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Introduction
Endothelium-Dependent Relaxation
The advent of dmgs such as PDE-5 inliibitors to treat male erectile dysfunction has driven 
research focusing on the vasodilator pathways of genital vasculature and tissues. Penile 
smooth muscle relaxation in response to increased parasympathetic activity is central to the 
erectile process and is under the control of both NANC neurons and the vascular 
endothelium (reviewed by Andersson & Wagner, 1995). Many studies have demonstrated 
the involvement of the neuronal NO pathway (reviewed by Burnett, 1997) but less is 
known about endothelium-dependent relaxation in genital tissues. Endothelial dysfunction 
has been associated with aging and diseases such as hypertension, diabetes and 
hypercholesterolemia (Martin-Morales et a l, 2001), all of which are also associated with a 
high prevalence of erectile dysfunction (Johannes et a l, 2000). Hence, endothelium- 
dependent vasodilation is an important area for consideration in the development of novel 
therapies for erectile dysfunction.
With scientific interest begimiing to shift to the treatment of FSD it has become important 
to extend our knowledge of vasodilator pathways to include similarities and differences in 
tissue from the two sexes. Sildenafil citrate has proven to have very limited effect on 
general FSD (Kaplan et a l, 1999; Basson et a l, 2002) suggesting that pathways other than 
those involving NO may be of more significance in females. However, nothing is known of 
the mechanisms of endothelium-dependent vasodilation in female genital tissues.
In blood vessels in general, endothelium-dependent relaxation of smooth muscle, induced 
by agonists such as ACh, bradykinin or substance P, has been attributed to tlnee 
endothelium-derived relaxing factors. Prostacyclin (PGI2) is synthesised from arachidonic 
acid by the action of cyclooxygenases. NO is produced via activation of endothelial nitric 
oxide synthase (eNOS). The third and least well elucidated pathway involves the 
production of an unknown endothelium-derived hypeipolarising factor (EDHF). Which 
particular factor/s are released from endothelial cells varies with the agonist used, the 
vascular bed and the size of the vessel (Shimokawa et a l, 1996; Schrage et al, 2005).
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Prostaglandins
Along with contractile prostanoids such as PGFza and tliromboxane A2 , male erectile and 
female vaginal tissues have been demonstrated to synthesise and metabolise relaxatory 
prostanoids. These include prostaglandins Ei, E2 and I2 (PGEi, PGE2 and PGI2) in males 
(Roy et a l,  1984, 1989; Jeremy et a l ,  1986; Daley et a l ,  1996a, 1996b) and PGEi and 
PGE2 in females (Asboth et a l ,  1985; Dubin et a l ,  1985; Fichorova & Anderson, 1999).
Prostaglandins, prostacyclin and thromboxane are synthesised from arachidonic acid by the 
action of cyclooxygenases and are inactivated by prostaglandin-specific enzymes found in 
high concentrations in the lungs. The production of prostaglandins has been shown to be 
regulated by oxygen tension, which causes inhibition of cyclooxygenase activity. This may 
be an important factor in male penile tissues where oxygen tension varies with the erectile 
state (Daley et a l ,  1996a). In human corpus cavemosum tissue synthesis, and release of 
PGI2 has been demonstrated to occur in response to muscarinic receptor stimulation 
(Jeremy era/., 1986).
Prostaglandins have been shown to have relaxation effects in both male and female erectile 
tissues. PGEi and PGE2 caused relaxation of corpus cavemosum tissue, coipus 
spongiosum tissue, cavemous artery and retractor penis muscle in several species (Luduena 
& Grigas, 1972; Klinge & Sjostrand, 1974, 1977; Hedlund & Andersson, 1985). In vivo 
administration of PGEi was demonstrated to increase intracavemous pressure and erection 
in dog (Cahn et a l ,  1996), human and monkey (Aboseif et a l ,  1993). In human erectile 
tissue cyclooxygenase inhibitors were shown to decrease both spontaneous 
vasoconstrictions and basal tone (Clnist et a l,  1990). In female vaginal tissues PGEi was 
demonstrated to decrease the contractility of human vaginal wall strips (Czekanowski, 
1975) and in vivo administration of PGEi increased vaginal blood flow in dogs (Leffler & 
Amberson, 1982).
The receptors responsible for the actions of P G E  and P G I are EP and IP receptors 
respectively. In erectile tissues four E P receptor subtypes have been demonstrated, EP] -  
EP4. The presence of E P receptors was demonstrated in male human and monkey corpus 
cavemosum tissue (Aboseif et a l ,  1993). In addition, in female tissue, EP receptors have 
been demonstrated in human and rabbit cultured vaginal smooth muscle cells and hen 
vaginal tissue (Asboth et a l ,  1985; Traish et a l ,  1999). Stimulation of receptors by P G E  
leads to relaxation of smooth muscle via activation of AC and an increase in cAMP 
concentration in male and female tissues (Traish et a l,  1999; Uckert et a l ,  2004).
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Nitric Oxide
The main source of NO in male erectile tissues has been demonstrated to be via nitrergic 
neurotransmission and the activation of nNOS. However, both constitutive isofomis of 
NOS, nNOS and eNOS, are present in penile erectile tissues. While most studies have 
demonstrated eNOS in vascular endothelium (Dail et a l, 1995; Bloch et a l, 1998;
Hedlund et a l, 1999; Vanliatalo et a l, 2000), Bloch et al (1998) also put foiward evidence 
o f eNOS in trabecular smooth muscle.
Female genital tissues have been shown to be innervated by NOS immunoreactive neurons 
(Grozdanovic et a l, 1994; Hoyle et a l, 1996) and both nNOS and eNOS are expressed in 
vaginal tissues. As with male penile tissues, eNOS has been demonstrated to be localised 
both in vaginal epithelium and smooth muscle cells (Chatterjee et a l, 1996; Uckert et al, 
2005). Activation of eNOS may occur via pathways involving cholinergic 
neurotransmission, activation of ETb receptors or as a result of shear stress.
The significance of nNOS as the main catalyst for NO production in erectile tissue was 
thrown into doubt by the generation of homozygous nNOS-knockout mice which proved to 
be both viable and fertile (Huang et a l, 1993; Burnett et a l, 1996). These mice showed 
normal mating behavioui" and erectile responses to neiwe stimulation but also demonstrated 
a reduced fecundity. It is possible that these mice express a variant form of nNOS similar 
to penile nNOS (PnNOS) isoforms found in the rat which contain a 102 base pair insert 
(Magee et a l, 1996; Gonzalez-Cadavid et a l, 2000). Alternatively, maintained viability 
may be due to trans-splice variants, termed nNOSa, nNOSp and nNOSy, which produce 
shorter but functional proteins and persist in nNOS knockout mice (Eliasson et a l, 1997).
A third explanation may be the upregulation of compensatory factors; for example Burnett 
et al (1996) demonstrated that eNOS was significantly increased in penile vasculature and 
sinusoids of nNOS knockout mice compared to their wild type controls.
Therefore, while nNOS is thought to be the main source of NO in penile tissues, a 
significant role for NO production via eNOS may exist; particularly in the event of reduced 
nitrergic neurotransmission. The downstream actions of NO, whether produced via 
cholinergic or shear stress activation of eNOS or via nitrergic neurotransmission, are 
identical and lead ultimately to relaxation of both male and female genital tissues.
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Endothelium-Derived Hyperpolarising Factor
There are many potential candidates for the identity of EDHF which all have studies to 
support or refute them (reviewed by Coleman et a l, 2004). In various studies EDHF has 
been suggested to be the potassium ion (K^, Edwards et a l, 1998), C-type natriuretic 
peptide (CNF, Chauhan et a l, 2003), hydrogen peroxide (H2O2 , Matoba et al, 2000) or 
arachidonic acid derivatives including metabolites (e.g. the endogenous camiabinoid, 
arachidonoylethanolamide (anadamide), Randall et al, 1996) or products of cytocluome 
P450 epoxygenases (e.g. epoxyeicosatrienoic acid (EET), Azadzoi et a l, 1992). It is 
therefore likely that more than one foini of EDHF may exist and contribute to 
endothelium-dependent relaxation and the involvement of different factors may vary 
depending on the vascular bed and species studied.
The proposed mechanisms of action of EDHF are almost as varied as the candidates for its 
identity. An initial agonist-induced increase in intracellular endothelial calcium 
concentration is thought to lead to activation of small- and/or intermediate-conductance 
calcium-activated potassiiun channels (SKca and IKca respectively) on the endothelium. 
This results in hypeipolarisation of endothelial cells which spreads passively through myo- 
endothelial gap junctions to cause hypeipolarisation of smooth muscle cells and relaxation. 
Evidence for this pathway lies in the use of connexin mimetics to block gap junctions 
(Chaytor et a l, 1998; Mather et a l, 2005) and the association of the incidence of myo- 
endothelial electrical coupling with EDHF-mediated relaxation (Sandow & Hill, 2000), 
Alternatively, activation of Kca channels may lead to extmsion of potassium from the cell 
causing the extracellular concentration of potassium to increase. This in turn could activate 
inward rectifying potassium channels (K ir) and/or sodium potassium ATPase (Na"^ /K"^  
ATPase) on the smooth muscle cells resulting in hyperpolarisation and relaxation. In many 
tissues complete abolition of EDHF-induced relaxation has been achieved using a 
combination of Apa (SKca, blocker) and ChTX (IKca, Ky and lai'ge conductance calcium- 
activated potassium channel, BKca, blocker) but not with either inhibitor alone (Petersson 
et a l, 1997; Doughty et a l, 1999; Angulo et a l, 2003b). Frnther studies have inhibited the 
EDHF pathway using barium (K ir blocker) and/or ouabain (Na"^ /K^ ATPase blocker) 
(Edwards et a l, 1998; Scotland et a l, 2005).
A second hypothesis suggests that EET causes activation of BKca on the smooth muscle 
leading to hyperpolarisation and relaxation. Blockers such as iberiotoxin (BKca blocker) 
and tetraethylammonium (BKca and some Ky channel blocker), however, have had limited 
success in inhibiting EDHF-induced relaxations (Petersson et a l, 1997; Chaytor et a l.
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1998; Archer et a l, 2003). It is likely that arachidonic acid metabolites such as EET affect 
EDHF-induced relaxation in a modulatory manner in certain tissues but are not involved in 
others (reviewed by Griffith, 2004).
Mechanisms of EDHF action may not be mutually exclusive and, as with the identity of 
EDHF itself, there may be multiple pathways/compounds which act simultaneously and 
potentially synergistically. The consensus of opinion is that while the precise mechanism 
has not yet been elucidated a hallmark of EDHF-induced relaxation is its abolition using a 
combination of Apa and ChTX. Therefore, in this study a combination of Apa and ChTX 
were used to block the action of EDHF and it is likely that this occurs via blockade of SKca 
and IKca channels respectively.
Aims
Due to a lack of research in this area, little is known about endothelium-dependent 
relaxation of isolated male and female genital arteries. The aims of this chapter were as 
follows.
To investigate the contribution of prostaglandins, NO and EDHF to endothelium- 
dependent relaxation of male and female rabbit genital arteries.
To compare the mechanisms of endothelium-dependent relaxation in male and 
female rabbit genital arteries.
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The primary antibody used to identify endothelial cells was a goat polyclonal antibody 
raised against mouse platelet/endothelial cell adhesion molecule-1 (PEC AM). PEC AM is a 
glycoprotein expressed on the cell surfaces of monocytes, neutrophils, platelets and some T 
cells that is involved in cell-cell interactions during growth. This antibody would be 
expected to bind to endothelial cells present in the tissues studied. In negative controls, the 
primary antibody was omitted and replaced with PBS since normal goat IgG was not 
available.
The secondary antibody used was a donkey anti-goat antibody conjugated to biotin. 
Vectastain® ABC Kit, mouse (Vector Laboratories, Inc) and Liquid DAB + Substrate 
Cliromogen System (Vector Laboratories, Inc) were used to label positive structures with 
horseradish peroxidase (HRP) followed by peroxidase substrate (DAB). Using this system, 
negative structures were stained blue with a haematoxylin nuclear counterstain, while 
positive structures stained brown and were visualised under a light microscope.
Vaginal sections prepared for immunohistochemical analysis contained the entire vaginal 
vestibule and surrounding tissues. On staining these sections the vaginal lumen could be 
identified as a large space in the centre of the section suiTounded by a convoluted wall. 
Vaginal tissue beyond the vaginal wall contained numerous blood vessels, neiwe ganglia 
and blood filled cavities identified as sinuses (Figure 5-1).
In female vaginal tissues endothelial cells of both arteries and arterioles within the vaginal 
tissue stained positive using PECAM (Figures 5-1 and 5-2). In addition, positive staining 
in vaginal sinuses demonstrated a layer of non-vascular endothelium. The wall of the 
vaginal lumen demonstrated diffuse staining that may be attributable to non-specific 
staining. Nerve ganglia did not demonstrate positive staining using PECAM (Figure 5-2). 
Positive structures demonstrated using the endothelial antibody, PECAM, did not match 




Figure 5-1: PECAM (1:100 dilution) staining in female vaginal tissue. A: Control, B: Brown 
staining positive for PECAM. Scale bar =100 pm.
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Figure 5-2: PECAM (1:100 dilution) staining in female vaginal tissue. A: Control, B: Brown 
staining positive for PECAM. Scale bar = 100 pm.
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Endothelium-Dependent Vasodilation 
Noradrenaline-Induced Vasoconstriction
NA (10 fiM) was used to induce tone in all preparations as described previously in Chapter 
4 -  Nitrergic Mechanisms. Sufficient time was allowed for tone to reach a stable plateau 
before experimental protocols were begun. Sustained tone was measured and vasodilation 
responses taken as a decrease from this level of tone.
Incubation with a combination of channel blockers, Apa (100 nM) plus ChTX (100 
nM), and NOS inhibitor, L-NAME (100 pM), significantly increased the magnitude of 
NA-induced vasoconstrictions in the dorsal artery (P < 0.001), EVA and IVA (P < 0.01).
Acetylcholine-Induced Vasodilation
From a stable NA-induced tone, ACh (1 nM to 30 pM) caused reproducible concentration- 
dependent vasodilation in all four aideries (Figure 5-3, Table 5-1). ACh responses were 
maximal at 10 to 30 pM and were greatest in IVA = dorsal artery > EVA > cavernous 
artery. The magnitude of ACh vasodilations were IVA: 98.2 ± 1.0% (n(N) = 15(30)), 
dorsal artery: 96.2 ± 1.3% {n(N) = 13(34)), EVA: 75.8 ± 4.4% (n(N) = 16(30)) and 
cavernous artery: 71.0 ± 3.4% (n(N) =11 (29)). ACh potency was not significantly different 
in IVA and dorsal arteries but there were significant differences in potency between all 
other arteries (P < 0.05). The rank order of agonist potency for ACh responses was; dorsal 
artery = IVA > cavernous artery > EVA.
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Figure 5-3: ACh-induced vasodilation in the genital arteries expressed as a percentage of 
NA (10 pM) induced baseline tone ± s.e.mean.
Table 5-1: Comparison of ACh-induced vasodilation between vessels.
n(N) % Maximum Relaxation (s.e.m ean) -Hill Slope (95% Cl) pECso (s.e.m ean)
Cavernous 11 (29) 70.96 (3.40) 1.32 (0.95 to 1.69) 6.42 (0.05)
Dorsal 13(34; 96.23 (1.28) 1.63 (1.24 to 2.03) 6.70 (0.04)
IVA 15(30; 98.17 (1.02) 1.42 (1.03 to 1.81) 6.68 (0.05)
EVA 16 (30; 75.78 (4.39) 1.06 (0.69 to 1.44) 6.03 (0.09)
Cl: confidence intei-val
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Prostaglandins
In both male and female genital arteries NA-induced vasoconstriction and ACh-induced 
vasodilation were unaffected hy incubation with the cyclooxygenase inhibitor 
indomethacin (1 p-M, P > 0.05, Figure 5-4, Table 5-2). Nevertheless, indomethacin was 
included in all experiments, alongside incubation with inhibitors and/or blockers, as part of 
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Nitric Oxide
In all four preparations incubation with L-NAME (100 pM) exposed a NOS-independent 
component of ACh-induced vasodilation (Figure 5-5, Table 5-3). The maximum size of 
this potentially EDHF-induced vasodilation was not significantly different amongst the 
four vessels, approximately 25% to 60% relaxation. However, the change from the control 
curve varied; particularly in the EVA at lower concentrations of ACh, below vessel pECso, 
where incubation with L-NAME had less effect on ACh-induced vasodilation.
Incubation of vessels with a combination of NOS inhibitor (L-NAME, 100 pM) and 
channel blockers (Apa, 100 nM and ChTX, 100 nM) greatly reduced ACh-induced 
vasodilation in all preparations {P < 0.01, Figure 5-5, Table 5-3). Maximal relaxations 
were decreased to approximately 4.9% to 9.5% demonstrating that the NOS-independent 
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Endothelium-Derived Hyperpolarising Factor
To investigate EDHF involvement further, channel blockers Apa (100 nM) and ChTX 
(100 nM) were tested alone against ACh-induced vasodilation.
ACh-induced vasodilation of cavernous arteries was partially inhibited by channel
blockers (Figure 5-6, Table 5-4). In these arteries the effects of NOS inhibitor and 
channel blockers appear to be additive suggesting proportionate contributions of 
approximately NO, 67% and EDHF, 33 %.
In the dorsal arteries ACh-induced vasodilation was unaffected by K’*' channel blockers: 
note that in these arteries, L-NAME resistant vasodilation occurred at only the highest two 
concentrations of ACh used, 10 and 30 pM (Figure 5-6, Table 5-4). EDHF, therefore, had a 
very minimal role in the vasodilation of dorsal arteries while production of NO was the 
predominant mechanism of ACh-induced vasodilation.
Maximal vasodilation to 10 and 30 pM ACh in IVA preparations was unaffected by 
channel inhibition (Figure 5-6, Table 5-4). However, at lower concentrations of ACh, Apa 
and ChTX did significantly inhibit ACh-induced vasodilation {P < 0.05) in the IVA in 
contrast to dorsal arteries. Hence both EDHF and NO can be implicated in responses of the 
IVA to ACh.
In the EVA, vasodilation was greatly reduced by channel blockers at all concentrations 
of ACh {P < 0.01, Figure 5-6, Table 5-4). Uniquely, in this vessel, inhibition by channel 
blockers was greater than that by L-NAME suggesting that EDHF was the predominant 
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Discussion
Endothelium
In male erectile tissues the tliree main events leading to erection are increased arterial 
inflow, relaxation of trabecular tissue and decreased venous outflow. The first two of these 
events require relaxation of both vascular and trabecular smooth muscle. Trabecular 
sinuses in the corpus cavernosum are lined by endothelium and, in addition to the vascular 
endothelium, provide a significant source of factors important in the relaxation of genital 
tissues. Immunohistochemical analysis of female vaginal tissues demonstrated that, similar 
to male erectile tissues, sinuses were present thi'oughout this tissue. In addition, sinuses in 
female vaginal tissues were lined by an endothelial layer which may have an important role 
in relaxation. The vascular endothelium of arteries and arterioles in female genital tissues 
was also demonstrated.
Staining of endothelial cells by PECAM was not found in the same regions as previous 
staining with the pan-neuronal antibody, PGP 9.5. This demonstrates that neuronal 
innervation does not penetrate through to endothelial layers of arteries and arterioles. 
Indeed, PGP 9.5 staining demonstrated a plexus of neurons on the outer edge of vascular 
smooth muscle. This is an important consideration when investigating endothelial- 
dependent relaxation mechanisms. The agonist used in this study to investigate endothelial- 
dependent relaxation was ACh. Physiologically, the source of ACh may be either via 
release from parasympathetic cholinergic neurons acting on smooth muscle cells or 
circulating ACh acting on endothelial cells. However, ACh can cause vasoconstriction 
when it binds directly to cholinergic receptors on arterial smooth muscle and the presence 
of acetylcholinesterases leads to rapid breakdown of ACh in the blood. Therefore, the 
initial stimulus for endothelium-dependent relaxation is uncertain but may include many 
factors such as circulating factors in the blood, the effect of shear stress or the co­
ordination of stimuli via myo-endothelial gap junctions. In both males and females, 
vascular and non-vascular (trabecular sinus) endothelial cells may have an important role 
in the relaxation of genital tissues; allowing increased arterial inflow during sexual arousal.
Endothelium-Dependent Relaxation
This study is the first comparison of the balance of NO and EDHF contributes to 
endothelium-dependent relaxation of isolated male and female genital arteries.
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The lack of any effect of indomethacin on ACh-induced relaxation in male and female 
genital arteries demonstrated no involvement of prostacyclin. The inclusion of 
indomethacin in all experiments ensured no further prostacyclin involvement.
Inliibition of NOS demonstrated that an L-NAME-resistant vasodilation was present in all 
genital arteries studied. What was most striking, however, was the much greater 
involvement of EDHF in the female upstream artery, the EVA. This follows the pattern of 
sex differences found in rat and mouse mesenteric beds (McCulloch & Randall, 1998; 
Scotland et a l, 2005) and rat tail artery (Pak et a l, 2002) where EDHF was found to 
contribute relatively more in females. In the present study, NO was clearly involved in all 
four arteries, as shown by the effect of L-NAME on its own or with Apa and ChTX. The 
striking difference amongst the arteries was the effect of Apa and ChTX, which had a very 
clear effect on the female inflow artery (EVA), a very small effect on the male dorsal 
artery and an intermediate effect on the smaller arteries from both sexes.
There is a known pattern of greater EDHF involvement in smaller, downstream arteries 
(Miura et a l, 1999; Coats et a l, 2001; Angulo et al, 2003a) and this corresponds to the 
present finding with the male arteries: there was a greater involvement of EDHF in ACh- 
induced relaxation of cavernous arteries compared with dorsal arteries. Interestingly, this 
was not the case with the female vaginal arteries; in which the upstream example, EVA, 
clearly had a gieater EDHF involvement than the downstream IVA. Since vasodilation of 
inflow arteries is cmcial to the onset of sexual arousal this is a significant point.
The clear role for NO in endothelium-mediated vasodilation in genital tissue arteries from 
both sexes suggests that it is not necessaiily a relatively greater involvement of NO in the 
male that explains the success of sildenafil in the treatment of sexual dysfunction in males 
but not in females. However, involvement of EDHF in vasodilation in both sexes and a 
relatively greater role in the female may point to an alternative approach to sexual 
dysfunction in both sexes, but particularly in the female. Faulty EDHF mechanisms could 
lead to sexual dysfunction and, if this was the source of the problem in the female then 
enhancing the NO signalling pathway by blocking PDE-5 would not necessarily be 
effective. This could also be a factor in male subjects who are not responsive to sildenafil. 
Evidence is emerging concerning the failur e of the EDHF system in general. The 
effectiveness of EDHF has been shown to decline with increasing age (Sandow, 2004) and 
in models of hypertension (Fujii et a l, 1992; Vanhoutte, 1996).
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The current study showed that in male penile arteries there was a greater involvement of 
EDHF in ACh-induced relaxation of cavernous arteries compared with dorsal arteries. In 
dorsal arteries vasodilation could be almost entirely attributed to NO since no inhibition of 
relaxation was demonstrated using chamiel blockers, with or without L-NAME. This 
demonstrated that NO was more dominant in larger calibre male genital arteries. Similarly, 
relaxations of human and horse penile helicine arteries, branches of the cavernous artery, 
have been shown to be mediated by a combination of NO and EDHF (Prieto et a l, 1998; 
Angulo et a l, 2003a) while that of bovine dorsal arteries was mediated largely by NO (Liu 
et a l, 1991). Interestingly, while isolated cavernous arteries appear to utilise both NO and 
EDHF (this study and Angulo et a l, 2003a), relaxation of human and rabbit corpus 
cavernosum tissue was shown to be almost completely mediated by NO (Azadzoi et a l, 
1992; Angulo et a l, 2003a); demonstrating the diverging results that can be obtained by 
looking at whole tissue or isolated vessel preparations.
The inversion of the concept of NO upstream, EDHF downstream, in the female is, as far 
as we know unprecedented. However, it does not appear to have been studied, so may 
reflect a general trend in other female vasculature.
Summary
In summary, male and female genital arteries demonstrated significant gender differences 
in endothelium-dependent relaxation (Table 5-5). In the female inflow artery, EVA, EDHF 
predominated but both NO and EDHF contributed to overall function, hi the male dorsal 
artery, NO mechanisms predominated and the involvement of EDHF appeared to be 
minimal. In the smaller genital arteries, the cavernous aitery in males and IVA in females, 
both NO and EDHF were shown to contribute to relaxation while NO was proportionately 
more dominant than EDHF. The hypothesis proposed by other studies of increased EDHF 
involvement with decreasing vessel size was found to be consistent for data in male 
arteries but was reversed in female arteries where EDHF contribution was greater in the 
larger EVA. Gender differences and the relative contributions of NO and EDHF to the 
relaxation of male and female genital resistance arteries described in this study provide an 
insight into the mechanisms of sexual function in both males and females, which could be 
used to direct futui'e investigations into the aetiology and hence the successful treatment of 
sexual dysfunction. While therapies for male sexual dysfunction have been directed 
towards NO pathways with the successes of drags such as the PDE-5 inliibitors Viagra®, 
Cialis® and Levitra®, this study shows that a method of enhancing EDHF-induced 
relaxation could be more beneficial in the treatment of FSD. Since EDHF has also been
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demonstrated to be involved in the relaxation of cavernous arteries a combination of 
treatments targeting both the NO and EDHF pathways could potentially have a greater 
effect on ED in males. In accordance with this hypothesis, Vick et a l (2002) demonstrated 
that a chamiel opener had potential as a treatment for ED. Therefore, an additional area 
of study would be to fully elucidate the physiological mechanisms and pathology of 
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Introduction
In this chapter investigations are made into some alternative candidates for sympathetic 
and parasympathetic neurotransmitters in male and female genital tissues. While 
adrenergic and NO mechanisms are often considered as the main excitatory and inhibitoiy 
pathways respectively, results presented in previous chapters have shown that this may not 
always be the case in the genital arteries being studied. The present chapter will review the 
role of peptides or purines as putative neurotransmitters within the genital arteries.
Adenosine 5'-Trlphosphate
ATP is abundant in almost all tissues in the body but was not initially considered by many 
as a potential neurotransmitter (Williams, 1987). ATP release from both neiwes and 
endothelium has since been shown to be involved in the control of vascular tone. ATP may 
act either via a direct action of ATP on Pgx or P^y receptors, or tlnough the breakdown of 
ATP to adenosine, which acts via A%, A2A, A2B and A3 receptors (reviewed by Burnstock, 
2002; Boeynaems et a l, 2005). There are cun-ently seven known subtypes of the P2X 
receptor and eight of the P2Y receptor.
Vasoconstriction
The receptor thought to be responsible for the neurotransmitter actions of ATP is the P2X 
purinoceptor. This is a ligand-gated ion chamiel whose actions include smooth muscle 
contraction, synaptic responses, bone foimation, pain and visceral perception (Rang et a l, 
2002; Vial et a l, 2004; Boeynaems et a l, 2005).
The presence of Pix receptors has been demonstrated in both male and female rat genital 
tissues (Bardini et a l, 2000; Lee et a l, 2000). However, very few studies have reported a 
contractile role for ATP in the genital tissues. In males, ATP and adenosine have been 
shown to cause contraction of rabbit cavernosal smooth muscle in vitro (Wu et a l, 1993), 
while in vivo adenosine decreased erectile responses in rats (Sharifzadeh et a l, 1995). In 
females, no studies have shown a direct vasoconstrictor effect of either ATP or adensosine.
Vasodilation
In addition to ? 2x receptors, niRNA for the P2Y receptor has been demonstrated in both 
male and female genital tissues (Obara et a l, 1998; Min et a l, 2003). The P2Y purinoceptor
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is a G-protein coupled receptor linked to either AC or hydrolysis of phosphoinositide 
(Rang et a l, 2002). ATP was first shown to cause vasodilation of male dog penile arteries 
by Bowman & Gillespie (1983). Since this time, ATP, adenosine and the P2Y agonist 
adenosine 5’-0-(2-thiodiphospate) (ADPpS) have been demonstrated to cause relaxation of 
pre-contracted genital tissues in vitro. Adenosine- and ATP-induced relaxations were 
antagonised by the A2A receptor antagonists CGS21680 and ZM-241385 (Mantelli et a l, 
1995; Filippi et a l, 1999; Noto et a l, 2001) but the P2 antagonists sui'amin and reactive 
blue-2 failed to inhibit responses to ATP (Ragazzi et a l, 1996; Filippi et a l, 1999; Noto et 
al, 2001). In contrast, the action of purines in human corpus cavernosum has been 
suggested to be via activation of endothelial P2Y receptors leading to NO production and 
subsequent relaxation (Shalev et a l, 1999). In support of this hypothesis, Chiang et al 
(1994) demonstrated that adenosine-induced relaxation of rabbit genital tissues was 
decreased by endothelium removal. In addition, demonstration of P2Y receptor mRNA in 
male tissues by Obara et al (1998) found it to be localised in the endothelium of cavernous 
sinuses and blood vessels but not smooth muscle. However, many studies have shown that 
adenosine- and ATP-induced relaxation in rabbit, dog and human genital tissues is both 
endothelium- (Tong et a l, 1992) and NO-independent (Levin et a l, 1994; Mantelli et al, 
1995; Ragazzi et a l, 1996; Kaya et a l, 1998; Filippi et a l, 1999; Noto et a l, 2001). In 
vivo, ATP and adenosine were shown to increase intracavemous pressure and cause 
erection in dogs (Takahashi et a l, 1992; Noto et a l, 2001).
On the basis of these experiments it was postulated that ATP is a NANC inhibitory 
neurotransmitter in corpus cavernosum tissue, indicating a purinergic involvement in 
penile erection. This view has since been questioned due to the inability of ATP or other 
purines to affect EFS responses in dogs or rabbits or penile tumescence in humans (Wu et 
al, 1993; Filippi et a l, 2000; Noto et a l, 2001). Current opinion suggests that the role of 
ATP may be as a modulator of NANC and/or adrenergic neurotransmission.
A similar conclusion was reached by Ziessen & Cellek (2002) when investigating the 
involvement of purines in the relaxation of female genital tissues. In their study ATP, 
adenosine and various other purines were shown to relax rabbit vaginal tissue. Similar to 
results in male penile tissues, ATP-induced relaxation was not inhibited by a P2 antagonist, 
suramin, while adenosine-induced relaxation was blocked by an A2A antagonist, ZM- 
241385. The authors concluded that while purinoceptors were present in the vaginal tissue, 
purines are not involved in EFS-induced relaxation.
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Vasoactive Intestinal Polypeptide
The limited success of sildenafil in the treatment of FSD (Basson et a l, 2002) has led to 
the suggestion that, in contrast to male genital tissues, NO may not be the main inhibitory 
neurotransmitter in female genital tissues. Many peptides have been demonstrated to be 
present in nerves innervating vaginal tissues including VIP, pituitary adenylate cyclase 
activating peptide (PACAP), peptide histidine methionine (PHM), peptide histidine valine 
(PHV), calcitonin gene-related peptide (CGRP), helospectin-I and -II and substance P 
(Palle et a l, 1989; Majewski et a l, 1995; Hoyle et a l, 1996). However, the endogenous 
release of peptides as neurotransmitters in vaginal tissues has yet to be proven.
VIP has been detected in nerves inneiwating both vascular and non-vascular smooth muscle 
in human (Lynch et a l, 1980; Palle et a l, 1989; Uckert et a l, 2005), bovine, porcine 
(Majewski et a l, 1995) and avian (Costagliola et a l, 1997) vaginal tissues. Neurogenic 
VIP was described as abundant and co-localised with other inliibitory neurotransmitters, 
such as NO (Majewski et a l, 1995; Costagliola et a l, 1997).
The functional significance of VIP in genital tissues has also been demonstrated. In vitro, 
VIP inhibited vaginal smooth muscle activity (Palle et a l, 1989; Bredkjoer et a l, 1997), 
while EFS-induced relaxation of rabbit vaginal tissue was partially inhibited by d-VIP, a 
VIP receptor antagonist (Oh et a l, 2003). In vivo, VIP increased vaginal blood flow, which 
is a physiological indicator of sexual arousal (Ottesen et a l, 1983; Palle et a l, 1990).
VIP causes relaxation of smooth muscle via activation of Gg-coupled VIP receptors,
VPACi and VPACz, leading to activation of AC (Fahrenkrug, 1993). In turn, this results in 
an elevation of cAMP levels and consequent activation of cAMP-dependent protein kinase 
(PKA); lowering the cytosolic Ca^  ^concentration (McDonald et a l, 1998). In female 
rabbit genital tissues, VIP caused a rise in cAMP concentration (Ziessen et a l , 2002), 
while in human vaginal tissue the cAMP specific phosphodiesterase, PDE-4, was found to 
be co-localised with VIP-IR neurons (Uckert et a l, 2005).
Aims
Female genital tissues are well innervated by VIP-immunoreactive neurons and it has been 
shown that VIP inhibitory neurotransmission causes relaxation of vaginal smooth muscle. 
However, little is known about the pharmacology of VIP responses in the vaginal tissue 
and no studies have determined the effect of VIP on isolated vaginal arteries.
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In addition, a role for purinergic neurotransmission in the function of genital tissues from 
both sexes remains unclear. While the effects of purines on male penile tissues have been 
investigated in more depth our current knowledge of purine pharmacology in female 
genital tissues is provided by a single study.
The aims of this chapter were as follows.
• To verify the presence of VIP- immunoreactive neurons in female rabbit vaginal 
tissues.
• To characterise responses to exogenous VIP and ATP in female rabbit vaginal 
arteries.
• To determine the involvement of peptides as neurotransmitters in rabbit genital 
arteries from both sexes.
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Results
Peptidergic innervation
Vasoactive intestinal Polypeptide Antibody
The primary antibody used to identify VIP neurons in female rabbit vaginal tissues was a 
sheep polyclonal antibody specific for VIP. Primary antibody was used at a dilution of 
1:2500, which was within the manufacturers’ recommended dilution range of 1:2500 to 
1:5000. The secondary antibody used was a donkey anti-sheep antibody conjugated to 
FITC at a concentration of 1:50, again within the manufacturers’ guidelines of 1:50 to 
1:200. Negative controls consisted of slides where primary antibody was omitted and 
replaced with PBS since normal sheep IgG was not available. These slides were incubated 
with secondary antibody as for experimental slides. Using these antibodies, positive 
structures were stained fluorescent green and were visualised under a fluorescence 
microscope using a HQ525/40mn (chroma technology) filter.
Slides stained using the VIP primary antibody demonstrated fluorescence in an area 
surrounding arteries that was similar to the plexus of nerves visualised using PGP 9.5 
(Figure 6-1). However, no ganglia or veins within the genital tissues were observed as 
staining positive for VIP. A large amount of non-specific staining was observed in 
connective tissues and in the endothelial layer of arteries but not of veins.
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Figure 6-1: VIP (1:2500 dilution) staining the female vaginal tissue. A: Control, B: Green 
fluorescent staining (FITC 1:50) positive for VIP indicated by arrow. Scale bar = 50 pm.
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Purines and Vasoconstriction 
Adenosine 5 -Triphosphate
ATP induced concentration-dependent vasoconstriction in both female arterial 
preparations, as illustrated by the responses of two IVA and two EVA vessels (Figure 6-2). 
Responses amounted to 46.8 ± 1.4% (n(N) = 5(10)) and 17.2 ± 11.5% {n(N) -  5(12)) of 
NA (10 pM) sighting responses in the IVA and EVA respectively (Figure 6-3, Table 6-1). 
ATP responses demonstrated Hill slopes that were not significantly different from unity in 
either vaginal artery.
Aipha, Beta, Methyiene Adenosine 5 -Triphosphate
In both female artery preparations, a, p, methylene adenosine 5’-triphosphate (a,p,mATP) 
a selective P2x purinoceptor agonist, induced vasoconstriction. The characteristics of these 
contractions are demonstrated by the responses of two IVA and two EVA vessels (Figure 
6-4). No contraction was obseiwed in response to a,p,mATP concentrations of 0.01 pM or 
lower. At 0.1 pM, a,p,mATP induced a small, non-maximal response. Upon further 
stimulation with 1 pM a,p,mATP a large, maximal vasoconstriction was observed in both 
vaginal artery preparations. This was followed by desensitisation of ATP receptors leading 
to a small residual response at 10 pM and complete abolition of a,p,mATP-induced 
contraction at 100 pM.
Analysis of mean data (Figure 6-5, Table 6-2) demonstrated that, in common with ATP- 
induced responses, vasoconstrictions to a,p,mATP were greater in IVA, 74.7 ± 4.7% (n(N) 
= 2(4)) NA (10 pM) sighting, than EVA, 33.0 ± 12.0% (n(N) = 1(2)) NA (10 pM) sighting, 
(P < 0.05). In IVA but not EVA, maximal responses to a,p,mATP were significantly 












Figure 6-2: Raw traces of responses to ATP (0.1 to 1000 pM, arrows) in the female genital 

















Figure 6-3: ATP-induced vasoconstriction in the female genital arteries expressed as a 
percentage of the NA (10 pM) sighting response ± s.e.mean.
Table 6-1: Comparison of ATP-induced vasoconstriction between vessels.
IVA
EVA
n(N) Emax grams (s.e.mean)
; % NA Sighting 
(s.e.mean) Hill Slope (95% C!)
pECso
(s.e.mean)
5 (10) 0.59 (0.08) 46.80 (1.38) 1.39 (-0.44 to 3.22) nd
5(12) 0.28(0.21) M .22 (11.49) 0.59 (-1.04 to 2.23) nd
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Figure 6-4: Raw traces of responses to a,p,mATP (0.01 to 100 pM, arrows) in the female 
genital arteries. IVA: pink and green lines. EVA: blue and red lines.
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Figure 6-5: a,P,mATP-induced vasoconstriction in the female genital arteries expressed as a 
percentage of the NA (10 pM) sighting response ± s.e.mean.
Table 6-2: Comparison of a,P,mATP-induced vasoconstriction between vessels.
Emax grams (s.e.mean) E^ax % NA Sighting (s.e.mean)
n (N) 0.1 pM 1 pM 0.1 pM 1 pM
IVA
EVA
2(4) 0A5 (0.03) 0.74 (0.20)
1 ( 2)  0.05 (0 .04)  0.51 ( 0 . 26)
12.32 (3.68) 74.71 (4.65)
2.82  ( 2 . 16)  32.97  ( 11.96)
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Peptides, Purines and Vasodiiation 
Vasoactive Intestinal Polypeptide
VIP induced concentration-dependent vasodilation of both female arterial preparations 
(Figure 6 -6 , Table 6-3). Maximal relaxation to VIP was greatest in IVA, 87.5 ± 3.2% {n(N) 
= 14(24)), compared to EVA, 69.2 ± 3.2% {n(N) = 14(23), P < 0.001). Responses to VIP 
were also significantly more potent in IVA, pECso 8.11 ± 0.06, compared to EVA, pECso 
7.59 ±0.05 ( f  <0.001).
Wlien compared to ACh-induced vasodilation in the same artery, 98.2 ± 1.0% (n(N) = 
15(30)), maximal responses to VIP in the IVA were significantly smaller (P < 0.01, Figure 
6-7, Table 6-3). However, VIP-induced vasodilation in the EVA was not significantly 
different from ACh, 75.8 ± 4.4% (n(N) ^  16(30), P > 0.05). In both female genital artery 
preparations the potency of VIP responses was found to be significantly gi'eater than those 
to ACh by approximately 1.5 log steps (P < 0.001). In the IVA the potency of VIP and 
ACh responses were pECso 8.11 ± 0.06 (n(N) = 14(24)) compared to pECso 6 .68  ± 0.05 
(n(N) = 15(30)), while in the EVA potencies were pECso 7.59 ± 0.05 (n(N) = 14(23)) and 
6.03 ± 0.09 (n(N) ~ 16(30)), respectively.
Vasodilation induced by VIP was reproducible following an extended two hour wash out 
period between first and second CRCs. Subsequent curves to VIP were well conserved 
with no significant changes in either potency or maximal relaxations {P > 0.05, Figure 6 -8 , 
Table 6-4).
VIP (6-28) -  VIP Receptor Selective Antagonist
VIP fragment (6-28) (10 pM), a VIP receptor antagonist, significantly inhibited VIP- 
induced vasodilation in the IVA but not the EVA (Figure 6-9, Table 6-4). No decrease was 
obseiwed in the maximal response in IVA, 80.6 ± 11.5% relaxation (nfTV) = 5(5)) compared 
to control, 87.8 ± 4.6% relaxation (n(7V) = 5(5), P > 0.05). A parallel shift of the CRC 
occuned giving a pECso of 7.37 ± 0.24 compared to control pECso 8.11 ± 0.14 (P < 0.05).
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Figure 6-6: VIP-Induced vasodilation in the female genital arteries expressed as a 
percentage of NA (10 pM) induced baseline tone ± s.e.mean.
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Figure 6-7: Comparison of VIP- (•)  and ACh- (o) induced vasodilation in the female genital 
arteries expressed as a percentage of NA (10 pM) induced baseline tone ± s.e.mean.
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Figure 6-8: VIP-Induced vasodilation in the female genital arteries, {•) and 2"  ^(o) 
controls, expressed as a percentage of NA (10 pM) Induced baseline tone ± s.e.mean.
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Figure 6-9: VIP-induced vasodilation in the female genital arteries in the absence (•)  or 
presence (o) of VIP (6-28) (10 pM), expressed as a percentage of NA (10 pM) induced
baseline tone ± s.e.mean.
Table 6-4: VIP-induced vasodilation In the female genital arteries in the absence, 1®* and 2"^
controls, or presence of VIP (6-28) (10 nM).
n(N) % Maximum Relaxation (s.e.mean) -Hill Slope (95% Cl) pECso (s.e.mean)
IVA 1®* Control 14 8 7 .5 0  (3.22) 1.57 (0.99 to 2.14) 8.11 (0.05)
2"*^  Control 5(5) 87.81 (4.64) 1.49 (0.22 to 2.76) 8.11 (0.14)
VIP (6-28) (10 pM) 6(5) 8 0 .5 5  (11.54) 1.06 (0.02 to 2.10) 7 .37  (0.24)
EVA Control 14(23) 6 9 .1 9  (3.23) 1.48 (1.07 to 1.90) 7 .59  (0.05)
2"'* Control 6 (6 ) 79.31 (5.00) 1.58 (0.81 to 2.35) 7 .52  (0.07)
VIP (6-28) (10 pM) 6 (6 ) 73 .49  (7.08) 1.52 (0.36 to 2.69) 7.32 (0.13)
Cl: confidence intei’val
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Adenosine 5’-Triphosphate
Experiments were performed to determine if ATP could induce relaxation of NA- 
contracted female artery preparations. Following the establishment of stable tone using NA 
(10 pM), ATP was added either as a single dose or in increasing concentrations during a 
CRC.
Little evidence was found in support of ATP-induced relaxation in either vaginal artery 
preparation. In the IVA, ATP (30 pM) was found to cause a degree, approximately 20% to 
38%, of relaxation in two of 16 vessels (Figure 6-1 Oa) while in the EVA, ATP (0.1 to 1 
mM) induced 5% to 26% relaxation in three of 11 vessels (Figure 6-1 la). In the majority 
of vessels, no vasodilation occurred in response to ATP concentrations ranging from 10 
nM to 1 mM (Figures 6 -10b and 6-1 lb).
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Figure 6-10: Raw traces demonstrating the effect of ATP in the IVA in the presence of 
guanethidine (10 pM) and NA-induced tone (10 pM). a. Relaxation in response to single dose 
ATP (30 pM, arrow), b. No relaxation In response to an ATP CRC (1 to 300 pM, arrows).
a- 0.01 pM 1 pM 100 pM b. 0.1 pM 10 pM 300 pM
0.1 pM 10 pM 300 pM 1 pM 100 pM
i , 1 , i I
0.5 g
5 min
Figure 6-11: Raw traces demonstrating the effect of ATP in the EVA In the presence of 
guanethidine (10 pM) and NA-induced tone (10 pM). a. Relaxation to 100 pM ATP but 
contraction to 300 pM (0.01 to 300 pM, arrows), b. No relaxation to increasing concentrations
of ATP (0.1 to 300 pM, arrows).
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Control Responses
As previously described in Chapter 3 -  Adrenergic Mechanisms, EFS-induced 
vasoconstriction was found to be highly reproducible in response to the parameters 
frequency 0.5 to 64 Hz, pulse duration 0.3 ms, current 35 mA, train duration 15 s with a 
train delay of 5 minutes. Control responses are not further described in this chapter.
Adenosine 6 ^Triphosphate
An initial exploratoiy experiment was performed in male genital arteries with EPS 
parameters frequency 0.5 Hz, pulse width 0.1 ms, current 150 mA and in the presence of 
the NOS inhibitor L-NAME. This experiment demonstrated that long train (30 s) responses 
could be substantially inhibited by a,p,mATP. As previously described in this chapter, 
a,p,mATP is a selective ?2x puiinoceptor agonist, which desensitises the Pzx receptor 
following stimulation. a,p,mATP (1 pM) was applied to the bath 10 minutes prior to EPS 
and caused a large vasoconstriction, which was allowed to return to baseline before 
electrical stimulation of the tissues. In this experiment, inhibition of the Pix receptor by 
a,p,mATP decreased the rate of rise and magnitude of the initial phase of the male artery 







Figure 6-%: EFS-induced (0.5 Hz, 30 s) vasoconstriction in the male genital arteries in the 
presence of L-NAME (100 pM, black line) or L-NAME (100 pM) plus a,p,mATP (1 pM, blue 
line). Hatched areas indicate change in responses, stimulation period indicated by bar 
under traces. Raw traces obtained with the EFS parameters frequency 0.5 Hz, current 150 
mA, pulse width 0.1 ms and train duration 30 s.
In all genital arteries, the selective Pzx receptor antagonist 2’,3’-0-(2,4,6- 
trinitrophenyl)adenosine-5 ’ -triphosphate (TNP-ATP, 1 pM) was tested against EPS-
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induced vasoconstriction in combination with AR inhibition with prazosin (10 nM) and 
rauwolscine (10 nM). The effect of a combination of adrenergic and purinergic inhibition 
was compared to relevant controls in the presence of AR inhibition alone.
In the cavernous artery, EFS-induced vasoconstriction was reduced by TNP-ATP (1 pM) 
alone in a single vessel by 9% at the highest frequency, 64 Hz, and by a combination of 
adrenergic and purinergic inhibition in three of four vessels by between 5% and 69% 
(Figure 6-13). Analysis of mean data obtained in the presence of adrenergic antagonists (10 
nM prazosin plus 10 nM rauwolscine) or a combination of adrenergic plus purinergic (1 
pM TNP-ATP) inhibition demonstrated no additional contribution of purinergic inhibition 
{P > 0.05, n(N) = A(4), Figure 6-14, Table 6-5).
EFS-induced vasoconstriction in dorsal arteries was decreased by a combination of 
adrenergic and purinergic inliibitors in six of six vessels by between 17% and 50% at the 
highest frequency, 64 Hz (Figure 6-13). Comparison of mean data with either adrenergic 
inhibition alone or a combination of adrenergic and purinergic inhibition did not 
demonstrate any change due to the addition of TNP-ATP (1 pM, P > 0.05, n(7V) = 5(5), 
Figure 6-14, Table 6-5).
In the female IVA, the effect of TNP-ATP (1 pM) on EFS-induced vasoconstriction was 
variable. Alone, TNP-ATP decreased contractions in one of three vessels by 2% at the 
highest frequency, 64 Hz (Figure 6-13). A combination of purinergic and adrenergic 
inliibition increased contractions by 8 % in one vessel and decreased contractions by 19% 
in another at 64 Hz. When the combination of adrenergic and purinergic inhibition was 
compared to adrenergic inhibition alone no change due to the addition of TNP-ATP was 
observed (P > 0.05, \\(N) = 3(5), Figure 6-14, Table 6-5).
TNP-ATP (1 pM) reduced EFS-induced vasoconstriction in a single EVA vessel by 5% at 
the highest frequency, 64 Hz (Figure 6-13). In contrast, a cornbination of adrenergic and 
purinergic inhibition decreased contractions by between 8% and 53% in tlxree of four 
vessels. Analysis of mean data demonstrated no change in EFS-induced contractions was 
given by addition of purinergic inliibition compared to adrenergic inliibition alone (P > 
0.05, n(A) = 4(¥), Figure 6-14, Table 6-5).
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Figure 6-13: Frequency-response curves (arrows, 0.5 to 64 Hz) in the genital arteries in the 
absence (a.) or presence (b.) of TNP-ATP (1 pM). Raw traces obtained with the EFS 
parameters current 35 mA, pulse width 0.3 ms, train duration 15 s and train delay 5 minutes.
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Peptides, Purines and EFS-induced Vasodilation 
Control Responses
To allow the study of EFS-induced vasodilation, vessels were incubated with guanethidine 
(10 pM) for 1.5 hours to inliibit adrenergic contractile responses. In all preparations tone 
was induced using NA (10 pM) and sufficient time allowed for tone to reach a stable 
plateau before experimental protocols were begun. As previously described in Chapter 4 -  
Nitrergic Mechanisms, incubation with cyclooxygenase (indomethacin) and K’*' channel 
(Apa and ChTX) blockers was found to maintain the stability of NA-induced tone over the 
course of a frequency-response curve without having a noticeable affect on EFS-induced 
relaxations. Therefore, during EFS protocols involving vasodilator responses, controls 
were performed both with and without channel blockers before the effects of 
antagonists were determined.
Vasoactive Intestinal Polypeptide Receptor Antagonism
EFS-induced vasodilation in female genital arteries was predominantly decreased by L- 
NAME (100 pM) as detailed in Chapter 4 -  Nitrergic Mechanisms, at low frequencies; 
responses were virtually abolished in EVA at 0.5 to 4 Hz, while at higher frequencies 
vasodilation was more resistant to L-NAME. VIP (6-28), a VIP receptor antagonist, was 
tested against the L-NAME-resistant component to determine if VIP was involved in 
female genital artery neurotransmission.
In the IVA, EFS-induced vasodilation at 64 Hz, 71.0 ± 10.1% relaxation (n(N) = 3(3)), was 
unaffected by incubation with L-NAME, 51.7 ± 4.8% relaxation (n(N) = 3(3), P > 0.05). A 
combination of nitrergic (NOS) and peptidergic (VIP receptor) inhibition caused no further 
inhibition of EFS-induced vasodilation, 41.5 ± 3.5% relaxation at 64 Hz ( n f TV)  ^3 (3 ),P >  
0.05, Figure 6-15). In contrast to L-NAME, which significantly inhibited EFS-induced 
relaxation at low frequencies, analysis of mean data demonstrated that no additional 
inhibition of relaxation was provided by incubation with VIP (6-28) at any frequency used 
{P > 0.05, Figure 6-16, Table 6 -6).
In the EVA, a combination of nitrergic and peptidergic inhibition greatly reduced 
vasodilation at all EFS fr equencies in tlu'ee of three vessels (Figure 6-15). Analysis of 
mean data showed a clear trend whereby at high frequencies (16 to 64 Hz) greater 
inhibition occumed of EFS-induced vasodilation using a combination of VIP (6-28) plus L-
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NAME, 17.6 ± 2.9% (n(N) = 3(3)), than by L-NAME alone, 34.9 ± 9.8% (n(N) = 3(3), 












Figure 6-15: Frequency-response curves {arrows, 0.5 to 64 Hz) In the genital arteries 
following incubation with guanethidine (10 pM) and tone raised with NA (10 pM), in the 
absence (a.) or presence (b.) of indomethacin (1 pM), Apa (100 nM), ChTX (100 nM), L-NAME 
(100 pM) plus VIP (6-28) (1 pM). Raw traces obtained with the EFS parameters current 35 mA, 
pulse width 0.3 ms, train duration 15 s and train delay 5 minutes.
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Figure 6-16: EFS-induced reiaxation in the female genital arteries in the absence (• )  or 
presence of 100 L-NAME (o) or 100 pM L-NAME plus 1 pM VIP (6-28) (A ) expressed as a 
percentage of NA (10 pM) induced baseline tone ± s.e.mean.
Table 6-6: EFS-induced relaxation in the genital arteries in the absence (control) or 
of L-NAME (100 pM) or L-NAME (100 pM) plus VIP (6-28) (1 pM).
presence
% Maximum Relaxation (s.e.mean)
IVA















































8.08 16.57 36.71 53.02 62.73 68.85 71.06 69.53Control 3(3) (5.03) (8.66) (7.47) (4.86) (3.64) (3.14) (2.96) (3.99)
3.38 5.69 7.13 8.99 14.97 28.59 34.94 34.94L-NAME 3(3) (1.01) (1.71) (2.42) (2.93) (4.65) (7.28) (9.22) (9.84)
L-NAME + 3.14 4.88 5.97 7.71 9.22 12.03 15.77 17.563(3)VIP (6-28) (0.08) (0.52) (0.78) (0.61) (0.72) (0.81) (2.14) (2.91)
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Adenosine 5’-Triphosphate
In male genital arteries the selective P2Y receptor antagonist I ’-deoxy-A^-methyladenosine 
3’,5’-bisphosphate (MRS 2179, 1 pM) was tested against EFS-induced relaxations. The 
effect of MRS 2179 was tested on a background of cyclooxygenase (indomethacin) and 
channel (Apa and ChTX) inhibition to maintain NA-induced tone in the male genital 
arteries. Since no inhibition of EFS-induced relaxation in male genital arteries had been 
previously shown using L-NAME, the effect of TNP-ATP was tested in isolation.
In the cavernous artery, vasodilation induced by EFS was increased by incubation with 
MRS 2179 (1 pM) in three of three vessels by between 4% and 23% at the highest 
frequency used, 64 Hz (Figure 6-17). Analysis of mean data demonstrated no significant 
change in the magnitude of EFS-induced vasodilation in the presence or absence of MRS 
2179 ( f  >0.05, Figure 6-18, Table 6-7).
As in cavernous aiteries, MRS 2179 (1 pM) increased EFS-induced vasodilations in the 
dorsal artery by between 6 % and 2 2 % in three of thiee vessels at the highest frequency 
used, 64 Hz (Figure 6-17). No significant change in EFS-induced relaxations was 
demonstrated by analysis of mean data (P > 0.05, Figure 6-18, Table 6-7).
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Figure 6-17: Frequency-response curves (arrows, 0.5 to 64 Hz) in the male genital arteries 
following incubation with guanethidine (10 pM), indomethacin (1 pM), Apa (100 nM) plus 
ChTX (100 nM) and tone raised with NA (10 pM). Curves in the absence (a.) or presence (b.) 
of MRS 2179 (1 pM). Raw traces obtained with the EFS parameters current 35 mA, pulse 
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Discussion
Adenosine S’-Triphospate
In contrast to the demonstration by Ziessen & Cellek (2002) of ATP-induced relaxation of 
female rabbit vaginal tissues, in the current study only a minority of vaginal arteries 
demonstrated ATP-induced vasodilation. In a single EVA vessel (Figure 6-11), 
vasodilation was observed that was replaced by a contractile response at a higher 
concentration. This suggests that contractile Pzx receptors comprise the predominant 
response in the vaginal arteries, while the Piv receptor has little or no role in the control of 
vascular tone.
When the ability of MRS 2179, a P2Y receptor antagonist, to decrease EFS-induced 
vasodilation in male genital arteries was investigated, no significant effect was shown. 
Indeed the only observed effect of P2Y inhibition in individual vessels appeared to be an 
increase in EFS-induced vasodilation, not a decrease. This is in agreement with the 
consensus of opinion that while purinoceptors are present in the male penile tissues, no 
involvement of pmines in EFS-induced vasodilation has been demonstrated.
Contractile responses to both ATP and a,(3,mATP in female genital arteries demonstrated 
that functional purinoceptors, likely to be the P2X receptor, were present in these tissues. 
a,p,mATP is marketed as a P2 agonist that is more potent at the P2X purinoceptor than ATP 
itself (Sigma-Aldrich Co., St Louis, USA, A-7699). This was confirmed in the cunnnt 
study which demonstrated vasoconstrictions to a,p,niATP in both IVA and EVA at 
concentrations (0.1 to 10 pM) lower than those at which ATP had any effect (>10 pM). 
The subsequent action of a,P,niATP was to function as an ATP receptor antagonist by 
causing desensitisation of the ATP P2X receptors. Vasoconstriction in response to long 
train EFS in male arteries was reduced dramatically by a,p,mATP (1 pM) but frequency- 
response curves were not reduced by the selective P2X antagonist TNP-ATP (1 pM). The 
lack of effect of TNP-ATP on EFS-induced vasoconstriction may be due either to a low 
potency of TNP-ATP or a lack of purinergic involvement in EFS-induced vasoconstriction. 
No studies have investigated the effect of purinergic inhibitors on EFS-induced 
vasoconstrictions in male or female genital tissues. The current study suggests that purines 
are not involved neiwe-mediated vasoconstriction of male and female genital arteries but 
further investigations would be necessary to determine the effect of higher concentrations
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of TNP-ATP and of a,p,mATP in the absence of L-NAME on EFS-induced 
vasoconstriction.
Vasoactive Intestinal Polypeptide
As previously described in Chapter 4 -  Nitrergic Mechanisms, EFS-induced vasodilation 
in female genital arteries was decreased by the NOS inhibitor L-NAME but a resistant 
component remained at high frequencies, 8 to 64 Hz. Oh et al. (2003) showed that EFS- 
induced relaxation of rabbit vaginal wall tissue could be partially inhibited by the VIP 
receptor antagonist, dVIP. VIP positive staining was shown in a plexus surrounding 
arteries but not veins during the cun'ent study, suggesting that peptidergic inneiwation may 
be involved in the control of vaginal arteries. To determine if the L-NAME-resistant 
component in the current study could be attributed to peptidergic neurotransmission, both 
NOS inhibition alone and in combination with VIP receptor inhibition were tested against 
EFS-induced vasodilation in the vaginal arteries.
Addition of the VIP receptor antagonist, VIP (6-28), did not affect EFS-induced 
vasodilation in the IVA but demonstrated a non-significant reduction in EFS vasodilations 
at high frequencies in the EVA. Wliile this trend proved, at this stage, to be non-significant 
the effect was clear and it may be found that with increased repetitions a significant role 
for VIP in EFS-induced vasodilation of the EVA could be demonstrated.
The functional significance of VIP in vaginal arteries was further demonstrated by 
pharmacological characterisation of responses to exogenous VIP. Female vaginal arteries 
were significantly more sensitive to VIP than to ACh, either reflecting a difference in the 
binding affinities of these two compounds to their respective receptors or a reduction in the 
effective concentration of ACh in the genital arteries by their rapid breakdown by 
acetylcholinesterases. Inhibition of EFS-induced vasodilation by VIP (6-28) in EVA but 
not IVA suggested that peptidergic, VIP mediated neurotransmission appears to have a 
greater role in upstream regions of the vaginal artery. In contrast, exogenous VIP 
demonstrated a greater affinity and was only inhibited by VIP (6-28) in the IVA. VIP has 
been shown to have a similar affinity at both VPACi and VPAC2 (Hannar et aL, 1998) and 
therefore the potency of VIP responses in the vaginal arteries provides no information 
about the VIP receptor subtype involved. A role for the VIP receptor in the IVA was 
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An extended recovery period of 2 hours was required between VIP CRCs to achieve 
reproducible responses. In addition, vasodilation to high concentrations of VIP, 0.3 pM to 
3 pM, demonstrated a suppression of maximal relaxation responses. Therefore, either VIP 
receptors were becoming desensitised at these high concentrations or, once bound VIP 
caused activation of a receptor followed by a latent period during which the receptor 
cannot be reactivated. This is in accordance with the demonstration in cultured cells (CHO, 
COS7 and HEK293 cell lines) of a rapid agonist-induced internalisation of VIP receptors 
and their re-expression at the cell surface within 2 hours (McDonald et a l, 1998; Langlet 
et a l, 2004). A greater degree of desensitisation of the VIP response was demonstrated 
compared to any other agonist used during this study, including ACh and SNP. Depending 
on the relative predominance of peptidergic neuro transmission in the female this may 
correspond to a latency period in the excitability of vaginal tissues via stimulation of VIP 
receptors.
There are currently few reliable antagonists of the VIP receptors. Vasoactive intestinal 
peptide fragment 6-28 (VIP (6-28)) is a carboxy-tenninal fragment of the VIP molecule 
found to be two-fold more potent than any previously used antagonists (Fishbein et a l, 
1994). However, the cuiTent study only demonstrated inhibition of VIP responses in the 
IVA using VIP (6-28) at a high, potentially non-selective, concentration of 10 pM. The 
development of more selective and potent inliibitors of VIP receptors would further assist 
the characterisation of VIP responses in the genital arteries.
Summary
In summary, the L-NAME-resistant component of EFS-induced vasodilation was not 
convincingly identified as either purinergic or due to VIP (Table 6 -8 ). A role for VIP in 
EVA neurotransmission was indicated and would require further investigation to detennine 
if VIP as a neurotransmitter could fully account for L-NAME-resistant vasodilation. 
Neither inhibition of VIP nor ATP receptors decreased EFS-induced vasodilation in IVA, 
cavernous or dorsal genital arteries, suggesting that an additional, unknown component 
remains unidentified in these arteries. The role of peptides in EFS-induced vasodilation 
could be investigated using peptidase inhibitors to determine if submaximal vasodilations 
can be increased.
The presence both of functional peptidergic, VIP, and purinergic, p2x, receptors was 
demonstrated in female genital arteries. The studies presented within this thesis indicate 
that in female tissues, VIP may be of more importance in the upstream region of the
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vaginal artery. In addition, the role of ? 2x purinoceptors appears more predominant than 
P2Y purinoceptors in both sexes. A role for purinergic neurotransmission, via P2X 
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Introduction
Myogenic Tone and Vasomotion
Myogenic tone is a response shown by arterial smooth muscle to a change in transmural 
pressure; contraction to increased pressure and relaxation to decreased pressure (Hughes & 
Bund, 2002). It is not dependent on vascular endothelium or innervation but can be 
modulated by the endothelium, in particular by the action of shear stress (Hughes & Bund, 
2002; Segal, 2005). Myogenic contraction of vascular smooth muscle cells may also 
translate into vasomotion which is rhythmic activity of vascular smooth muscle (Griffith et 
a l, 2005). Myogenic tone is thought to be involved in the regulation of peripheral 
resistance and hence blood pressure (Hughes & Bund, 2002) and in the oxygenation of 
tissues (Segal, 2005). In addition, changes in myogenic activity have been implicated in the 
aetiology of hypertension (Hughes & Bund, 2002).
Aims
Various incidences of spontaneous activity were noted throughout previous experimental 
protocols. These observations were frequent and interesting enough to waiTant a detailed 
examination of their characteristics. Since myogenic tone may be important in the 
regulation of blood flow tlirough the genital tissues the aims of this chapter were as 
follows.
• To describe the characteristics of spontaneous/myogenic activity obseiwed in male 
and female rabbit genital arteries.
• To determine the underlying basal mechanisms active in each genital artery studied.
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Results
Spontaneous Activity
During equilibration periods, vessels were occasionally observed to contract in the absence 
of agonists or antagonists. While this induction of endogenous tone was seen inteimittently 
in each artery group, the most common vessel type to exhibit spontaneous vasoconstriction 
was the cavernous artery; n(N) of n(N) = cavernous, 5S(144) of 100(422); dorsal, 13(17) of 
101(361); IVA, 10(15) o f 49(226) and EVA, \0(14) o f 44(209). This equated to 13% to 
58% of animals and 5% to 34% of vessels. Spontaneous vasoconstrictions could generally 
be returned to the pre-activity baseline by multiple changes of bathing media but in some 
instances would recur following the wash.
Effect of a-Adrenoceptor Antagonists
As previously mentioned, spontaneous vasoconstrictions were obseiwed during 
equilibration periods either prior to or between experimental protocols. Experimental 
protocols often included incubation of antagonists during equilibration periods between 1®^ 
and 2"  ^CRCs to an agonist. On occasion, the addition of antagonists coincided with the 
occurrence of spontaneous activity within a vessel, hi these instances it could be noted 
whether the antagonist in use had any effect on endogenous tone.
In the cavernous artery, a small percentage of vessels, seven of 144, demonstrated 
spontaneous vasoconstrictions whose timing coiTesponded with the addition of AR 
antagonists. In these experiments, inhibition of endogenous tone by prazosin (1 to 100 nM) 
and rauwolscine (0.1 to 1 pM) was observed (Figure 7-1). Similarly, in dorsal arteries 
inhibition of spontaneous vasoconstrictions in three of 17 vessels was given by prazosin 
(10 to 100 iiM, Figure 7-2). No inhibition of endogenous tone by any other antagonists was 
observed.
In the IVA, the timing of spontaneous vasoconstrictions did not occur such that any were 
inhibited by antagonists while in the EVA a few small magnitude spontaneous 











Figure 7-1: Raw traces demonstrating the effect of prazosin or rauwolscine (arrows) on 
spontaneous vasoconstrictions in the cavernous artery. Addition of a. Prazosin 100 nM 
(black) compared to an earlier spontaneous vasoconstriction in the same vessel (blue), b. 
Rauwolscine 0.1 pM (green and blue) and 1 pM (red), c. Prazosin 1 nM (blue), 10 nM (red)







Figure 7-2: Raw traces demonstrating the effect of prazosin (arrows) on spontaneous 
vasoconstrictions in the dorsal artery. Addition of a. Prazosin 100 nM (black) compared to 
an earlier spontaneous vasoconstriction in the same vessel (blue), b. Prazosin 10 nM (blue)




Figure 7-3: Raw traces demonstrating the effect of prazosin 10 nM (arrow, blue and black) 
on spontaneous vasoconstrictions in the EVA.
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Effect of Noradrenaline Uptake Blockers
Vasoconstriction was observed in some vessels in the absence of agonists but during 
incubation with inlribitors (Figure 7-4, Table 7-1). Inhibitors which caused an increase in 
endogenous tone included the NA uptake blockers cocaine (3 pM) and corticosterone (30 
pM).
As previously described, spontaneous vasoconstrictions in the absence of antagonists were 
predominantly observed in cavernous arteries, 34% of vessels. The induction of 
endogenous tone was significantly increased during incubation with NA uptake blockers, 
0.38 ± 0.15 g, (n(N) = 5(7)), compared to controls, 0.06 ± 0.01 g {n(N) = 23(61), P < 
0 .001).
In the IVA, EVA and dorsal arteries, few vessels exhibited spontaneous vasoconstrictions 
in the absenee of agonists or antagonists, 5% to 7% of vessels. In contrast to cavernous 
arteries, NA uptake blockers did not significantly increase endogenous tone in the dorsal 
artery, IVA or EVA {P > 0.05).
Effect of Nitric Oxide Synthase and Channel Blockers
Increases in endogenous tone were also observed in some vessels in the absence of 
agonists but during incubation with the NOS inhibitor L-NAME (100 pM) and the 
channel blockers Apa (100 nM) and ChTX (100 nM, Figure 7-4, Table 7-1).
Cavernous arteries demonstrated vasoconstriction during incubation with L-NAME, 0.13 ± 
0.04 g (nfTV) = 15(28)), IC^  channel blockers, 0.30 ± 0.09 g (n(N) = 4(4)) or a combination 
of L-NAME plus channel blockers, 0.29 ± 0.12 g (n(N) = 4(4)). However, only 
vasoconstriction during incubation with channel blockers alone was significantly 
gi'eater than those in control vessels, 0.06 ± 0.01 g (n(N) = 13(61), P < 0.05).
In the dorsal arteries, incubation with L-NAME, 0.15 ± 0.06 g {n(N) = \1(30), P < 0.01), 
channel blockers, 0.12 ± 0.04 g (nfTV) = 5(6), P < 0.01), or a combination of L-NAME 
plus channel blockers, 0.68 ± 0.49 g (nfTV) = 6(7), P < 0.001), all caused 
vasoconstrictions of dorsal arteries significantly greater than those in control vessels, 0.03 
± 0.01 g {n(N) = 25(67)).
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Similarly, in the IVA incubation with L-NAME, 0.17 ± 0.05 g (n(N) = 5(9), P  < 0.001), 
channel blockers, 0.08 ± 0.04 g (n(N) = 6(6), P  < 0.01), or a combination of L-NAME plus 
channel blockers, 0.91 ± 0.42 g (n(N) = 6(8), P  < 0.001), all caused vasoconstriction 
significantly greater than those in control vessels, 0.04 ± 0.01 g (n(N) = 15(44)).
Incubation with L-NAME, 0.39 ± 0.18 g (n(N) = 11(30), P  < 0.001), or a combination of 
L-NAME plus chaimel blockers, 0.67 ± 0.54 g (n(N) = 6(7), P  < 0.001), caused 
vasoconstrictions in the EVA signifieantly greater than controls, 0.02 ± 0.01 g (n(N) = 
25(67)). Incubation with channel blockers alone caused no significant increase in 
endogenous tone, 0.06 ± 0.04 (n(N) = 6(6), P  > 0.05).
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Table 7-1: Increased endogenous tone observed In the genital arteries in the absence 
(control) or presence of NOS inhibitor (L-NAME, 100 pM), channel blockers (Apa, 100 nM 
+ ChTX, 100 nM), NOS plus K* channel blockers (Combination) or NA uptake blockers 
























n(N) ^max grams (s.e.mean)




23 (61) 0.06 (0.01) 9.40 (2.30) -
-\5(28) 0.13 (0.04) 16.01 (4.07) ns
4(4) 0.30 (0.09) 29.04 (7.57) P < 0 .05
4(4) 0.29 (0.12) 21.78 (7.21) ns
5(7) 0.38 (0.15) 37.42 (14.28) P <  0.001
25 (67) 0.03 (0.01) 2.15(0.45) -
M (30) 0.15(0.06) 7.25 (2.49) P<0.01
5(6) 0.12 (0.04) 6.69 (2.54) P<0.01
Q(7) 0.68 (0.49) 26.47 (17.30) P <  0.001
6(7) 0.09 (0.05) 3.77 (2.33) ns
15(44) 0.04 (0.01) 1.94 (0.03) -
5(9) 0.17 (0.05) 7.86 (1.96) P < 0.001
6(6) 0.08 (0.04) 4.96 (1.37) P<0.01
6(8) 0.91 (0.42) 46.47 (18.51) P <  0.001
6(6) 0.04 (0.03) 1.74 (1.37) ns
25 (67) 0.02 (0.01) 0.71 (0.24) -
U  (30) 0.39(0.18) 11.48(4.96) P <  0.001
5(6) 0.06 (0.04) 1.64 (1.08) ns
6(7) 0.67 (0.54) 20.07 (15.24) P <  0.001
6(7) 0.04 (0.02) 1.36 (0.34) ns
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Spontaneous Activity in Pre-contracted Tissues
Rhytlimic activity or vasomotion, characterised by a continual cycle of vasoconstriction 
and vasodilation around a stable baseline of agonist-induced tone, was the most commonly 
obseiwed type of spontaneous activity. Rhytlimic activity occurred in all artery groups 
(Figure 7-5), being most frequent in dorsal artery preparations; n(N) of n(N) = cavernous, 
61(138) on00(422); dorsal, 94(232) of 101(367;; IVA, 41(110) o f 49(226), and EVA, 
24(44) of 44(209). This equated to 55% to 93% of animals and 21% to 64% of vessels. 
Spontaneous activity of this type was only observed following an agonist-induced increase 
in tone and therefore may not strictly speaking be considered ‘spontaneous’. Rliythmic 
activity occuiTed randomly and when present appeal ed to be dependent on the level of 
tone, being more prevalent at higher tensions. Therefore, this activity shall be referred to 






Figure 7-5: Raw traces demonstrating typical examples of rhythmic activity in the genital 
arteries following an agonist-induced increase in tone (NA, 10 pM, arrows).
In the cavernous artery, following tone raised with NA or PE, rhythmic activity occurred in 
the presence of various adrenergic antagonists, including prazosin (10 nM), phentolamine 
(100 nM) and rauwolscine (10 nM). In addition, rhythmic activity was not inhibited in four 
of four vessels by the cyclooxygenase inhibitor indomethacin (1 pM), nor, in four of five 
vessels, by the NOS inhibitor L-NtVME (100 pM). In a single case, rhythmic activity was
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observed prior to, but not following, a 40 minute incubation with L-NAME (100 pM). 
Rliythmic activity was also removed in tlu'ee o f three vessels following a 30 minute 
incubation with channel blockers Apa (100 nM) plus ChTX (100 nM) (Figure 7-6) or a 





Figure 7-6: Raw traces demonstrating rhythmic activity in the cavernous artery following 
tone raised with NA (10 pM, arrows); present prior to (a.) but not following (b.) a 30 minute 
incubation with K* channel blockers Apa (100 nM) plus ChTX (100 nM).
In the dorsal artery, rhythmic activity was observed in the presence of adrenergic 
antagonists, including prazosin (10 nM), phentolamine (100 nM) and rauwolscine (10 nM), 
and was not blocked by the cyclooxygenase inhibitor indomethacin (1 pM) in two of two 
vessels. In contrast to cavernous arteries, rhytlimic activity in the dorsal artery was not 
affected by chamiel blockers Apa (100 nM) and ChTX (100 nM) in five of five vessels. 
Eiowever, rhytlimic activity was decreased or abolished in six of nine vessels by the NOS 
inhibitor L-NAME (100 pM) (Figiue 7-7) and in fom* of six vessels by a combination of 




Figure 7-7: Raw traces demonstrating rhythmic activity in the dorsal artery following tone 
raised with NA (10 pM, arrows); present prior to (a.) but not following (b.) a 40 minute
incubation with L-NAME (100 pM).
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In female vaginal arteries, rhythmic activity was not affected by adrenergic antagonists, 
including prazosin (10 nM) and rauwolscine (10 nM), nor by the cyclooxygenase inliibitor 
indomethacin (1 pM) in two of two vessels. In addition, in IVA and EVA rhythmic activity 
was not blocked by channel blockers Apa (100 nM) and ChTX (100 nM) in tliree of 
three vessels, nor by L-NAME (100 pM) in four of four vessels. However, in both IVA 
and EVA rhythmic activity was abolished by a combination of K.^  channel blockers Apa 
(100 nM) and ChTX (100 nM) plus NOS inhibitor L-NAME (100 pM) in tln ee of three 





Figure 7-8: Raw traces demonstrating rhythmic activity in the IVA following tone raised with 
NA (10 pM, arrows); present prior to (a.) but not following (b.) a 30 minute incubation with a 





Figure 7-9: Raw traces demonstrating rhythmic activity in the EVA following tone raised 
with NA (10 pM, arrows); present prior to (a.) but not following (b.) a 30 minute incubation 
with a combination of Apa (100 nM) plus ChTX (100 nM) plus L-NAME (100 pM).
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Vasodilation
Large, pronounced relaxations of AR agonist-induced tone (NA, 10 pM or PE, 10 pM) 
were evident in the EVA. In this artery distinct vasodilations of varying magnitude, from 
12% to 95% of agonist-induced tone, were observed in 7% of vessel preparations (30% of 
animals), n(N) ofn(N) = 13(15) o f 44(209). Vasodilations differed from previously 
described rhythmic activity in that they did not occur as small oscillatory, spontaneous 
cycles but rather as a discreet vasodilation followed by a return to previous tone in less 
frequent regularity.
Spontaneous vasodilations occuiTed during the performance of various protocols involving 
an elevation in tone (NA, 10 pM). It was noted that this type of vasodilation was not 
blocked by incubation with the VIP receptor antagonist, VIP (6-28) (10 iiM or 3 pM) in 
three of three vessels. However, in six vessels, spontaneous vasodilations coincided with a 
40 minute incubation with the NOS inhibitor, L-NAME (100 pM). In all six vessels, 
spontaneous vasodilations present prior to L-NAME incubation were completely abolished 
following the equilibration period (Figure 7-10). In two vessels (Figures 7-11 and 7-12), 
the occurrence of spontaneous vasodilations were progressively abolished over a shorter 
timeframe by the addition of L-NAME (100 pM) without a wash-out of NA-induced tone.
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a. Spontaneous Vasodilatations




Figure 7-10: Raw traces demonstrating spontaneous vasodiiations (arrows) in the EVA 
foliowing the induction of tone using NA (10 pM); present prior to (a.) but not following (b.) a
40 minute incubation with L-NAME (100 pM).
Spontaneous Vasod ila ta tions
1
100 pM L-N AM E2 min
Figure 7-11: Raw traces demonstrating the effect of L-NAME (100 pM, upward arrow) on 
spontaneous vasodiiations (downward arrows) in the EVA following the Induction of tone
using NA (10 pM).
Spontaneous V asod ila ta tions
1
2 min
Figure 7-12: Raw traces demonstrating the effect of L-NAME (100 pM, upward arrow) on 
spontaneous vasodilations (downward arrows) in the EVA foliowing the induction of tone
using NA (10 pM).
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Discussion
Spontaneous activity of blood vessels or tissues is a phenomenon that is either rarely 
observed or rarely reported. In the current study, many incidences of spontaneous activity 
with differing characteristics occurred and an examination of this activity provided a novel 
insight into the basal control of vascular function.
Spontaneous increases in endogenous tone were observed in all genital arterial 
preparations which could be returned to a pre-contractile baseline by multiple changes of 
the bathing media; suggesting that the release of endogenous factors was responsible for 
triggering spontaneous activity. Endogenous tone could also be returned to a pre- 
contractile baseline by a-AR antagonists in all vessels except the IVA. Additionally in the 
cavernous artery, endogenous tone was increased by incubation with NA uptake blockers; 
signifying that basal tone was due to NA acting at vascular smooth muscle ARs. If 
endogenous tone were due to spontaneous myogenic activity, this would not involve the 
activation of ARs by extracellular NA and so neither uptake blockers nor AR antagonists 
would be expected to have an effect. In turn, release of endogenous NA implies that tonic 
activity of adrenergic neurons was responsible for subsequent contraction of the smooth 
muscle; a hypothesis which could be tested using TTX to block neurogenic activity. This 
supports literature suggesting that erections induced by injection of a-AR antagonists and 
the association of priapism (prolonged erection) following treatment with ai-AR selective 
antagonists are due to a basal tonic sympathetic activity in penile tissues (Brindley, 1986; 
Saenz de Tejada et a l, 1991; Munoz et a l, 1994; Zorgniotti, 1994; Becker et a l, 1998; 
Marquer & Bressolle, 1998). However, blockade of receptors or neural mechanisms 
involved in adrenergic transmission does not universally lead to erection, or in this study 
reduction of endogenous tone, so perhaps spontaneous myogenic activity was partly 
responsible. Myogenic activity is frequently due to release of Ca^^ from internal stores 
(Griffith et a l, 2005), a pathway which could be tested using nifedipine, an L-type Ca^^ 
chamiel blocker.
It is interesting to note that spontaneous increases in endogenous tone were more 
frequently observed in the cavernous artery than in any other genital artery preparation.
The cavernous tissues, and in particular the cavernous artery, have a pivotal role in penile 
erection since increased arterial inflow via this artery is one of the first stages of an erectile 
response. Therefore, basal vasoconstriction of the cavernous artery is particularly 
important in maintenance of penile flaccidity in the resting state. NA uptake blockers did
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not increase endogenous tone in IVA, EVA or dorsal arteries and reduction of spontaneous 
endogenous tone by a-AR antagonists was less often observed in the female arteries. This 
suggests that basal release of endogenous NA is of less significance in female arteries than 
males and the action of a-AR antagonists in reducing endogenous tone may be via an 
inverse agonist action, i.e. inhibition of constitutively active receptors.
In opposition to endogenous contractile factors, the release of NO occuiTed in all genital 
arterial preparations, as shown by increased endogenous tone in the presence of L-NAME. 
Therefore, not only was NO a predominant inhibitory factor in dorsal arteries but it was 
also basally released to maintain resting tone. With the available information it was not 
possible to determine whether basal NO release was due to endothelial or nerve activity; 
and therefore eNOS or iiNOS activity respectively. In the IVA, a combination of NOS and 
channel inhibitors was required to reveal maximal increases in endogenous tone while 
incubation with channel blockers increased endogenous tone in all vessels except the 
EVA. This suggests that basal channel activity, potentially due to release of 
endogenous EDHF, is also responsible for the maintenance of basal tone in the genital 
arteries. In addition in the IVA, NO and EDHF are each capable of partially compensating 
for a loss of the other in maintaining basal tone in these arteries.
Spontaneous rhythmic activity, induced by pre-contraction with a-AR agonists, was 
blocked by L-NAME in the dorsal artery, channel blockers in the cavernous artery and 
a combination of both in female vaginal arteries. This provides further evidence for the 
importance of a basal NO release in the dorsal arteries. In the cavernous arteries, 
channel activity predominated in the regulation of basal tone while a combination of 
endogenous factors, including NO and EDHF, mediated endogenous tone in the female 
vaginal arteries. Agonist-induced rhythmic activity was also observed in rabbit vaginal 
strips (Oh et a l, 2003), being more prevalent in the upper and middle than lower regions, 
but no evidence was provided that this activity could be blocked.
The novel finding of large relaxations of the EVA which could be blocked by L-NAME 
demonstrated the physiological importance of NO in these arteries.
Summary
In summary, evidence was provided for spontaneous basal activity in all genital arteries 
studied (Table 7-2). The existence of spontaneous activity prior to and coinciding with 
antagonist addition also provided some insights into underlying basal mechanisms
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responsible. Factors controlling spontaneous vasoconstriction and vasodilation of the 
genital arteries may originate from neurons, smooth muscle or endothelial cells. Tonic 
sympathetic nerve activity has previously been implicated in the maintenance of basal tone 
in male cavernous tissues and it would, therefore, be reasonable to assume that tonic 
activity of other nerves, e.g. parasympathetic nitrergic nerves, may also act to oppose 
smooth muscle contraction. Myogenic activity has been suggested to be responsible for the 
regulation of peripheral resistance and oxygenation; a role that may be of particular 
importance in the penile tissues, hi addition, results obtained in the current study 
implicated a spontaneous basal release of endothelial factors.
Basal tone in both EVA and dorsal arteries was maintained by a balance of NO release and 
AR activity. These factors may be due to basal neurogenic activity involving both NA and 
NO release from adrenergic and nitrergic neurons respectively. Equally, NO may be 
released spontaneously from the endothelium and ARs may be constitutively active. In 
EVA, the unique occun'ence of spontaneous vasodilation suggests that relaxation 
mechanisms predominate in this vessel, predisposing the artery to vasodilation.
In the IVA, data suggests that basal levels of spontaneously released endothelial factors 
maintain tone in this vessel. Both basal channel activity, potentially due to EDHF 
release, and NO release exist and some pathway redundancy was shown to occur between 
NO and EDHF in this respect. The nature of the opposing vasoconstrictor factor could not 
be deteimined on the evidence available.
Basal tone in the cavernous artery was maintained by a balance of EDHF and adrenergic 
nerve activity. In this artery basal adrenergic nerve activity appeared to predominate, 
predisposing the artery to vasoconstriction; an attribute that would be of particular 
physiological relevance in the cavernous tissue.
Further investigation would be required to further elucidate the mechanisms behind basal 
tone of genital arteries. In particular, protocols would be designed to include time and 
vehicle controls in addition to further investigations into the effects of blocking nerve 
activity or Ca^ "^  channels. Basal mechanisms of vasoconstriction and vasodilation may 
have an important role in genital tissue circulation and may, therefore, be an important 
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Phaimacological and physiological data on vasoconstrictor and vasodilator responses of 
genital arteries is extremely limited. In the cuiTent study, small vessel wire myography 
combined with EPS and a plethora of agonists, antagonists and blocking agents were used 
to enhance cun-ent understanding of AR-mediated vasoconstriction, NO- peptide- and 
purine-mediated and endothelium-dependent vasodilation in isolated genital arteries from 
male and female New Zealand White rabbits. By improving our current understanding of 
genital vascular function a more coherent and sophisticated approach to the treatment of 
both male and female sexual dysfunction will be made possible.
While current therapies for male ED have enjoyed the recent successes of oral PDE-5 
inhibitors, even these do not provide a definitive answer for all patients. In particular, 
patients with diabetes do not respond well to PDE-5 inhibitors and the use of PDE-5 
inhibitors is contra-indicated in any patients taking nitrates or with a high cardiovascular 
risk (Reffelmann & Kloner, 2005; Wyllie, 2006). Therefore, the current study may provide 
the rationale for alternative approaches, e.g. targeting peptide or endothelial pathways, 
which could help to treat a further subset of both male and female patients. In addition, 
while this study has considered the peripheral mechanisms involved in sexual function of 
male and female tissues, it has not considered the central mechanisms thought to be of 
particular importance in the female. A combination of peripherally and centrally acting 
phaimacotherapies may provide a more effective approach; but whether this is a route 
which major leading manufacturers of compounds used to treat sexual dysfunction wish to 
persue remains to be seen.
Adrenoceptor-Mediated Responses
Several important vasoconstrictor and vasodilator pathways in the genital arteries were 
investigated in detail during the current study. Male and female arteries were shown to be 
innervated by sympathetic adrenergic nerves using immunohistochemistry and/or EPS. 
During the investigation of adrenoceptor-mediated pathways, NA-induced vasoconstriction 
and active NA uptake mechanisms were demonstrated in both penile and vaginal arteries. 
AR-induced vasoconstriction was mediated by a combination of Uia-ARs and a 2 -ARs, 
potentially the U2 A-AR subtype, in male penile arteries; providing clarification of ai-AR 
pharmacology in a field containing conflicting evidence for all thi'ee ai-AR candidates.
The tt2 -AR was shown to be of particular importance in the vasoconstriction of dorsal 
penile arteries; reflected by the potency order of AR agonists, UK 14,304 > Medetomidine 
> NA = PE. Œ2 -ARS have previously been shown to mediate NA-induced vasoconstriction
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of cavernous arteries (Hedlund & Andersson, 1985a) and in the current study, while a%- 
ARs could not be excluded, a clearer role for uia-ARs was demonstrated in the cavernous 
arteries. Therefore, when considering treatments for male sexual dysfunction a 
combination of u r  and CI2 -AR antagonists may provide a more efficient approach to 
inhibition of sympathetic nerve-mediated vasoconstriction.
In female vaginal arteries the presence of functional ai-ARs was confirmed. However, a%- 
ARs were shown to make little or no contribution to AR-mediated responses in isolated 
vaginal arteries but had previously been demonstrated in vaginal tissue strips. The lack of 
a 2 -AR-mediated responses highlights a clear gender difference between male and female 
rabbits that was reflected in the order of agonist potencies in female vaginal arteries, NA = 
UK 14,304 = PE = Medetomidine. This study was the first investigation of AR-mediated 
responses in isolated vaginal arteries and provides a rationale for the use of a p  but not tt2 - 
AR antagonists as a potential therapy to enhance vaginal blood flow.
Evidence was found for basal AR activity, either via spontaneous NA release from nerves 
or constitutive AR activity, which could be involved in the maintenance of endogenous 
tone in both male and female genital arteries. To date, constitutively active receptors have 
only been shown in cell cultures (McLean et a l, 2002) and their significance, or indeed 
presence, in in vitro or in vivo environments is unknown. The presence of basal tone has 
implications for the development of novel treatment strategies since this would need to be 
overcome to allow vasodilation of genital arteries during sexual arousal.
Nitric Oxide-Mediated Responses
The contribution of NO to endothelium-dependent, direct smooth muscle, and nerve 
mediated relaxation was investigated during the current study. Considering the wealth of 
data proposing NO as the main NANC neurotransmitter in males using strips of penile 
tissue, surprisingly little evidence was found for NO involvement in EES-induced 
relaxation in isolated male penile arteries. In female vaginal arteries, a greater inhibition of 
EPS-induced relaxation by blockade of NOS activity using L-NAME was demonstrated 
than in male penile ai*teries. hr female arteries, L-NAME predominantly inhibited EFS- 
induced responses at low fr equencies while an L-NAME-resistant component persisted at 
high stimulation frequencies.
Direct stimulation of smooth muscle by the NO donor dmg, SNP, caused vasodilation of 
both male and female genital arteries. However, this relaxation was not potentiated by the
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PDE-5 inhibitor, UK 343,664. These findings directly contradict previous data from 
cavernous arteries showing increased NO-mediated vasodilation (exogenous NO added as 
acidified sodium nitrate (NaNOi)) in the presence of sildenafil (Simonsen et a l, 2001) and 
are a major consideration for the use of PDE-5 inhibitors in male ED. Further research is 
required to determine the PDE type involved in NO-mediated vasodilation of genital 
arteries. In particular, the effect of UK 343,664 on baseline tone, EFS-induced vasodilation 
and ACh-induced vasodilation would be studied to hilly characterise UK 343,664 
responses in the genital arteries. In addition, a comparison of UK 343,664 with alternative 
PDE-5 inhibitors (e.g. sildenafil) and inhibitors of different PDE isoforms (e.g. PDE-1, 2,
4, 9 or 10) would provide fuither information about the phosphodiesterases important to 
the function of male and female genital arteries. NO was foimd to contribute significantly 
more to endothelium-dependent relaxation of male than female genital arteries; which begs 
the question of whether PDE-5 inhibitors potentiate a neurogenic or endothelium- 
dependent increase in NO production. The main synthase activity in isolated male genital 
arteries, therefore, appears to be eNOS while in female vessels NO production is more 
likely to be via activity of nNOS. This finding may be of considerable significance when 
determining future approaches aimed to potentiate vasodilation of genital blood vessels in 
both genders.
ACh-induced, endothelium-dependent relaxation of male and female genital arteries was 
mediated by a combination of NO and K^ chamiel activity. K^ channel activity was 
demonstrated by inhibition of K^ channels using Apa and ChTX and was, therefore, 
potentially due to release of EDHF. While prostaglandins were previously found to have 
direct vasodilator effects in penile and vaginal tissues, no role was demonstrated in ACh- 
induced relaxation of male or female genital arteries in the current study. Relative 
contributions of NO and K^ channels (EDHF-like vasodilation) to endothelium-dependent 
vasodilation demonstrated significant gender differences. Vasodilation was predominantly 
mediated by NO in male dorsal arteries, K^ channels in female EVA and a combination of 
both in smaller IVA and cavernous arteries. These findings confirm data that has 
previously concluded that a combination of NO and K^ channels are responsible for 
endothelium-dependent relaxation of human and horse cavernous arteries (Prieto et a l , 
1998; Angulo et a l, 2003). The gieater contribution of EDHF than NO to relaxation of 
female genital arteries provides an explanation for the lack of effect of PDE-5 inhibitors in 
the treatment of FSD. Contrary to previous studies, the involvement of EDHF was 
demonstrated to be greater in upstream sections of the vaginal artery (EVA) compared to 
smaller downstream sections (IVA). Due to a lack of literature in this area, it is difficult to 
ascertain if  this is a common trend in female systemic circulation or specific to the
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genitalia. This study was the first to determine the relative contributions of EDHF and NO 
to endothelium-dependent relaxation of male and female genital arteries. Uniquely, the 
importance of EDHF was highlighted in female arteries, along with a partial role in male 
arteries.
Basal release of NO was found to contribute significantly to the balance of factors 
maintaining endogenous tone in both male and female genital arteries. The unique 
observation of L-NAME-sensitive, pronounced, spontaneous vasodilations in the EVA 
demonstrated the importance of NO in controlling vascular tone in this artery. Basal 
channel activity, thought to be due to a basal release of EDHF, also influenced endogenous 
tone in all genital arteries. In the I VA, NO and EDHF pathways showed some degree of 
compensation in that blockade of either pathway alone was significantly less effective than 
blockade of both pathways together.
Peptide- and Purine-Mediated Responses
L-NAMB-resistant, EFS-induced vasodilation was shown not to be due to ATP in the 
female genital arteries. In contrast to published data in vaginal tissues, no direct vasodilator 
effect of ATP was demonstrated in isolated female vaginal arteries. However, functional 
P2 X receptors (ATP-induced vasoconstrictions) were demonstrated; suggesting that ATP 
may be involved in sympathetic, excitatory neurotransmission. Until now, no previous 
studies have investigated this role for ATP in isolated genital arteries.
Functional VIP receptors were demonstrated in female genital arteries and the presence of 
VIPergic neurons was confirmed by immunohistochemical studies. A role for VIP as a 
neurotransmitter in the EVA could not be excluded but the concept could not be fully 
tested due to the lack of selective antagonists. This peptide was previously thought to be 
compatible with a neurotransmitter role (Hedlund & Andersson, 1985b) but to date no 
studies have managed to conclusively delineate the physiological function of VIP. 
However, an additional, unknown vasodilator neurotransmitter remained unidentified in 
both male and female genital arteries and identification of this compound may solve the 
characterisation of L-NAME-resistant, non-adrenergic, non-cholinergic neurotransmission.
Gender Differences
One of the aims of this study was to provide a balanced investigation of vasoconstrictor 
and vasodilator mechanisms important in male and female genital arteries. This provided
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the unique opportunity to make a direct comparison of mechanisms important to vascular 
function in both sexes.
When comparing the magnitude and potency of responses to various vasoconstrictor, 
adrenoceptor agonists, including NA, PE, UK 14,304 and medetomidine, clear differences 
became apparent. Vasoconstrictions in the EVA consistently gave the greatest magnitude 
but were least potent, while vasoconstrictions in the cavernous artery gave the smallest 
magnitude but were most potent. The size and potency of responses in the IVA and dorsal 
arteries lay between. Due to the volume of this data and its dispersion throughout previous 
chapters, it is summarised here in the following figure and corresponding table (Figure 8-1, 
Table 8-1). This data suggested that IV A and dorsal arteries m aybe comparable in 
function. However, while dorsal arteries demonstrated a significant contribution from both 
ttiA" and a 2 -ARs to adrenoceptor mediated vasoconstriction, a 2 -ARs were found not to 
have a significant role in female arteries.
Responses of IVA and dorsal arteries to vasodilator agonists, including SNP, ACh and 
VIP, were similar in potency and magnitude. Responses to vasodilator agonists are 
summarised in the following figure and corresponding table (Figure 8-2, Table 8-1). In 
addition, EVA and cavernous artery vasodilator responses were similar in magnitude and 
potency. It is interesting that EVA and cavernous arteries were comparable in vasodilator 
but not vasoconstrictor responses, where they represented opposite ends of an extreme. 
EVA and cavernous arteries were the most comparable in physiological function, being the 
main inflow arteries in both sexes, and therefore may have similar requirements in regard 
to vasodilation. However, detailed investigation of vasodilator pathways in the genital 
arteries demonstrated significant gender differences. Endothelium-dependent relaxation of 
genital arteries particularly demonstrated a greater involvement of EDHF in females and 
NO in males. In contrast, EFS-induced relaxation of genital arteries demonstrated a greater 
involvement of NO in females than in males.
This study demonstrates that while male and female genital systems may show some 
general similarities, the specifics of signal transduction pathways are often different. In this 
respect the function of female genital tissues may not be directly inferred from the more 
extensively studied function of male genital tissues. Consequently, simply using available 
data from males does not provide a suitable approach to understanding the physiology of 
female tissues. It is my opinion that each gender should be studied in isolation and that 
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Future Studies
W hile  the cuiTent study  has m ade sign ifican t advances in to  the  understand ing  o f  genital 
artery  p h an n aco lo g y , several areas have b een  iden tified  th a t w ou ld  benefit from  fu ith er 
investigation .
In particular, the use of EPS raised almost as many questions as it answered. These 
included the demonstration of EFS-induced, TTX-resistant responses. The stimulation 
parameters used would be expected to lead to a neiwe-induced response and would not be 
expected to result from direct smooth muscle stimulation. Direct nerve varicosity 
depolarisation, TTX-resistant Na^ channels or a Na^ chamiel-independent 
neurotransmission have previously been hypothesised to accoimt for TTX-resistant 
neurotransmission (Campbell, 1993; Jackson et a l, 2002; Ikeda et a l, 2005).
Investigation into the role of NO and peptides in vasodilator neurotransmission revealed a 
potential role for VIP in the EVA and the presence of an unknown vasodilator 
neurotransmitter in all arteries that both require further investigation, hi addition, further 
studies would be required to investigate the role of purinoceptors in EFS-induced 
vasoconstriction, a role that could not be excluded in the current study and that has not 
previously been shown.
Significant volumes of data have been presented herein describing the ARs involved in 
vasoconstriction of isolated male and female genital arteries, including full subtyping of 
tti-ARs, demonstration and partial subtyping of uz-ARs in male penile aiferies and 
characterisation of the role of ai- and U2 -ARs in female vaginal arteries. However, due to 
the constraints of time and resources, the ai- (female) and Ui-AR (male and female) 
subtype/s responsible for vasoconstriction were not fully tested.
Many interesting points were raised as to the exact role of NO in vascular function of male 
and female genital arteries. In particular the role of PDE-5 in both male and females was 
questioned and this area would require further investigation to determine the PDE subtype 
responsible for the breakdown of cGMP in isolated genital arteries. Determination of the 
specific NO pathways, including identification of important NOS and PDE subtypes, 
would provide a more coherent rationale for the use of drugs such as PDE-5 inhibitors in 
the treatment of male and female sexual dysfunction.
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The identification of spontaneous activity in genital arteries was made diuing the current 
study. This indicated the basal release of endogenous vasoconstrictor and vasodilator 
factors in both genders. Since these observations were made during the course of studies, 
sufficient time was not available to assess this phenomenon in isolation. Therefore, only 
suggestions could be made as to the mechanisms responsible for spontaneous activity in 
genital arteries. Basal mechanisms could be rigorously examined using protocols designed 
to investigate the time course of responses and their dependence on tonic nerve activity, 
constitutive receptors and/or myogenic activity.
A brief immunohistochemical analysis of female vaginal tissues was earned out during this 
study. While some interesting obseiwations were made, the findings presented here would 
be enhanced further by studies to identify other nerve classes and their proportionate 
representation in the vaginal tissues. The presence of specific neurons and their location 
may provide an indication of the mechanisms likely to contribute to the control of both 
vascular and non-vascular smooth muscle.
The current study demonstrated the successful use of wire myogi'aphy to examine the 
function of isolated genital arteries. This provided information concerning one of the three 
main events of penile erection; which include increased arterial inflow, decreased venous 
outflow and trabecular smooth muscle relaxation, hi addition, the function of corpus 
cavemosum strips, and therefore trabecular smooth muscle, has previously been 
investigated in some depth. A few studies have begun to consider the role of active venous 
regulation, in addition to the veno-occlusive mechanism, in the control of venous outflow 
(Kirkeby et a l, 1991; Holmquist et a l, 1992; SegarTa et a l, 1998; Recio et a l, 2004). 
Small vessel wire myography could be applied to examine the role of vasoconstrictor and 
vasodilator pathways controlling male and female genital veins.
Pathologies including heart failure, diabetes, hypercholesterolaemia and aging have all 
been implicated in the development of sexual dysfunction. A natural progression from the 
studies presented here on the normal vascular function of genital arteries would be to study 
these same mechanisms in animal models of pathological states.
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